

PATENT COOPERATION TREATY

PCT/US99/20948

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C. 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 24 May 2000 (24.05.00)	Applicant's or agent's file reference 00530/089W01
International application No. PCT/US99/20948	Priority date (day/month/year) 14 September 1998 (14.09.98)
International filing date (day/month/year) 14 September 1999 (14.09.99)	
Applicant DUKE-COHAN, Jonathan, S. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
06 April 2000 (06.04.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer S. Mafla
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

Form PCT/IB/331 (July 1992)

US99

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 07 FEB 2001

WIPO

PCT

4

Applicant's or agent's file reference 00530/089WO1	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/20948	International filing date (day/month/year) 14 SEPTEMBER 1999	Priority date (day/month/year) 14 SEPTEMBER 1998
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant DANA-FARBER CANCER INSTITUTE		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 5 sheets.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 06 APRIL 2000	Date of completion of this report 05 JANUARY 2001
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer <i>Gerald R. Ewoldt</i> GERALD R. EWOLDT
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/20948

I. Basis of the report**1. With regard to the elements of the international application:***☒ the international application as originally filed☒ the description:

pages 1-52, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____

☒ the claims:

pages 53-59, as originally filed
pages NONE, as amended (together with any statement) under Article 19
pages NONE, filed with the demand
pages NONE, filed with the letter of _____

☒ the drawings:

pages 1-22, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____

☒ the sequence listing part of the description:

pages NONE, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
☐ the language of publication of the international application (under Rule 48.3(b)).
☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in printed form.
☐ filed together with the international application in computer readable form.
☐ furnished subsequently to this Authority in written form.
☐ furnished subsequently to this Authority in computer readable form.
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

☒ the description, pages NONE
☒ the claims, Nos. NONE
☒ the drawings, sheets/fig NONE

5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

**Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US99/20948

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been and will not be examined in respect of:

☐ the entire international application.

☒ claims Nos. 4-5, 7-19, 28-37

because:

☐ the said international application, or the said claim Nos. _ relate to the following subject matter which does not require international preliminary examination (*specify*).

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _ are so unclear that no meaningful opinion could be formed (*specify*).

☐ the claims, or said claims Nos. _ are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for said claims Nos. 4-5, 7-19, 28-37.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/20948

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. statement**

Novelty (N)	Claims <u>none</u>	YES
	Claims <u>1-3, 6, 20-27</u>	NO
Inventive Step (IS)	Claims <u>none</u>	YES
	Claims <u>1-3, 6, 20-27</u>	NO
Industrial Applicability (IA)	Claims <u>1-3, 6, 20-27</u>	YES
	Claims <u>none</u>	NO

2. citations and explanations (Rule 70.7)

Claims 1-3, 6, and 20-27 lack novelty under PCT Article 33(2) as being anticipated by Duke-Cohan et al. (1995) or Duke-Cohan et al (1996).

The Duke-Cohan et al. references describe the isolation and characterization of both the membrane and soluble forms of the polypeptides encoded by the claimed DNA nucleic acid sequences. Further characterization, i.e., sequencing, adds no novelty to the invention. The amino acid or nucleotide sequence of a polypeptide, or the DNA encoding said polypeptide respectively, is an inherent property of said polypeptide or DNA.

Absent evidence to the contrary, the attractions of the claimed invention are considered to be soluble and membrane Novel Form of Dipeptidylpeptidase IV, as taught by Duke-Cohan et al. (1995), or DPPT-L, as taught in the Duke-Cohan et al. (1996), described supra.

Claims 1-3, 6, and 20-27 meet the criteria set out in PCT Article 33(4) for industrial applicability. The claimed nucleic acids would possess utility in being used to express recombinant polypeptides for use in a method for treatment of a subject in need of an enhanced immune response.

----- NEW CITATIONS -----
none

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/20948

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below:
IPC(7): C07H 21/04; C12N 15/63, 1/21, 15/00 and US Cl.: 536/23.5, 23.4; 435/320.1, 252.1, 69.7

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To: FRASER, JANIS K.
FISH AND RICHARDSON P.C.
225 FRANKLIN STREET
BOSTON, MASSACHUSETTS 02110-2804
UNITED STATES OF AMERICA

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

Applicant's or agent's file reference 00530/089WO1	Date of Mailing (day/month/year) 07 FEB 2000
International application No. PCT/US99/20948	International filing date (day/month/year) 14 SEPTEMBER 1999
Applicant DANA-FARBER CANCER INSTITUTE	

1. ☒ The applicant is hereby notified that the international search report has been established and is transmitted herewith.
Filing of amendments and statement under Article 19:
 The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
 34, chemin des Colombettes
 1211 Geneva 20, Switzerland
 Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in rules 90 bis 1 and 90 bis 3, respectively, before the completion of the technical preparations for international publication.

 Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

 Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>G. Lawrence</i> GERALD R. EWOLDT Telephone No. (703) 308-0196
---	--

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 00530/089WO1	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/US99/20948	International filing date (day/month/year) 14 SEPTEMBER 1999	(Earliest) Priority Date (day/month/year) 14 SEPTEMBER 1998
Applicant DANA-FARBER CANCER INSTITUTE		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☐ Certain claims were found unsearchable (See Box I).
2. ☒ Unity of invention is lacking (See Box II).
3. ☐ The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing
 - ☐ filed with the international application.
 - ☐ furnished by the applicant separately from the international application,
 - ☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.
 - ☐ transcribed by this Authority.
4. With regard to the title,
 - ☒ the text is approved as submitted by the applicant.
 - ☐ the text has been established by this Authority to read as follows:
5. With regard to the abstract,
 - ☒ the text is approved as submitted by the applicant.
 - ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. The figure of the drawings to be published with the abstract is:
Figure No. _____
 - ☐ as suggested by the applicant.
 - ☐ because the applicant failed to suggest a figure.
 - ☐ because this figure better characterizes the invention.
 - ☒ None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/20948

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking. (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-3, 6, 20-27

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/20948

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04; C12N 15/63, 1/21, 15/00

US CL : 536/23.5, 23.4; 435/320.1, 252.1, 69.7

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.5, 23.4; 435/320.1, 252.1, 69.7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, medline, embase, BIOSIS, caplus,
KEYWORDS: attractin, DPPT-L**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DUKE-COHAN et al. A Novel Form of Dipeptidylpeptidase IV Found in Human Serum. J. Biol. Chem. June 1995, Vol. 270, No. 23, pages 14107-14114, see entire document.	1-3, 6, 20-27
Y	DUKE-COHAN et al. Serum High Molecular Weight Dipeptidyl Peptidase IV (CD26) Is Similar To A Novel Antigen DPPT-L Released From Activated T Cells. J. Immunol. 1996, Vol. 156, pages 1714-1721, see entire document.	1-3, 6, 20-27

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

06 JANUARY 2000

Date of mailing of the international search report

07 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

GERALD R. EWOLDT

Telephone No. (703) 308-0196

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07H 21/04, C12N 15/63, 1/21, 15/00	A1	(11) International Publication Number: WO 00/15651 (43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/US99/20948 (22) International Filing Date: 14 September 1999 (14.09.99) (30) Priority Data: 60/100,137 14 September 1998 (14.09.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/100,137 (CON) Filed on 14 September 1998 (14.09.98) (71) Applicant (for all designated States except US): DANA-FARBER CANCER INSTITUTE [US/US]; 44 Binney Street, Boston, MA 02115 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DUKE-COHAN, Jonathan, S. [IL/US]; 93 Parker Avenue, Newton High- lands, MA 02161 (US). SCHLOSSMAN, Stuart, F. [US/US]; 1 Fox Place, Newton Centre, MA 02195 (US). (74) Agent: FRASER, Janis, K.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).	(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: REGULATION OF IMMUNE RESPONSES BY ATTRACTIN (57) Abstract The invention features attractin polypeptides and nucleic acids encoding them. The attractin polypeptides are useful for enhancing immune responses.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

REGULATION OF IMMUNE RESPONSES BY ATTRACTINBackground of the Invention

5 The present invention relates to agents that regulate immune responses.

 Analysis of *in vitro* immune responses allows basic interactions between cells and soluble modulators to be studied, but interpretations may be difficult to extend
10 to actual responses *in vivo*, where reactions occur in complex cellular environments with constant dynamic modification of the extracellular environment. An important role is played by the extracellular matrix which interacts with adhesion structures on the surface
15 of immune cells, directing cell migration, localization and clustering and subsequently influences the activity of local cytokines and lymphokines [Shimizu et al. (1991) *FASEB J.* 5, 2292-2299; Gilat et al. (1996) *Immunol. Today* 17, 16-20]. The passage of activated leukocytes between
20 endothelial cells and their migration through the extracellular matrix to sites of inflammation is facilitated by the upregulated surface expression of several adhesion molecules and proteases [Hauzenberger et al. (1995) *Crit. Rev. Immunol.* 15, 285-316].

25 On activated T cells, one of the most prominently expressed proteases is CD26, which is a marker of T lymphocytes capable of migrating across endothelial barriers [Masuyama et al. (1992) *J. Immunol.* 148, 1367-1374; Brezinschek et al. (1995) *J. Immunol.* 154, 3062-3077] and has a collagen-binding domain [Loster et al. (1995) *Biochem. Biophys. Res. Commun.* 217, 341-348].
30 CD26 is now known to be identical to both dipeptidyl peptidase IV (DPPIV) and adenosine deaminase binding protein [Kameoka et al. (1993) *Science* 261, 466-469].
35 The understanding of the multifunctionality of CD26, which is the prototype for a family of related molecules

- 2 -

which includes Fibroblast Activation Protein [Scanlan et al. (1994) *Proc. Natl. Acad. Sci. USA* 91, 5657-5661], DPPIV [Wada et al. (1992) *Proc. Natl. Acad. Sci. USA* 89, 197-201] and Seprase [Goldstein et al. (1997) *Biochim. Biophys. Acta* 1361, 11-19; Pineiro-Sanchez et al. (1997) *J. Biol. Chem.* 272, 7595-7601], has expanded to include T lymphocyte costimulatory activity, where it enhances immune responses channeled through the CD3/T cell receptor complex [Dang et al. (1990) *J. Immunol.* 144, 4092-4100].

A soluble serum form of DPPIV had previously been identified [Tanaka et al. (1994) *Proc. Natl. Acad. Sci. USA* 91, 3082-3086], and its circulating levels were determined to be related to the ability of peripheral blood mononuclear cells (PBMC) to react *in vitro* to recall antigens such as tetanus toxoid. Based on this activity, it was conjectured that the identified soluble serum protein was a soluble form of CD26. However, upon purification of the protein, its glycosylated form was found to have a molecular weight of 175 kDa, and therefore, it was distinct from the 105 kDa glycosylated form of DPPIV/CD26 [Duke-Cohan et al. (1995) *J. Biol. Chem.* 270, 14107-14114]. The soluble serum protein having DPPIV activity was designated DPPT-L. DPPT-L appeared to be related to CD26 in that it displayed some CD26 antigenic epitopes, it was rapidly expressed as a T lymphocyte activation antigen, after 48-72 hr it was released from the lymphocyte membrane, and it could upregulate recall antigen-specific T cell responses in a manner similar to that of CD26 [Duke-Cohan et al. (1996) *J. Immunol.* 156, 1714-1721].

Summary of the Invention

The invention features four isolated forms of the human attractin polypeptide. These are soluble

- 3 -

attractin-1 (previously named DPPT-L in the mistaken belief that it was related to, and even a soluble form of, DPPIV/CD26), membrane attractin-1, soluble attractin-2, and membrane attractin-2. Text that refers to

5 attractin without specifying soluble versus membrane or attractin-1 versus attractin-2 is pertinent to all forms of attractin. Membrane attractin differs from soluble attractin in that it has a transmembrane domain and a cytoplasmic domain. Attractin-2 differs from attractin-1

10 in that it contains a 74-amino acid insert in the N-terminal part of the polypeptide. The attractin molecules serve to enhance immune response by promoting macrophage and monocyte spreading in the presence of T cells. The invention also includes nucleic acid

15 molecules encoding attractin polypeptides, vectors containing the nucleic acid molecules, and cells transformed with the vectors. In addition, the invention includes methods of enhancing or inhibiting immune responses and methods of identifying compounds that

20 enhance or inhibit immune responses.

Specifically, the invention features an isolated DNA including: (a) a nucleic acid sequence that encodes a polypeptide that enhances spreading of a macrophage or a monocyte and that hybridizes under stringent conditions

25 to the complement of a sequence that encodes a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:18; or (b) a complement of this nucleic acid sequence. The nucleic acid sequence

30 included in the isolated DNA will be at least 10 bp, 15 bp, 25 bp, 50 bp, 75 bp, 100 bp, 125 bp, 150 bp, 175 bp, 200 bp, 250 bp, 300 bp, 400 bp, 500 bp, 600 bp, 700 bp, 800 bp, 900 bp, 1000 bp, 1,500 bp, 2,000 bp, 3,000 bp, or 4,000 bp long. The nucleic acid sequence

35 can encode a polypeptide that includes the amino sequence

- 4 -

of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:18. Examples include nucleotide sequences SEQ ID NO:1, SEQ ID NO:11, SEQ ID NO:13, and SEQ ID NO:19.

An isolated polypeptide within the invention can include the amino acid sequence of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:18, or can differ from one of these sequences solely by one or more conservative amino acid substitutions. The polypeptides of the invention also embrace fusion proteins containing both (a) an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:18, but lacking methionine at position 1 of said amino acid sequence; and (b) a heterologous leader peptide. Also included are isolated nucleic acid molecules encoding the fusion proteins.

The invention features methods of enhancing spreading of a macrophage or a monocyte *in vitro*. These methods include coculturing a monocyte or a macrophage and a T cell with one or more of the following agents: (a) an isolated attractin polypeptide with the amino acid sequence of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:18; (b) a functional fragment of one or more of these attractin polypeptides; or (c) the polypeptide or the functional fragment, but with at least one conservative amino acid substitution.

The above polypeptides and nucleic acids can be used in a method of treating a mammal (e.g., a human) in need of an enhanced immune response. The method includes the step of delivering, to a tissue of a mammal where the tissue contains T cells and macrophages or monocytes, one of the above agents. The method can involve administration of the agent or a nucleic acid encoding the agent to the mammal. The human can be one suspected of being immunodeficient (e.g., one having common variable immunodeficiency) and/or of having cancer; and

- 5 -

can be performed before, during, or after chemotherapy or radiation therapy.

The invention also embodies a method of inhibiting spreading of a macrophage or a monocyte in a mammal. The method includes administering to the mammal an isolated compound that binds to an attractin polypeptide, and interferes with its function. The product can be an antibody and the mammal can be a human, e.g., a human suspected of having an autoimmune disease or a transplant recipient.

The invention also features vectors including any of the isolated DNAs of the invention, e.g. a vector in which the nucleic acid sequence encoding the relevant polypeptide is operably linked to a regulatory element which allows expression of the coding sequence in a cell. Cultured cells including the above vectors can be used in methods of producing any of the polypeptides of the invention. These methods include culturing the appropriate cell and purifying the polypeptide from it.

The invention also features a method of identifying a compound that inhibits an immune response. The method includes: a) providing an isolated polypeptide containing an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:18, or the same amino acid sequence but with one or more conservative amino acid substitutions; b) co-culturing a T cell and a macrophage or a monocyte with the isolated polypeptide and the test compound; c) determining whether the test compound inhibits spreading of the macrophage or the monocyte, as an indication that the test compound inhibits an immune response. Alternatively, the method can include: a) providing a test compound; b) combining the test compound, a T cell, a macrophage or a monocyte, and the isolated polypeptide; and c) determining whether the test compound enhances

- 6 -

spreading of the macrophage or the monocyte, as an indication that the test compound inhibits an immune response.

Also within the invention is a method of
5 identifying a compound that enhances an immune response. The method includes: a) providing a test compound; b) combining the test compound, a T cell, a macrophage or a monocyte, and an isolated polypeptide of the invention; and c) determining whether the test compound enhances
10 spreading of the macrophage or the monocyte, as an indication that the test compound inhibits an immune response. Alternatively, the method can include: a) providing the isolated polypeptide; b) co-culturing a T cell and a macrophage or a monocyte with the isolated
15 polypeptide and the test compound; c) determining whether the test compound inhibits spreading of the macrophage or the monocyte, as an indication that the test compound inhibits an immune response.

Also within the invention is an antibody (e.g., a
20 scFv) that binds to a polypeptide with the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:18, but does not bind to CD26 or to a polypeptide with the sequence of SEQ ID NO:2.

The invention also features an ex vivo method of
25 treating a mammal (e.g., a human patient) in need of an enhanced immune response. The method includes: a) providing a recombinant cell which is the progeny of a cell obtained from the mammal and has been transfected or transformed ex vivo with a nucleic acid encoding an
30 "agent" or a functional fragment of the agent so that the cell expresses the agent or functional fragment; and b) administering the cell to the mammal. The "agent" is:
(i) an attractin polypeptide that includes the amino acid sequence of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, or
35 SEQ ID NO:18; (ii) a functional fragment of the attractin

- 7 -

polypeptide; or (iii) the polypeptide or the functional fragment, but with one or more conservative amino acid substitutions.

Another aspect of the invention is an isolated
5 functional attractin fragment including at least amino acid residues 31-104 of SEQ ID NO:12 or SEQ ID NO:18, amino acid residues 1279-1301 of SEQ ID NO:12, amino acid residues 1219-1429 of SEQ ID NO:12, or amino acid residues 1302-1429 of SEQ ID NO:12.

10 "Polypeptide" and "protein" are used interchangeably and mean any peptide-linked chain of amino acids, regardless of length or post-translational modification. The invention also features attractin polypeptides with conservative substitutions.
15 Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, alanine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine, glutamine, serine and threonine; lysine, histidine and arginine; and
20 phenylalanine and tyrosine.

The term "isolated" polypeptide or peptide fragment as used herein refers to a polypeptide or a peptide fragment which either has no naturally-occurring counterpart (e.g., a peptidomimetic), or has been
25 substantially separated or purified from components which naturally accompany it, e.g., in tissues such as pancreas, liver, spleen, ovary, testis, muscle, joint tissue, neural tissue, gastrointestinal tissue, or body fluids such as blood, serum, or urine. Typically, the
30 polypeptide or peptide fragment is considered "isolated" when it is at least 70%, by dry weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, a preparation of a polypeptide (or peptide fragment
35 thereof) of the invention is at least 80%, more

- 8 -

preferably at least 90%, and most preferably at least 99%, by dry weight, the polypeptide (or the peptide fragment thereof), respectively, of the invention. Thus, for example, a preparation of polypeptide x is at least 80%, more preferably at least 90%, and most preferably at least 99%, by dry weight, polypeptide x. Since a polypeptide that is chemically synthesized is, by its nature, separated from the components that naturally accompany it, a synthetic polypeptide is by definition "isolated."

An isolated polypeptide (or peptide fragment) of the invention can be obtained, for example, by extraction from a natural source (e.g., from human tissues or bodily fluids); by expression of a recombinant nucleic acid encoding the peptide; or by chemical synthesis. A peptide that is produced in a cellular system different from the source from which it naturally originates is "isolated," because it will be separated from components which naturally accompany it. The extent of isolation or purity can be measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

An "isolated DNA" means a DNA which either (a) has a non-naturally occurring sequence (e.g., a cDNA from a gene that naturally has introns), or (b) has a naturally occurring (i.e., genomic) sequence, but is free of the genes that flank the sequence in the genome of the organism in which the gene of interest naturally occurs. The term "isolated DNA" therefore includes a recombinant DNA incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote at a site other than the site at which it occurs naturally. It also includes a separate molecule such as a cDNA; a genomic fragment; a fragment produced by polymerase chain reaction (PCR); a

- 9 -

restriction fragment; a DNA encoding a non-naturally occurring mutein, fusion protein, or fragment of a given protein; or a nucleic acid which is a degenerate variant of a naturally occurring nucleic acid. In addition, it
5 includes a recombinant nucleotide sequence that is part of a hybrid gene, i.e., a gene encoding a fusion protein.

"Spreading" of a macrophage or a monocyte, which occurs after exposure of the macrophage or monocyte to an attractin protein and a T cell, involves flattening of
10 the macrophage or monocyte on a surface, expansion of the macrophage's or monocyte's margins, and an increase in the cell's surface area. The spread macrophage or monocytes may produce cellular processes visible microscopically. Macrophages and monocytes that have
15 spread can be distinguished from, e.g., fibroblasts or T cells, by their expression of surface CD14.

As used herein, a "fragment" of an attractin polypeptide contains part but not all of the full-length polypeptide. Generally, fragments will be five or more
20 amino acids in length. An antigenic fragment has the ability to be recognized and bound by an antibody.

As used herein, a "functional fragment" of an attractin polypeptide is a fragment of the polypeptide that has the ability to induce spreading of a macrophage
25 or a monocyte in the presence of a T cell. Methods of establishing whether a fragment of an attractin molecule is functional are based upon those described herein for full-length polypeptides. For example, fragments of interest can be made by either recombinant, synthetic, or
30 proteolytic digestive methods. Such fragments can then be isolated and tested for their ability to enhance spreading of macrophages or monocytes by procedures described herein.

As used herein, "operably linked" refers to an
35 expression control sequence (e.g., a promoter, enhancer,

- 10 -

or the like) linked to a coding sequence in a manner that permits the expression control sequence to control expression of the coding sequence.

As used herein, the term "antibody" refers not only to whole antibody molecules, but also to antigen-binding fragments, e.g., Fab, F(ab')₂, Fv, and single chain Fv fragments. Also included are chimeric antibodies.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.

Other features and advantages of the invention, e.g., enhancing immune responses in mammalian subjects, will be apparent from the following description, from the drawings and from the claims.

Brief Description of the Drawings

Figs. 1A-1F are photomicrographs showing monocyte spreading and T cell clustering after a 48 hr incubation of peripheral blood mononuclear cells (PBMC) with various concentrations of purified, natural soluble attractin-1. PBMC were incubated with no soluble attractin-1 (Fig. 1A) or soluble attractin-1 at a concentration of 0.5 µg/ml (Fig. 1B), 1 µg/ml (Fig. 1C), 2 µg/ml (Fig. 1D), 5 µg/ml

- 11 -

(Fig. 1E), or 10 μ g/ml (Fig. 1F). Figs. 1G-1I are photomicrographs of cells from cultures to which soluble attractin-1 (10 μ g/ml) had been added. The cells in the cultures, which were incubated for 48 hours, were PBMC
5 separated into E⁺ T lymphocytes (Fig. 1G), E⁻ monocytes/B cells (Fig. 1H), and E⁺ T lymphocytes remixed with E⁻ monocytes/B cells (Fig. 1I).

Fig. 2 is a depiction of the amino acid sequence of soluble attractin-1 (SEQ ID NO:2). The sequences
10 identified by N-terminal sequencing of tryptic and chymotryptic peptides are underlined.

Figs. 3A-3B are photographs showing attractin mRNA expression in Northern blots of multiple tissue mRNA (Fig. 3A) and resting and PHA-activated PBMC total RNA
15 (Fig. 3B). Fig. 3C is a photograph showing an ethidium bromide stained electrophoretic gel of 3,164 bp attractin DNA fragments obtained by PCR using three independent cDNA libraries as sources of templates.

Figs. 4A-4C are diagrams showing the organization
20 of soluble attractin-1 cDNA and peptide domains. Fig. 4A is a diagram of soluble attractin-1 cDNA. The bases shown in upper case at the origin represent bases satisfying the Kozak consensus. Fig. 4B shows a comparison of soluble attractin-1 protein domains and
25 motifs with those of *C. elegans* F33C8.1 protein. The horizontal bars depict the position of cysteines shared by both sequences. Fig. 4C shows a comparison of the putative catalytic serine motif of soluble attractin-1 with the catalytic serine motifs of other serine
30 proteases. The shaded box indicates agreement with the consensus, '#' or exclusion from the shaded boxes indicates conflict, and 'X' indicates satisfaction by any amino acid. The parentheses enclose amino acids any of which would satisfy the consensus.

- 12 -

Figs. 5A-5D are photomicrographs showing the intracellular localization of glycosylated soluble attractin-1 by immunogold electron microscopy using rabbit polyclonal antibody specific for soluble attractin-1; in resting T lymphocyte with no evidence of soluble attractin-1 expression (Fig. 5A); in T cells activated for 48 hr with PHA and in which, soluble attractin-1 is expressed in large vacuoles (Fig. 5B); in vesicles in which soluble attractin-1 localizes in an electron dense core (Fig. 5C); and in vesicles containing soluble attractin-1 breaking open at the cell surface, releasing soluble attractin-1 (Fig. 5D).

Figs. 6A-6C are photographs showing expression of recombinant soluble attractin-1 and immunoprecipitation by antibody specific for natural soluble attractin-1. Fig. 6A shows a photograph of an SDS-PAGE gel of soluble attractin-1 transcribed and translated *in vitro* in the absence or presence of glycosyl transferases. Fig. 6B is a photograph of a Western blot (developed with antibody specific for myc) of lysates of 293T cells transiently-transfected with pSecTag2B-soluble attractin-1 or pSecTag2B vector control. Fig. 6C shows a photograph of an SDS-PAGE gel of soluble attractin-1 precipitated with pre-immune serum or polyclonal antibody specific for soluble attractin from lysates of CHO cells stably transfected with pSecTag2B-attractin.

Figs. 7A-7D are photomicrographs showing that recombinant soluble attractin-1 mediates monocyte/macrophage spreading and T cell clustering. Resting PBMC were incubated for 48 hr without soluble attractin-1 (Fig. 7A) or with soluble attractin-1 at a concentration of 1 μ g/ml (Fig. 7B), 2 μ g/ml (Fig. 7C), or 5 μ g/ml (Fig. 7D).

Fig. 8 is a depiction of the nucleotide sequence of soluble attractin-1 cDNA (SEQ ID NO:1).

- 13 -

Fig. 9 is a depiction of the amino acid sequence of membrane attractin-1 (SEQ ID NO:10).

Fig. 10 is a depiction of the nucleotide sequence of membrane attractin-1 encoding cDNA (SEQ ID NO:11).

5 Fig. 11 is a depiction of the amino acid sequence of soluble attractin-2 (SEQ ID NO:18).

Fig. 12 is a depiction of the nucleotide sequence of soluble attractin-2 encoding cDNA (SEQ ID NO:19).

10 Fig. 13 is a depiction of the amino acid sequence of membrane attractin-2 (SEQ ID NO:12).

Fig. 14 is a depiction of the nucleotide sequence of membrane attractin-2 encoding cDNA (SEQ ID NO:13).

Fig. 15 is a series of fluorescence flow cytometric histograms showing the expression of MHC class I, MHC class II, B7.1, B7.2, CD11a, CD29, CD54, and CD58 molecules on the surface of total peripheral blood leukocytes ("All"), lymphocytes ("Lymph"), and monocytes ("Mono"), prior to culture ("DO"), and after a 72 hr incubation of peripheral blood leukocytes with either recombina

20 nt soluble attractin-1 ("X") or granulocyte macrophage colony-stimulating factor ("GM-CSF").

Description of the Invention

The invention is based, in part, on the cloning of cDNA molecules encoding different overlapping regions of human soluble attractin-1, membrane attractin-1, soluble attractin-2, and membrane attractin-2. Contrary to initial indications when soluble attractin-1 was first studied, It was determined that there is no significant amino acid sequence homology between attractin and CD26, or any other characterized human protein. Both purified serum-derived and recombinant soluble attractin-1 induce the spreading of macrophages and monocytes that become the focus for the clustering of non-proliferating T lymphocytes. T lymphocytes use soluble attractin-1, at least, to marshall together the cells required to form a

35

- 14 -

cluster of co-operating immune cells. Since membrane attractin-1 and the putative attractin-2 molecules contain all the functional domains of soluble attractin, it is likely that they have similar activity. Thus,
5 attractin has an important role in the regulation of the immune response.

The various forms of attractin are encoded by alternatively spliced mRNA molecules transcribed from a single gene. The 134-kDa soluble attractin-1 protein
10 includes a putative serine protease catalytic serine at amino acid residue 26, four EGF-like motifs, a CUB domain, a C-type lectin domain and a domain homologous with the ligand-binding region of the common cytokine receptor γ chain (Fig. 4C). Except for the latter two
15 domains, the overall structure shares high homology with the *C. elegans* F33C8.1 protein, suggesting that attractin has evolved new domains and functions in parallel with the development of cell-mediated immunity. Membrane attractin-1 contains all these domains and, in addition,
20 C-terminal transmembrane and cytoplasmic domains. Furthermore, attractin-2 has a 74 amino acid insertion, immediately after amino acid residue 30 of attractin-1. This insertion is likely to be important as a glycosylation targeting motif (e.g., a Golgi-targeting
25 motif.

The experiments described in Examples 2, 5, and 10 below show that soluble attractin-1 mediates an interaction between T lymphocytes and monocytes, leading to adherence and spreading of the monocytes which become
30 a focus for T lymphocyte clustering. No difference was observed in attractin mRNA expression between resting and activated PBMC, indicating that a regulatory step exists between transcription and glycosylation rather than in induction of *de novo* mRNA synthesis. Despite extensive
35 N-glycosylation of the isolated serum (soluble)

- 15 -

attractin, there are no consensus signal sequences encoded in the cDNA sequences encoding attractin. Another protein may chaperone attractin through the Golgi complex and endoplasmic reticulum. However, several
5 proteins are known to be secreted without a signal peptide, including FGF-9 [Miyamoto et al. (1993) *Mol. Cell. Biol.* 13, 4251-4259], IL1- α and β [Rubartelli et al. (1990) *EMBO J.* 9, 1503-1510], FGF-1 [Tarantini et al. (1995) *J. Biol. Chem.* 270, 29039-29042], FGF-2 [Mignatti
10 et al. (1992) *J. Cell. Physiol.* 151, 81-93], and platelet-derived endothelial cell growth factor [Mignatti et al. (1992) *J. Cell. Physiol.* 151, 81-93]. This has led to the proposal of alternative secretory pathways with slow exocytic release from large cytoplasmic pools
15 [Rubartelli et al. (1997) In *Unusual Secretory Pathways: from Bacteria to Man*, eds. Kuchler et al. (R.G. Landes Co., Austin, TX), pp. 87-114]. The electron microscopy results described above confirm that the early activated T lymphocyte secretion of soluble attractin, at least,
20 results from vesicular release at the plasma membrane.

Expression of attractin on the surface of activated T cells could involve any of the forms of the protein described herein. Thus, for example, surface could be the membrane form of attractin (-1 or -2) bound
25 via its transmembrane domain to the T cell membrane. Alternatively, it could be soluble attractin (-1 or -2) that has been secreted into the milieu of the T cell and then binds via a cell-surface receptor, or via a non-specific hydrophobic interaction, to the T cell. In
30 addition, attractin on the T cell could be soluble attractin (-1 or -2) that is in transit from the cytoplasm to the exterior of the T cell. The invention is not limited by any particular mechanism of T cell surface expression of attractin.

- 16 -

Proteins, such as attractin, containing EGF-like motifs are usually involved in extracellular signalling or cell guidance [Davis, C.G. (1990) *New Biol.* 2, 410-419]. Attractin also contains a motif representing the
5 ligand-binding region of the cytokine receptor common γ chain [D'Andrea et al. (1990) *Curr. Opin. Cell Biol.* 2, 648-651]. In overall structure and organization of domains, attractin most closely resembles the CUB-containing protein BMP1 (bone morphogenic protein-1)
10 which influences cell interactions during development [Li et al. (1996) *Proc. Natl. Acad. Sci. USA* 93, 5127-5130]. The acronym "CUB" derives from the names of the three prototypic proteins (complement component-1 r/s (C1r/s), U-EGF (epidermal growth factor), and BMP-1). The C-type
15 lectin domain recognizes carbohydrate and is characteristic of the selectin family of proteins involved in adhesion of leukocytes to vascular endothelia. This domain is also characteristic of proteins involved in endocytosis for antigen processing
20 in macrophages and dendritic cells [Weis et al. (1996) *Ann. Rev. Biochem.* 65, 441-473].

There is a high level of identity between attractin and the 143 kDa *C. elegans* F33C8.1 protein. The potential γ -chain ligand binding motif and C-type
25 lectin domain present in attractin are missing in the *C. elegans* transcript, suggesting an evolutionary development in which the human form incorporated these new domains in parallel with the development of cell-mediated immunity.

30 Like CD26, soluble attractin-1 alone is unable to induce cell proliferation, but is able to enhance the proliferative response of PBL to recall antigens such as tetanus toxoid [Duke-Cohan et al. (1995) *J. Biol. Chem.* 270, 14107-14114; Duke-Cohan et al. (1996) *J. Immunol.*
35 156, 1714-1721]. Therefore, it appears that soluble

- 17 -

attractin-1, and indeed the other attractin molecules described herein, modulate the interaction between T cells and macrophages and monocytes, permitting more rapid and/or more effective antigen presentation. It is likely that the minimal immunoregulatory unit consists of an antigen-presenting cell which acts as a focus for a cluster of T helper cells and effector cells [Stuhler et al. (1997) *Proc. Natl. Acad. Sci. USA* 94, 622-627]. The association of the three cell types is neither simultaneous nor random. Rather, the antigen-presenting cell clusters first with the helper T cells, and this cluster acts as a focus for recognition by effector cells [Ridge et al. (1998) *Nature* 393, 474-478]. In the absence of antigen, no proliferation occurs in soluble attractin-1-induced clusters of monocytes and T cells, but if a recall antigen such as tetanus toxoid is present, the clustering of cells maximizes the potential response to the antigen. Attractin may regulate local cytokine activity, either by influencing binding and presentation or by proteolytic modification. Soluble attractin-1 has recently been shown to cleave an N-terminal dipeptide which converts full-length RANTES 1-68 (consisting of amino acid residues 1-68), a potent monocyte chemoattractant, to RANTES 3-68 (consisting of residues 3-68), an equally potent inhibitor of monocyte chemotaxis [Proost et al. (1998) *J. Biol. Chem.* 273, 7222-7227]. Soluble attractin-1 has also been found to bind to macrophages and monocytes. It is possible that it is via this binding that attractin, in any of its forms, may regulate the activity of macrophages and monocytes. It could, for example, provide one of two or more requisite signals necessary for the induction of spreading and subsequent enhanced T-cell clustering. Alternatively, it could complement binding of another molecule to a receptor on macrophages/monocytes.

- 18 -

Furthermore, it could form a bridge between T cells and macrophages/monocytes. Since membrane attractin (-1 and -2) has a cytoplasmic domain, it is likely that binding of a putative ligand to an extracellular region of
5 membrane attractin results in signalling to the T cell. It should be understood, however, that the instant invention is not limited by a particular mechanism of action. The concatenation in attractin of domains related to regulation of cell interactions together with
10 domains related to lymphokine/cytokine binding, the rapid upregulation of attractin cell surface expression by activated T cells, and the clear effect upon T cell-monocyte/macrophage association all suggest that attractin, either as a normal circulating serum protein
15 or as a membrane bound protein, plays a significant role in the immune response *in vivo*.

Attractin Nucleic Acid Molecules

The attractin nucleic acid molecules of the invention can be cDNA, genomic DNA, synthetic DNA, or
20 RNA, and can be double-stranded or single-stranded (*i.e.*, either a sense or an antisense strand). Segments of these molecules are also considered within the scope of the invention, and can be produced, for example, by the polymerase chain reaction (PCR) or generated by treatment
25 with one or more restriction endonucleases. A ribonucleic acid (RNA) molecule can be produced by *in vitro* transcription. Preferably, the nucleic acid molecules encode polypeptides that, regardless of length, are soluble under normal physiological conditions the
30 membrane forms would not be soluble.

The nucleic acid molecules of the invention can contain naturally occurring sequences, or sequences that differ from those that occur naturally, but, due to the degeneracy of the genetic code, encode the same

- 19 -

polypeptide (for example, the polypeptides with SEQ ID NOS:2, 10, 12, and 18). In addition, these nucleic acid molecules are not limited to coding sequences, e.g., they can include some or all of the non-coding sequences that lie upstream or downstream from a coding sequence.

The nucleic acid molecules of the invention can be synthesized (for example, by phosphoramidite-based synthesis) or obtained from a biological cell, such as the cell of a mammal. Thus, the nucleic acids can be those of a human, non-human primate (e.g., monkey) mouse, rat, guinea pig, cow, sheep, horse, pig, rabbit, dog, or cat.

In addition, the isolated nucleic acid molecules of the invention encompass segments that are not found as such in the natural state. Thus, the invention encompasses recombinant nucleic acid molecules, (for example, isolated nucleic acid molecules encoding any of the forms of attractin described herein) incorporated into a vector (for example, a plasmid or viral vector) or into the genome of a heterologous cell (or the genome of a homologous cell, at a position other than the natural chromosomal location). Recombinant nucleic acid molecules and uses therefor are discussed further below.

Certain nucleic acid molecules of the invention are antisense molecules or are transcribed into antisense molecules. These can be used, for example, to down-regulate translation of attractin mRNA within a cell.

Techniques associated with detection or regulation of genes are well known to skilled artisans and such techniques can be used to diagnose and/or treat disorders associated with aberrant attractin expression. Nucleic acid molecules of the invention are discussed further below in the context of their therapeutic utility.

An attractin family gene or protein can be identified based on its similarity to the relevant

- 20 -

attractin gene or protein, respectively. For example, the identification can be based on sequence identity. The invention features isolated nucleic acid molecules which are at least 50% (or 55%, 65%, 75%, 85%, 95%, or 98%) identical to: (a) a nucleic acid molecule that encodes the polypeptide of SEQ ID NO:2, 10, 12, or 18; (b) the nucleotide sequence of SEQ ID NO:1, 11, 13, or 19; or (c) a nucleic acid molecule which includes a segment of at least: (i) 30 (e.g., at least 50, 60, 100, 125, 150, 175, 200, 250, 300, 325, 350, 375, 400, 425, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 2000, 3000, or 3540) nucleotides of SEQ ID NO:1; (ii) 30 (e.g., at least 50, 60, 100, 125, 150, 175, 200, 250, 300, 325, 350, 375, 400, 425, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 2000, 3000, 4000, or 4050) nucleotides of SEQ ID NO:11; (iii) 30 (e.g., at least 50, 60, 100, 125, 150, 175, 200, 250, 300, 325, 350, 375, 400, 425, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 2000, 3000, 4000, or 4250) nucleotides of SEQ ID NO:13; or (iv) 30 (e.g., at least 50, 60, 100, 125, 150, 175, 200, 250, 300, 325, 350, 375, 400, 425, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 2000, 3000, or 3800) nucleotides of SEQ ID NO:19. The invention also features nucleic acid molecules which include a nucleotide sequence encoding a polypeptide that is at least 65% (e.g., at least 70%, 75%, 85%, 95%, or 98%) identical to the amino acid sequence of SEQ ID NO:2, 10, 12, or 18.

The determination of percent identity between two sequences is accomplished using the mathematical algorithm of Karlin and Altschul, *Proc. Natl. Acad. Sci. USA* 90, 5873-5877, 1993. Such an algorithm is incorporated into the BLASTN and BLASTP programs of Altschul et al. (1990) *J. Mol. Biol.* 215, 403-410. BLAST nucleotide searches are performed with the BLASTN program, score = 100, wordlength = 12 to obtain

- 21 -

nucleotide sequences homologous to attractin-encoding nucleic acids. BLAST protein searches are performed with the BLASTP program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to attractin. To obtain
5 gapped alignments for comparative purposes, Gapped BLAST is utilized as described in Altschul et al. (1997) *Nucleic Acids Res.* 25, 3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) are used
10 (See <http://www.ncbi.nlm.nih.gov>).

Hybridization can also be used as a measure of homology between two nucleic acid sequences. An attractin-encoding nucleic acid sequence, or a portion thereof, can be used as hybridization probe according to
15 standard hybridization techniques. The hybridization of an attractin probe to DNA from a test source (e.g., a mammalian cell) is an indication of the presence of attractin DNA in the test source. Hybridization conditions are known to those skilled in the art and can
20 be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y., 6.3.1-6.3.6, 1991. Moderate hybridization conditions are defined as equivalent to hybridization in 2X sodium chloride/sodium citrate (SSC) at 30°C, followed by one or more washes in 1 X SSC, 0.1%
25 SDS at 50-60°C. Highly stringent conditions are defined as equivalent to hybridization in 6X sodium chloride/sodium citrate (SSC) at 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C.

The invention also encompasses: (a) vectors that
30 contain any of the foregoing attractin-related coding sequences and/or their complements (that is, "antisense" sequence); (b) expression vectors that contain any of the foregoing attractin-related coding sequences operatively associated with any transcriptional/translational
35 regulatory elements (examples of which are given below)

- 22 -

necessary to direct expression of the coding sequences;
(c) expression vectors containing, in addition to
sequences encoding an attractin polypeptide, nucleic acid
sequences that are unrelated to nucleic acid sequences
5 encoding attractin, such as molecules encoding a
reporter, marker, or a signal peptide, e.g., fused to
attractin; and (d) genetically engineered host cells that
contain any of the foregoing expression vectors and
thereby express the nucleic acid molecules of the
10 invention.

Recombinant nucleic acid molecules can contain a
sequence encoding a soluble attractin membrane attractin,
or attractin having an heterologous signal sequence. The
full length attractin polypeptide, a domain of attractin,
15 or a fragment thereof may be fused to additional
polypeptides, as described below. Similarly, the nucleic
acid molecules of the invention can encode the mature
form of attractin or a form that includes an exogenous
polypeptide which facilitates secretion.

20 The transcriptional/translational regulatory
elements referred to above and which are further
described below, include, but are not limited to,
inducible and non-inducible promoters, enhancers,
operators and other elements, which are known to those
25 skilled in the art, and which drive or otherwise regulate
gene expression. Such regulatory elements include but
are not limited to the cytomegalovirus hCMV immediate
early gene, the early or late promoters of SV40
adenovirus, the lac system, the trp system, the TAC
30 system, the TRC system, the major operator and promoter
regions of phage A, the control regions of fd coat
protein, the promoter for 3-phosphoglycerate kinase, the
promoters of acid phosphatase, and the promoters of the
yeast α -mating factors.

35 Similarly, the nucleic acid can form part of a

- 23 -

hybrid gene encoding additional polypeptide sequences, for example, sequences that function as a marker or reporter. Examples of marker or reporter genes include β -lactamase, chloramphenicol acetyltransferase (CAT),

5 adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo^r , $G418^r$), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), lacZ (encoding β -galactosidase), and

10 xanthine guanine phosphoribosyltransferase (XGPRT). As with many of the standard procedures associated with the practice of the invention, skilled artisans will be aware of additional useful reagents, for example, additional sequences that can serve the function of a marker or

15 reporter. Generally, the hybrid polypeptide will include a first portion and a second portion; the first portion being an attractin polypeptide and the second portion being, for example, the reporter described above or an immunoglobulin constant region.

The expression systems that may be used for

20 purposes of the invention include, but are not limited to, microorganisms such as bacteria (for example, *E. coli* and *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors containing the nucleic acid molecules of the

25 invention; yeast (for example, *Saccharomyces* and *Pichia*) transformed with recombinant yeast expression vectors containing the nucleic acid molecules of the invention (preferably containing the nucleic acid sequence encoding attractin (contained within SEQ ID NOS:2, 10, 12, or 18);

30 insect cell systems infected with recombinant virus expression vectors (for example, baculovirus) containing the nucleic acid molecules of the invention; plant cell systems infected with recombinant virus expression

35 tobacco mosaic virus (TMV)) or transformed with

- 24 -

recombinant plasmid expression vectors (for example, Ti plasmid) containing attractin nucleotide sequences; or mammalian cell systems (for example, COS, CHO, BHK, 293, VERO, HeLa, MDCK, WI38, and NIH 3T3 cells) harboring
5 recombinant expression constructs containing promoters derived from the genome of mammalian cells (for example, the metallothionein promoter) or from mammalian viruses (for example, the adenovirus late promoter and the vaccinia virus 7.5K promoter). Also useful as host cells
10 are primary or secondary cells obtained directly from a mammal, transfected with a plasmid vector or infected with a viral vector.

Polypeptides and Polypeptide Fragments

The polypeptides of the invention include soluble
15 attractin-1 and -2, membrane attractin-1 and -2, and functional fragments of these polypeptides. The polypeptides embraced by the invention also include fusion proteins which contain either full-length attractin (any of the forms) or a functional fragment of
20 it fused to unrelated amino acid sequence. The unrelated sequences can be additional functional domains or signal peptides. Signal peptides are described in greater detail and exemplified below.

The polypeptides can be purified from natural
25 sources (e.g., blood, serum plasma, tissues or cells such as T cells or any cell that naturally produces attractin). Smaller peptides (less than 50 amino acids long) can also be conveniently synthesized by standard chemical means. In addition, both polypeptides and
30 peptides can be produced by standard *in vitro* recombinant DNA techniques and *in vivo* recombination/genetic recombination (e.g., transgenesis), using the nucleotide sequences encoding the appropriate polypeptides or peptides. Methods well known to those skilled in the art

- 25 -

can be used to construct expression vectors containing relevant coding sequences and appropriate transcriptional/translational control signals. See, for example, the techniques described in Sambrook et al.,

- 5 Molecular Cloning: A Laboratory Manual (2nd Ed.) [Cold Spring Harbor Laboratory, N.Y., 1989], and Ausubel et al., Current Protocols in Molecular Biology, [Green Publishing Associates and Wiley Interscience, N.Y., 1989].

- 10 Polypeptides and fragments of the invention also include those described above, but modified for *in vivo* use by the addition, the amino- and/or carboxyl-terminal ends, of a blocking agent to facilitate survival of the relevant polypeptide *in vivo*. This can be useful in
15 those situations in which the peptide termini tend to be degraded by proteases prior to cellular uptake. Such blocking agents can include, without limitation, additional related or unrelated peptide sequences that can be attached to the amino and/or carboxyl terminal
20 residues of the peptide to be administered. This can be done either chemically during the synthesis of the peptide or by recombinant DNA technology by methods familiar to artisans of average skill.

- Alternatively, blocking agents such as
25 pyroglutamic acid or other molecules known in the art can be attached to the amino and/or carboxyl terminal residues, or the amino group at the amino terminus or carboxyl group at the carboxyl terminus can be replaced with a different moiety. Likewise, the peptides can be
30 covalently or noncovalently coupled to pharmaceutically acceptable "carrier" proteins prior to administration.

- Also of interest are peptidomimetic compounds that are designed based upon the amino acid sequences of the functional peptide fragments. Peptidomimetic compounds
35 are synthetic compounds having a three-dimensional

- 26 -

conformation (i.e., a "peptide motif") that is substantially the same as the three-dimensional conformation of a selected peptide. The peptide motif provides the peptidomimetic compound with the ability to induce macrophage/monocyte spreading in a manner qualitatively identical to that of the attractin functional peptide fragment from which the peptidomimetic was derived. Peptidomimetic compounds can have additional characteristics that enhance their therapeutic utility, such as increased cell permeability and prolonged biological half-life.

The peptidomimetics typically have a backbone that is partially or completely non-peptide, but with side groups that are identical to the side groups of the amino acid residues that occur in the peptide on which the peptidomimetic is based. Several types of chemical bonds, e.g., ester, thioester, thioamide, retroamide, reduced carbonyl, dimethylene and ketomethylene bonds, are known in the art to be generally useful substitutes for peptide bonds in the construction of protease-resistant peptidomimetics.

Methods of Therapy

The methods of the invention involve combining a macrophage/monocyte, an attractin molecule of the invention, and a T cell, in order to induce spreading of macrophages/monocytes. The T cell can be a CD4+ T cell or a CD8+ T cell. The attractin molecule can be added to the solution containing the cells or it can be expressed on the surface of a T cell, e.g., the T cell that is added to the combined attractin and macrophages/monocytes. The methods can be performed *in vitro*, *in vivo*, or *ex vivo*. *In vitro* application of attractin can be useful, for example, in basic scientific studies of immune mechanisms or for production of

- 27 -

macrophages with increased ability to activate T cells for use in studies on macrophage/monocyte function. Furthermore, attractin could be added to *in vitro* assays (e.g., in T cell proliferation assays) designed to test
5 for immunity to an antigen of interest in a subject from which the T cells were obtained. Addition of attractin to such assays would be expected to result in a more potent, and therefore more readily detectable, *in vitro* response. However, the methods of the invention will
10 preferably be *in vivo* or *ex vivo* (see below).

The attractin proteins and variants thereof are generally useful as immune response-stimulating therapeutics, as described in International Application No. WO 96/38550 (published December 5, 1996), which is
15 incorporated by reference herein in its entirety. For example, the polypeptides of the invention can be used for treatment of disease conditions characterized by immunosuppression: e.g., cancer, AIDS or AIDS-related complex, other virally or environmentally-induced
20 conditions, and certain congenital immune deficiencies. The compounds may also be employed to increase immune function that has been impaired by the use of radiotherapy of immunosuppressive drugs such as certain chemotherapeutic agents, and therefore are particularly
25 useful when given in conjunction with such drugs or radiotherapy. These methods of the invention can be applied to a wide range of species, e.g., humans, non-human primates, horses, cattle, pigs, sheep, goats, dogs, cats, rabbits, quinea pigs, hamsters, rats, and mice.

30 In Vivo Approaches

In one *in vivo* approach, the attractin polypeptide (or a functional fragment thereof) itself is administered to the subject. Generally, the compounds of the invention will be suspended in a pharmaceutically-

- 28 -

acceptable carrier (e.g., physiological saline) and administered orally or by intravenous infusion, or injected subcutaneously, intramuscularly, intraperitoneally, intrarectally, intravaginally, intranasally, intragastrically, intratracheally, or intrapulmonarily. They are preferably delivered directly to an appropriate lymphoid tissue (e.g. spleen, lymph node, or mucosal-associated lymphoid tissue (MALT)). The dosage required depends on the choice of the route of administration, the nature of the formulation, the nature of the patient's illness, the subject's size, weight, surface area, age, and sex, other drugs being administered, and the judgment of the attending physician. Suitable dosages are in the range of 0.01-100.0 $\mu\text{g/kg}$. Wide variations in the needed dosage are to be expected in view of the variety of polypeptides and fragments available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by i.v. injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization as is well understood in the art. Administrations can be single or multiple (e.g., 2- or 3-, 4-, 6-, 8-, 10-, 20-, 50-, 100-, 150-, or more fold). Encapsulation of the polypeptide in a suitable delivery vehicle (e.g., polymermic microparticles or implantable devices) may increase the efficiency of delivery, particularly for oral delivery.

Alternatively, a polynucleotide containing a nucleic acid sequence encoding the attractin polypeptide or functional fragment can be delivered to an appropriate cell of the animal. Expression of the coding sequence will preferably be directed to lymphoid tissue of the subject by, for example, delivery of the polynucleotide

- 29 -

to the lymphoid tissue. This can be achieved by, for example, the use of a polymeric, biodegradable microparticle or microcapsule delivery vehicle, sized to optimize phagocytosis by phagocytic cells such as
5 macrophages. For example, PLGA (poly-lacto-co-glycolide) microparticles approximately 1-10 μm in diameter can be used. The polynucleotide is encapsulated in these microparticles, which are taken up by macrophages and gradually biodegraded within the cell, thereby releasing
10 the polynucleotide. Once released, the DNA is expressed within the cell. A second type of microparticle is intended not to be taken up directly by cells, but rather to serve primarily as a slow-release reservoir of nucleic acid that is taken up by cells only upon release from the
15 micro-particle through biodegradation. These polymeric particles should therefore be large enough to preclude phagocytosis (i.e., larger than 5 μm and preferably larger than 20 μm). Microparticles useful for nucleic acid delivery, methods for making them, and methods of use are
20 described in greater detail in U.S. Patent No. 5,783,567, incorporated herein by reference in its entirety.

Another way to achieve uptake of the nucleic acid is using liposomes, prepared by standard methods. The vectors can be incorporated alone into these delivery
25 vehicles or co-incorporated with tissue-specific antibodies. Alternatively, one can prepare a molecular conjugate composed of a plasmid or other vector attached to poly-L-lysine by electrostatic or covalent forces. Poly-L-lysine binds to a ligand that can bind to a
30 receptor on target cells [Cristiano et al. (1995), *J. Mol. Med.* 73, 479]. Alternatively, lymphoid tissue specific targeting can be achieved by the use of lymphoid tissue-specific transcriptional regulatory elements (TRE) such as a B lymphocyte, T lymphocyte, or dendritic cell
35 specific TRE. Lymphoid tissue specific TRE are known

- 30 -

[Thompson et al. (1992), *Mol. Cell. Biol.* 12, 1043-1053; Todd et al. (1993), *J. Exp. Med.* 177, 1663-1674; Penix et al. (1993), *J. Exp. Med.* 178, 1483-1496]. Delivery of "naked DNA" (i.e., without a delivery vehicle) to an intramuscular, intradermal, or subcutaneous site, is another means to achieve *in vivo* expression.

In the relevant polynucleotides (e.g., expression vectors) the nucleic acid sequence encoding the attractin polypeptide or functional fragment of interest with an initiator methionine and optionally a targeting sequence is operatively linked to a promoter or enhancer-promoter combination.

Short amino acid sequences can act as signals to direct proteins to specific intracellular compartments. For example, hydrophobic signal peptides (e.g., MAISGVPLGFFIIAVLMSAQESWA (SEQ ID NO:14)) are found at the amino terminus of proteins destined for the ER. While the sequence KFERQ (SEQ ID NO:15) (and other closely related sequences) is known to target intracellular polypeptides to lysosomes, other sequences (e.g., MDDQRDLISNNEQLP (SEQ ID NO:16) direct polypeptides to endosomes. In addition, the peptide sequence KDEL (SEQ ID NO:17) has been shown to act as a retention signal for the ER. Each of these signal peptides, or a combination thereof, can be used to traffic the attractin polypeptides or functional fragments of the invention as desired. DNAs encoding the attractin polypeptides or functional fragments containing targeting signals will be generated by PCR or other standard genetic engineering or synthetic techniques. Targeting sequences are described in greater detail in U.S. Patent No. 5,827,516, incorporated herein by reference in its entirety.

A promoter is a TRE composed of a region of a DNA molecule, typically within 100 basepairs upstream of the point at which transcription starts. Enhancers provide

- 31 -

expression specificity in terms of time, location, and level. Unlike a promoter, an enhancer can function when located at variable distances from the transcription site, provided a promoter is present. An enhancer can
5 also be located downstream of the transcription initiation site. To bring a coding sequence under the control of a promoter, it is necessary to position the translation initiation site of the translational reading frame of the peptide or polypeptide between one and about
10 fifty nucleotides downstream (3') of the promoter. The coding sequence of the expression vector is operatively linked to a transcription terminating region.

Suitable expression vectors include plasmids and viral vectors such as herpes viruses, retroviruses,
15 vaccinia viruses, attenuated vaccinia viruses, canary pox viruses, adenoviruses and adeno-associated viruses, among others.

Polynucleotides can be administered in a pharmaceutically acceptable carrier. Pharmaceutically
20 acceptable carriers are biologically compatible vehicles which are suitable for administration to a human, e.g., physiological saline. A therapeutically effective amount is an amount of the polynucleotide which is capable of producing a medically desirable result in a treated
25 animal. As is well known in the medical arts, the dosage for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs
30 being administered concurrently. Dosages will vary, but a preferred dosage for administration of polynucleotide is from approximately 10^6 to 10^{12} copies of the polynucleotide molecule. This dose can be repeatedly administered, as needed. Routes of administration can be
35 any of those listed above.

- 32 -

Ex Vivo Approaches

Peripheral blood leukocytes can be withdrawn from the patient or a suitable donor and treated ex vivo with the attractin protein or polypeptide fragment (whether in
5 soluble form or attached to a solid support by standard methodologies). The leukocytes containing newly-activated monocytes are then introduced into the same or a different patient.

An alternative ex vivo strategy can involve
10 transfecting or transducing cells obtained from the subject with a polynucleotide encoding an attractin polypeptide or functional fragment-encoding nucleic acid sequences described above. The transfected or transduced cells are then returned to the subject. While such cells
15 would preferably be lymphoid cells, they could also be any of a wide range of types including, without limitation, fibroblasts, bone marrow cells, macrophages, monocytes, dendritic cells, epithelial cells, endothelial cells, keratinocytes, or muscle cells in which they act
20 as a source of the attractin polypeptide or functional fragment for as long as they survive in the subject. The use of lymphoid cells would be particularly advantageous in that such cells would be expected to home to lymphoid tissue (e.g., lymph nodes or spleen) and thus the
25 attractin polypeptide or functional fragment would be produced in high concentration at the site where they exert their effect, i.e., enhancement of an immune response. In addition, if T cells are used, the T cell expressing the exogenous attractin molecule can be the
30 T cell that is required, together with attractin, to induce spreading and activation of macrophages or monocytes. The attractin can be secreted by the T cell or expressed on the surface of the T cell. The same genetic constructs and trafficking sequences described

- 33 -

for the *in vivo* approach can be used for this *ex vivo* strategy.

The *ex vivo* methods include the steps of harvesting cells from a subject, culturing the cells, transducing them with an expression vector, and maintaining the cells under conditions suitable for expression of the attractin polypeptide or functional fragment. These methods are known in the art of molecular biology. The transduction step is accomplished by any standard means used for *ex vivo* gene therapy, including calcium phosphate, lipofection, electroporation, viral infection, and biolistic gene transfer. Alternatively, liposomes or polymeric microparticles can be used. Cells that have been successfully transduced are then selected, for example, for expression of the coding sequence or of a drug resistance gene. The cells may then be lethally irradiated (if desired) and injected or implanted into the patient.

20 Methods of Screening for Compounds that Inhibit or Enhance Immune Responses.

The invention provides methods for testing compounds (small molecules or macromolecules) that inhibit or enhance an immune response. Such a method could involve, e.g., culturing macrophages or monocytes with: (a) any of the attractin molecules of the invention, (b) T cells; and (c) a candidate compound. The attractin molecule can be in solution or membrane bound (e.g., expressed on the surface of the T cells) and it can be natural or recombinant. Furthermore, it can be a functional fragment of an attractin molecule. Compounds that inhibit macrophage or monocyte spreading will likely be compounds that inhibit an immune response

- 34 -

while those that enhance macrophage and monocyte spreading will likely be compounds that enhance an immune response. Instead of testing for an effect of a compound on macrophage or monocyte spreading, the ability of the
5 compound to inhibit or enhance induction of B7.1 or MHC class II molecule expression on the macrophage could also be measured.

The invention also relates to using attractin or functional fragments thereof to screen for
10 immunomodulatory compounds that can interact with attractin. One of skill in the art would know how to use standard molecular modeling or other techniques to identify small molecules that would bind to the unique sites of attractin described herein. On such example is
15 provided in Broughton (1997) Curr. Opin. Chem. Biol. 1, 392-398.

A candidate compound whose presence requires at least 1.5-fold (e.g., 2-fold, 4-fold, 6-fold, 10-fold, 150-fold, 1000-fold, 10,000-fold, or 100,000-fold) more
20 attractin in order to achieve macrophage or monocyte spreading than in the absence of the compound can be useful for inhibiting an immune response. On the other hand, a candidate compound whose presence requires at least 1.5 fold (e.g., 2-fold, 4-fold, 6-fold, 10-fold,
25 100-fold, 1000-fold, 10,000 fold, or 100,000-fold) less attractin to achieve macrophage or monocyte spreading than in the absence of the compound can be useful for enhancing an immune response. Compounds capable of interfering with or modulating attractin function are
30 good candidates for immunosuppressive immunoregulatory agents, e.g., to modulate an autoimmune response or suppress allogeneic or xenogeneic graft rejection.

- 35 -

Attractin Antibodies

The invention features antibodies that bind to any or all of the described attractin polypeptides or fragments of such polypeptides. Such antibodies can be
5 polyclonal antibodies present in the serum or plasma of animals (e.g., mice, rabbits, rats, guinea pigs, sheep, horses, goats, cows, or pigs) which have been immunized with the relevant attractin polypeptide or peptide fragment using methods, and optionally adjuvants, known
10 in the art. Such polyclonal antibodies can be isolated from serum or plasma by methods known in the art. Monoclonal antibodies that bind to the above polypeptides or fragments are also embodied by the invention. Methods of making and screening monoclonal antibodies are well
15 known in the art.

Once the desired antibody-producing hybridoma has been selected and cloned, the resultant antibody can be produced in a number of methods known in the art. For example, the hybridoma can be cultured *in vitro* in a
20 suitable medium for a suitable length of time, followed by the recovery of the desired antibody from the supernatant. The length of time and medium are known or can be readily determined.

Additionally, recombinant antibodies specific for
25 attractin, such as chimeric and humanized monoclonal antibodies comprising both human and non-human portions, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example,
30 using methods described in Robinson et al., International Patent Publication PCT/US86/02269; Akira et al., European Patent Application 184,187; Taniguchi, European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., PCT Application
35 WO 86/01533; Cabilly et al., U.S. Patent No. 4,816,567;

- 36 -

Cabilly et al., European Patent Application 125,023;
Better et al. (1988) *Science* 240, 1041-43; Liu et al.
(1987) *J. Immunol.* 139, 3521-26; Sun et al. (1987) *PNAS*
84, 214-18; Nishimura et al. (1987) *Canc. Res.* 47,
5 999-1005; Wood et al. (1985) *Nature* 314, 446-49; Shaw et
al. (1988) *J. Natl. Cancer Inst.* 80, 1553-59; Morrison,
(1985) *Science* 229, 1202-07; Oi et al. (1986)
BioTechniques 4, 214; Winter, U.S. Patent No. 5,225,539;
Jones et al. (1986) *Nature* 321, 552-25; Veroeyan et al.
10 (1988) *Science* 239, 1534; and Beidler et al. (1988) *J.*
Immunol. 141, 4053-60.

Also included within the scope of the present
invention are antibody fragments and derivatives which
contain at least the functional portion of the antigen
15 binding domain of an antibody that binds specifically to
attractin. Antibody fragments that contain the binding
domain of the molecule can be generated by known
techniques. For example, such fragments include, but are
not limited to: F(ab'), fragments which can be produced by
20 pepsin digestion of antibody molecules; Fab fragments
which can be generated by reducing the disulfide bridges
of F(ab'), fragments; and Fab fragments which can be
generated by treating antibody molecules with papain and
a reducing agent. See, e.g., National Institutes of
25 Health, 1 Current Protocols In Immunology, Coligan et
al., ed. §§ 2.8, 2.10 (Wiley Interscience, 1991).
Antibody fragments also include Fv (e.g., single chain Fv
(scFv)) fragments, i.e., antibody products in which there
are no constant region amino acid residues. Such
30 fragments can be produced, for example, as described in
U.S. Patent No. 4,642,334.

The following examples are meant to illustrate,
not limit, the invention.

- 37 -

Example 1. Materials and Methods

Cell techniques: PBMC, erythrocyte rosetting (E⁺) T cells and erythrocyte non-rosetting (E⁻) monocytes/B cells were purified as described previously [Morimoto et al. (1985) *J. Immunol.* 134, 3762-3769]. CHO (dhfr⁻) cells and the Jurkat T cell line were obtained from the American Type Culture Collection (ATCC, Manassas, VA). 293T cells were obtained from Dr. B. Mayer (Children's Hospital, Boston, MA). All cell lines were maintained in RPMI 1640 containing 10% fetal bovine serum. For assessing the biological effects of soluble attractin-1, leukocytes were cultured in serum-free AIM V medium (Life Technologies Inc., Gaithersburg, MD) in 48-well plates (Costar, Cambridge, M). For cell activation, E⁺ lymphocytes (10⁶/ml) supplemented with 0.1% E⁻ cells were incubated in AIM V medium together with phytohemagglutinin (PHA, 1 µg/ml; Murex, Dartford, U.K.) for 48 hr. Cell proliferation was assessed using [³H]-thymidine incorporation as described previously [Duke-Cohan et al. (1995) *J. Biol. Chem.* 270, 14107-14114].

RNA/DNA preparation and analysis: mRNA was isolated using the Poly(A)Pure kit (Ambion, Austin, TX). Northern blots were prepared using standard denaturing formaldehyde agarose electrophoresis techniques and transferred to GeneScreen Plus (NEN-Dupont, Boston, MA). The EST clone R84298 was obtained from the I.M.A.G.E. consortium (Lennon et al. (1996) *Genomics* 33, 151-152) through the ATCC. Both fetal liver cDNA libraries (λgt11 and Marathon cDNA) were obtained from Clontech (Palo Alto, CA). The J5DC T cell library was prepared from 48 hr PHA-activated T lymphocyte mRNA using the Superscript Choice system (Life Technologies Inc.) and ligated into pcDNAI/Amp (Invitrogen, Carlsbad, CA). The GF activated T cell library was prepared and ligated into pCDM8 as described previously [Hall et al. (1996) *Proc.*

- 38 -

Natl. Acad. Sci. USA 93, 11780-11785]. The expression vectors, pRc/CMV and pSecTag2B were obtained from Invitrogen. All labeling of DNA probes with ³²P-dCTP was by random priming (Life Technologies Inc.).

5 **Isolation of cDNA encoding soluble attractin-1:**

Tryptic/chymotryptic peptides were prepared and analyzed as described previously [Duke-Cohan et al. (1995) *J. Biol. Chem.* 270, 14107-14114]. A multiple human hematopoietic tissue Northern blot (Clontech) was
10 screened using the 1.2 kb MfeI/EcoNI R84298 EST. The λgt11-fetal liver library was screened using the 1.3 kb ClaI/HindIII R84298 EST which yielded the pks-43 (4kb) fragment. Hind III digestion of pks-43 released a 5' 982
15 pb fragment which was used to rescreen the fetal liver library and a further 5' sequence, including the putative start codon, was identified (pks-43-1). In order to produce full length recombinant soluble attractin-1, PCR-generated fragments encoding soluble attractin-1 were cloned into the expression vector, pRc/CMV. Using the
20 pks-43-1 as template, a PCR (PCR1) was carried using the following primers: CCCAAGCTTGGGATGGGTGTCGGGCTCAGCCCGC - forward (SEQ ID NO:3) and, ATAAGAATGCGGCGCTAAACTCATTGTTCAGTTTCGACCTG - reverse (SEQ ID NO:4). A second PCR (PCR2) using the pks-43 fragment
25 as template was carried out using the following primers: CCCAAGCTTGGGATGGTGGCCGCAGCGGCGGC - forward, (SEQ ID NO:5) and CCAGGTCCATCTGTCACAAACCCAG - reverse (SEQ ID NO:6). The fragment obtained from PCR1 was digested with HindIII and NaeI and that from PCR2 was digested with NaeI and
30 NotI. The two digested fragments were then cloned together into HindIII/Not-I-digested pRc/CMV. For production of recombinant soluble attractin-1 with disabled start and stop codons into pSecTag2B, a 3.5 kb fragment was amplified from pRc/CMV-attractin using the
35 Advantage GC cDNA PCR system (Clontech) and the primers

- 39 -

GTGCGTGAAGCTTGTACCGGCAACTGAGGCAAGGCTGA - forward (SEQ ID NO:7) and GTAGTTTTTAAGTCCACGTTTGAAGTTCGCCGGCGTGCGTG - reverse (SEQ ID NO:8), digested with Hind II/Not I, and ligated into pSecTag2B.

5 **Expression of functional soluble attractin-1:** The Quick TnT system together with canine microsomal membranes (Promega, Madison, WI) was used for *in vitro* transcription and translation. 293T cells were transfected transiently using pSecTag2B-soluble attractin
10 complexed with Lipofectamine Plus (Life Technologies Inc.) and assayed for soluble attractin-1 expression at 48 hr. For Western blotting experiments, cells were lysed in boiling SDS-PAGE sample buffer (x2) and samples run on SDS-PAGE gels, transferred to nitrocellulose by
15 electroblotting, and the membranes were blocked with Tris-buffered saline containing 0.1% Tween 20 and 1% BSA. Blots were incubated with murine antibody specific for myc (1:5000; Amersham, Arlington Heights, IL) or with a horseradish peroxidase (HRP) monoclonal antibody specific
20 for myc (1:2000; Invitrogen) and detected using the Phototope chemiluminescent system (New England Biolabs). For immunoprecipitation experiments, the cells were solubilized in lysis buffer (1% Triton X-1000, 0.1% NP-40, 150 mM NaCl). Lysates were precleared with mIgG-
25 agarose beads (Sigma) followed by incubation with Protein A-purified polyclonal rabbit antibody specific for soluble attractin or Protein A-purified normal preimmune IgG. Antibody complexes were isolated by incubation with agarose beads conjugated with antibody specific for
30 rabbit IgG (Sigma) followed by boiling in 2x SDS-PAGE loading buffer, after which the procedure was identical with that described for Western transfers above.

For stable transfections, pSecTag2B-soluble attractin-1 was introduced into CHO cells by
35 electroporation (250V, 1600 μ F) using the Cell-Porator

- 40 -

apparatus (Life Technologies) and selection with zeocin (500 $\mu\text{g/ml}$; Invitrogen). To purify recombinant soluble attractin-1, cells were lysed and loaded onto a Talon Superflow metal affinity resin (Clontech) and eluted with 5 250 mM imidazole. DPPIV activity of the recombinant soluble attractin-1 was determined using gly-pro-pNA as substrate as described previously [Duke-Cohan et al. (1995) *J. Biol. Chem.* 270, 14107-14114].

Binding assays: PBMC were activated for 24 hr 10 with PHA in AIM V medium as described above, washed in AIM V and 10^6 cells/100 μl were incubated for 1 hr at 4°C with doubling dilutions of ^{125}I -labeled soluble attractin [Duke-Cohan et al. (1996) *J. Immunol.* 156, 1714-1721], starting at 2 $\mu\text{g/ml}$ (10^7 dpm/ μg). The cells were washed 15 with cold PBS, and the pellet and first wash supernatant were counted by scintillation. Results were analyzed by Scatchard analysis.

Electron microscopy: Cells were prepared as described previously [Xu et al. (1994) *J. Histochem. Cytochem.* 42, 1365-1376] and were analyzed by 20 transmission electron microscopy (model JEM 100 CX II; JEOL, Peabody, MA).

Example 2. Soluble Attractin-1 Binds Strongly to T Cells and Induces Spreading of Monocytes.

25 Purified serum (soluble) attractin-1 had previously been found to enhance the proliferative responses of PBMC to recall antigens such as tetanus toxoid. In the absence of the antigen, the soluble attractin-1 had no effect. Scatchard analysis showed 30 that about 1,000 molecules of soluble attractin-1 bound to the surface of a resting T cell, and about 2,000 molecules to a PHA-activated T cell, with a K_d for both of between 5 and 50 pM which is indicative of a specific, high affinity interaction. To determine whether the

- 41 -

binding of soluble attractin-1 had a functional effect upon cells, a population of PBMC was tested for morphological changes due to the presence or absence of soluble attractin-1. It was found that, within 48 hr of addition to PBMC in serum-free medium, soluble attractin-1 caused spreading of adherent macrophage-like cells, generating long processes to which lymphocytes attached. This process was dose-dependent, with the maximum effect occurring between 5 to 10 μ g/ml soluble attractin-1 (Figs. 1A-1F). Soluble attractin-1 had no effect on E⁺ lymphocytes alone (Fig. 1G) or E⁻ monocytes/B lymphocytes alone (Fig. 1H), but clustering occurred if the E⁺ T and E⁻ populations were combined (Fig. 1I). After non-adherent cells had been washed away, the adherent cells were released by incubation with EDTA in PBS. By using immunofluorescence analysis, it was found that the small adherent cells were exclusively CD3⁺ T cells, while the large adherent cells were predominantly CD14⁺ monocytes/macrophages.

20 Example 3. Cloning of cDNA Encoding Soluble Attractin-1 and Analysis of the Deduced Protein Structure.

Peptide sequences within the soluble attractin-1 polypeptide were identified with a view to cloning cDNA encoding it. Natural soluble attractin-1 was purified to homogeneity and the N-termini of 16 proteolytic peptides (underlined in Fig. 2) were sequenced. One of the sequences (17 amino acids) was 100% identical to part of the derived amino acid sequence of a translated 3' EST sequence (R84298) which codes for 1.9 kb sequence including the 3' end of soluble attractin. By using this sequence as a probe, two mRNA species of 4.4 kb and 8-9 kb were detected, both of which were heavily represented in fetal liver and spleen (Fig. 3A). The larger form was dominant in thymus while the smaller form was dominant in

- 42 -

PBMC. No upregulation of attractin mRNA transcription was observed in activated T cells (Fig. 3B).

Based on mRNA expression, a fetal liver library was screened, and a 982 bp 5' fragment derived from the longest clone (pks43) was used to rescreen the library, leading to identification of a further clone containing additional 5' sequence (pks43-1). Sequencing of both overlapping clones yielded an open reading frame (ORF) of 3.594 kb that encoded all 16 peptides previously identified. PCR amplification of the main body of soluble attractin-1 cDNA from the two activated T cell libraries and from the fetal liver library produced PCR products of the same size, i.e., about 3 kb (Fig. 3C). The nucleotide sequence coding for soluble attractin-1 (SEQ ID NO:2) has been deposited in GenBank and given the accession number AF034957.

The codon encoding the first methionine of soluble attractin-1 is within a consensus Kozak sequence, and the subsequent ORF codes for a 134 kDa protein with 26 potential N-glycosylation sites. Although soluble attractin-1 is heavily glycosylated, no consensus leader sequence/signal peptides could be identified. Several distinct domains and motifs can be identified in the ORF, as depicted in Fig. 4B. These include a serine (Ser-26) within a hybrid of prolyl oligopeptidase and trypsin-like serine protease catalytic motifs (Fig. 4C), an EGF domain (Gly-24 to Gln-54), a CUB domain (His-57 to Phe-173), an EGF domain (Met-175 to Ala-207), the ligand-binding motif of the common γ cytokine chain (Cys-636 to Trp-648), a C-type lectin domain (Ile-713 to Cys-844), and 2 cysteine-rich regions incorporating the C-terminal laminin-like EGF domains (Ala-988 to Lys-1031 and Pro-1034 to Cys 1066). Fragments of soluble attractin-1 containing one or more of these domains are within the invention, as are nucleic acids encoding such fragments.

- 43 -

The only highly significant match at both the nucleotide and amino acid level (31% identity, 45% similarity across the complete 1198 amino acids) is with the nematode F33C8.1 perlecan-like protein, which has an identical organization of the CUB and EGF domains and conserved cysteine positioning suggestive of a similar secondary structure in the two proteins (Fig 4B). In contrast to soluble attractin-1, F33C8.1 does not express the γ chain binding motif or the C-type lectin domain.

10 Soluble attractin-1 appears to be a new member of the CUB domain family of proteins, initially consisting of the complement proteins C1r/C1s, Uegf and BMP-1 [Bork et al. (1993) *Mol. Biol.* 231, 539-545].

15 Example 4. Subcellular Localization and Synthesis of the Soluble Attractin Molecule.

To understand the secretory route followed by soluble attractin-1 in the absence of a signal peptide, we determined the subcellular localization of soluble attractin-1 in resting and activated E⁺ T lymphocytes. No glycosylated soluble attractin-1 could be detected anywhere in resting T cells (Fig. 5A), whereas in T cells activated for 48 hr with PHA, soluble attractin-1 was clearly localized in large vesicular structures (Fig. 5B) that often contained an electron-dense core (Fig. 5C).

25 Vesicles containing soluble attractin-1 were often clustered close to the plasma membrane where they released soluble attractin-1 into the extracellular space (Fig. 5D). Soluble attractin-1-encoding cDNA was cloned into the expression vector pRc/CMV which was transfected in CHO cells. Glycosylated soluble attractin-1 could not be detected in the transfected CHO cells. The post-translational glycosylation of soluble attractin-1 was "forced" by cloning soluble attractin-1 cDNA into the pSecTag2B expression vector which supplies a N-terminal

- 44 -

leader sequence. In an *in vitro* transcription/translation system, pSecTag2B-soluble attractin-1 produced a protein of 134 kDa and in the presence of glycosyl transferases yielded a product of about 180 kDa (Fig. 6A). The correctly sized product was also detected by Western blotting, with antibody specific for myc, of a whole cell lysate of 293T cells transiently transfected with pSecTag2B-soluble attractin-1 (Fig. 6B). The polyclonal antibody specific for soluble attractin immunoprecipitated recombinant soluble attractin-1 from CHO cells stably transfected with pSecTag2B-attractin, confirming that the overall structure of the recombinant protein was similar to that of the purified natural material (Fig. 6C).

15 Example 5. Functional Activities of Recombinant Soluble Attractin-1.

Soluble attractin-1 was isolated from lysates of stably transfected CHO cells. Even with a signal peptide, the recombinant attractin localized intracellularly and was not secreted. The DPPIV enzyme activity of the recombinant protein was 0.42 units/mg, in comparison with 0.79 units/mg for T cell-released soluble attractin-1, 1.78 units/mg for serum attractin, and 4.12 units/mg for recombinant CD26.

25 The PBMC interaction assays depicted in Fig. 1 were repeated using recombinant rather than natural serum-purified soluble attractin-1. This experiment showed that the spreading effect of recombinant soluble attractin-1 on monocytes/macrophages was, as in the experiments with natural serum-purified soluble attractin-1, dose-dependent (Figs. 7A-7D). At a concentration of 5 μ g/ml, the effect was similar to that of 5 μ g/ml natural soluble attractin-1 and thus confirmed the results observed with purified natural soluble

- 45 -

attractin-1. There was a greater tendency for clustering of T cells when the recombinant soluble attractin-1 was used. However, these clusters were not proliferating cells, as indicated by the fact that no increase in [³H]-
5 thymidine incorporation could be detected over background in cultures of PBMC containing recombinant soluble attractin-1.

Example 6. Evidence for Involvement of Attractin in Human Immune Responses.

10 Clinical studies were performed in order to investigate whether attractin plays a role in the human immune system *in vivo*. Common variable immunodeficiency (CVI) is a late-onset primary immunodeficiency affecting either humoral or cellular immunity. The mechanism
15 underlying this disease is still unknown. In a normal immune response, the surface expression of attractin is upregulated during T cell activation. The early signaling events during T cell activation were studied in 11 patients (age range: 7-27 years) affected by CVI to
20 determine if the expression pattern of attractin is different from that of normal individuals. Cell-surface activation markers, including attractin, were evaluated on resting or 24-48 hour CD3-activated T cells by dual color fluorescence. In cells from all patients but one,
25 in contrast to those from normal control subjects, the T cell surface expression of attractin was not upregulated after CD3 crosslinking. The lack of attractin upregulation was selective in that an increase of the other activation markers was observed in the CVI
30 patients.

- 46 -

Example 7. Production of Single Chain Variable Region
Fragment (scFv) Antibodies Specific for Attractin.

Initial efforts to produce murine monoclonal antibodies were unsuccessful, apparently as a direct
5 consequence of the high degree of conservation between
the mouse sequence identified to date and the human
sequence for attractin. To overcome the problem of
antigen conservation across species, techniques have been
developed for cloning antigen-binding regions of V^H and V^L
10 genes from the mRNA of non-immune spleen cells,
connecting the variable regions with a flexible peptide
linker to produce single chain variable region fragments
(scFv). The scFv are then expressed as fusion proteins
with phage coat protein [Sheets et al. (1998) *Proc. Natl.*
15 *Acad. Sci. USA.* 95, 6157-6162] in phage particles. Using
this technique, it is possible to generate repertoires of
 10^7 to 10^{10} scFv variants. The reagents for generating a
library and subsequent enrichment of murine antigen-
specific scFv are now available in kit form from Amersham
20 Pharmacia Biotech.

Three separate libraries are simultaneously
produced from murine spleen cells. The first library is
produced from mRNA of non-immune spleen cells, the second
from spleen cells of mice which have received prior
25 immunization with glycosylated native attractin, and a
third library from spleen cells of mice which have been
immunized with deglycosylated attractin. Messenger RNA
is extracted from the lysed spleen cell populations by
hybridization to oligo dT cellulose and first strand cDNA
30 is synthesized using M-MuLV reverse transcriptase. Using
primers designed to anneal to the 5' and 3' ends of
murine heavy chain and kappa light chain variable region
sequence, the repertoire of expressed variable regions
sequences is amplified by PCR. Lambda light chain
35 sequences are not amplified as they represent only a

- 47 -

small fraction of mature antibody-expressed light chain, and the flanking sequences are variable. The PCR products from the heavy chain amplification (≈ 400 bp) and the kappa light chain amplification (≈ 300 bp) are
5 separated by agarose gel electrophoresis, gel plugs cut out, and the DNA extracted by freezing and thawing followed by membrane centrifugation.

A linker that hybridizes to the 3' end of the heavy chain and the 5' end of the light chain and encodes
10 the peptide liner (e.g., Gly₄Ser₃) is then used to amplify out a full length scFv region of 750 bp. Through use of 5' and 3' primers which carry 5' tails encoding restriction endonuclease sites, Sfi I and Not I sites are added by PCR to the 5' and 3' termini, respectively, of
15 the scFv. After digestion with Sfi I followed by Not I, the phenol/chloroform-precipitated fragments are directionally ligated into the pCANTAB 5E phagemid and the construct encoding multiple scFv is used to transform *E. coli* TG1 cells. The transformed cells are then
20 infected with M13K07 helper phage to rescue the phagemid which will result in expression of the recombinant scFv as a fusion protein based on the gene III phage protein, the fusion protein being displayed on the phage particles.

25 At this point, the scFv-expressing phages are panned on attractin-coated plates, unbound phages are washed away, bound phage eluted, the phage DNA isolated, and TG1 cells reinfected and allowed to express by superinfection with helper phage. The panning process is
30 repeated up to 3 times in order to refine the specificity. Once antigen-reactive clones have been identified, they are tested for binding by adding the scFv-expressing phage to attractin-coated wells, washing away unbound phage, adding horseradish peroxidase
35 conjugated antibody specific for M13 phage, washing away

- 48 -

unbound conjugate and adding ABTS substrate. After confirmation of specific binding by ELISA, the recombinant phage is used to infect *E. coli* HB2151, which recognizes the amber stop codon encoded by pCANTAB 5E, allowing production of soluble scFv not in the context of the phage gene III protein. The soluble scFv can be isolated from *E. coli* periplasm using standard procedures and the sample can then be applied to an affinity column bearing antibody directed against a peptide region (-Gly-Ala-Pro-Val-Pro-Tyr-Pro-Asp-Pro-Leu-Glu-Pro-Arg-Ala-Ala-COOH (SEQ ID NO:9)) downstream from the kappa light chain and which generates a C-terminal common to all the scFv fragments. Binding occurs at neutral pH and, comparable to a normal antigen-antibody reaction, can be eluted at acidic pH. This peptide can be recognized by its specific antibody under native and denatured conditions. scFv produced in this way will provide a very specific handle for studying T lymphocyte intracellular expression and surface expression of attractin, for determining the kinetics of surface expression during clustering, for blocking functional clustering assays, and for determining both levels of attractin released from T cells during assays in vitro and levels in biological fluids.

In addition to maximizing selection of antibodies with the greatest affinity, panels of scFv directed against specific epitopes of attractin are developed. This is achieved by taking all isolated attractin-specific scFv and repeating the ELISA assays described above using the above-described forms of attractin and attractin deletion mutants as the target antigen. Selective binding of the scFv to one form of attractin but not to another or the deletion mutants will indicate that the scFv is specific for the relevant form of

- 49 -

attractin or the deleted part of the polypeptide, respectively.

Example 8. Identification of the Nucleotide and Amino Acid Sequence of Membrane Attractin-1

5 Initially, a 9 kb murine mRNA was shown to encode a molecule which was similar to human attractin-1. Sequence analysis of murine cDNA revealed that the nucleotide sequence diverged, extended the open reading frame, and coded for a transmembrane domain and a
10 cytoplasmic domain. Given the 93% identity in the amino acid sequences of the regions shared by human soluble attractin-1 and murine attractin, it was hypothesized that an oligonucleotide probe based on the region coding for the murine cytoplasmic tail would also hybridize to a
15 human mRNA that coded for an attractin with a cytoplasmic tail. This was found to be the case. Such a probe hybridized to the 9 kb human attractin mRNA but not to the 4.5 kb form, while a probe based on sequence coding for the common N-terminal sequence hybridized to both
20 forms. This indicated that the 9kb human mRNA coded for a long attractin similar to the murine molecule. Searching of the EST database then revealed a deposited human sequence (KIAA0548; GenBank AB011120) that coded for 451 amino acids at the C-terminal of a human membrane
25 attractin. The identification of this sequence re-enforced the hypothesis that a natural mRNA for membrane attractin existed. Using KIAA0548 as a base, a human genomic clone that contained an apparent attractin exon corresponding to the sequence coding for the amino acid
30 sequence CEVENRYQGNPLRGTCY (SEQ ID NO:20), close to the C-terminal of attractin, was identified. Complete sequencing of this genomic clone proved conclusively that the divergence between soluble attractin-1, and membrane attractin-1, was the result of alternate splicing.

- 50 -

The nucleotide sequence of cDNA encoding human membrane attractin-1 (SEQ ID NO:11) is shown in Fig. 10 and the amino acid sequence of the human membrane attractin-1 protein (SEQ ID NO:10) is shown in Fig. 9.

- 5 Note that the C-terminal five amino acids of soluble attractin-1 (SEQ ID NO:2 in Fig. 2) differs from the equivalent five amino acids in membrane attractin-1 and it lacks an additional 156 C-terminal amino acid residue region containing a transmembrane domain (amino acid
10 residues 1205-1225) domain and a cytoplasmic domain C-terminal to the transmembrane domain.

Example 9. Deduction of the Attractin-2 cDNA and Protein Sequences.

- Multiple attractin cDNA species covering the 5'
15 region have been identified which include or do not include a 222-bp insertion encoding a 74 amino acid region that defines attractin-2 proteins. Since there is no reason to suppose that this region can in any way influence 3' splicing events, it is likely that both
20 membrane and soluble attractin mRNA species containing the 222-bp insertion are generated. Further evidence that such transcripts exist comes from experiments with mouse mRNA from which it is clear that there are multiple mouse attractin mRNA species of which the membrane form,
25 at least, contains a 72 amino acid (216 bp) insertion corresponding to the 74 amino acid insertion of human attractin-2. Thus, the invention includes both soluble attractin-2 (SEQ ID NO:18) (Fig. 11), membrane attractin-2 (SEQ ID NO:12) (Fig. 13) and the cDNA sequences
30 encoding soluble attractin-2 (SEQ ID NO:19) (Fig. 12) and membrane attractin-2 (SEQ ID NO:13) (Fig. 14). The transmembrane domain of membrane attractin-2 is predicted to include residues 1279-1301 of SEQ ID NO:12 and its

- 51 -

cytoplasmic domain is predicted to include all residues C-terminal of the transmembrane domain.

Example 10. Recombinant Soluble Attractin-1 Increases Expression of MHC Class II and B7.1 Molecules on Monocytes.

Peripheral blood leukocytes were isolated (from blood donated by normal donors in the Blood Bank of the Dana Farber Cancer Institute) by centrifugation over Ficoll-Hypaque. The isolated cells were suspended in defined lymphocyte culture medium (AIM V; GIBCO-BRL) at a concentration of 2×10^6 per ml and incubated at 37°C in an atmosphere of 7.5% CO₂ for 72 hr with soluble recombinant attractin-1 (at 5 ug/ml) or with GM-CSF (10 U/ml). Non-adherent cells were then discarded and adherent cells were recovered using PBS containing 5 mM EDTA and washed in AIM V medium. All cells were suspended at a concentration of 10^7 per ml. 100 ul aliquots (corresponding to 10^6 cells) were incubated with 0.25 to 1 ug of a panel of FITC- or phycoerythrin-labelled antibodies directed against a selection of known pan-leukocyte, T cell-specific, B cell-specific, monocyte-specific and NK-specific markers. Using the Coulter XL fluorescence analysis machine, fluorescence windows were gated on the total cell population, the lymphocyte population, and the monocyte population that is distinguished by size and light "scatter" (Fig. 15). The profiles with dark fill were obtained with control cells incubated with antibodies of irrelevant specificity conjugated with appropriate fluorophores, and those with light fill were obtained with cells incubated with antibodies with the indicated specificity. Also shown in Fig. 15 are similar data obtained with peripheral blood leukocytes prior to culture (DO).

- 52 -

Monocytes incubated with GM-CSF differentiated by losing CD14 (Fig. 15) and expressing CD1a (not shown), indicating a differentiation towards early dendritic cells. For monocytes incubated with soluble attractin-1 in the presence of CD3+ T lymphocytes, CD14 remains high, there is no induction of CD1a (not shown), B7-1 expression begins to increase, and MHC Class II expression increases off scale (Fig. 15). These findings indicate that attractin serves to enhance the antigen presenting function of monocytes.

While the present invention has been described in conjunction with a preferred embodiment, one of ordinary skill, after reading the foregoing specification, will be able to effect various changes, substitutions of equivalents, and other alterations to the compositions and methods set forth herein. It is therefore intended that the protection granted by Letters Patent hereon be limited only by the definitions contained in the appended claims and equivalents thereof.

- 53 -

CLAIMS

What is claimed is:

1. An isolated DNA comprising:
 - (a) a nucleic acid sequence that encodes a polypeptide that enhances spreading of a macrophage or a monocyte and that hybridizes under highly stringent conditions to the complement of a sequence that encodes a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:18; or
 - (b) the complement of the nucleic acid sequence.
2. The DNA of claim 1, wherein the nucleic acid sequence encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:18.
3. The DNA of claim 1, wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:11, SEQ ID NO:13, and SEQ ID NO:19.
4. An isolated polypeptide comprising:
 - an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:18; or differing from SEQ ID NO: 10, 12, or 18 solely by one or more conservative amino acid substitutions.
5. A fusion protein comprising:
 - (a) an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:18, but lacking methionine at position 1 of said amino acid sequence; and
 - (b) a heterologous leader peptide.

- 54 -

6. An isolated nucleic acid encoding the fusion protein of claim 5.

7. A method of enhancing spreading of a macrophage or a monocyte *in vitro*, the method comprising
5 co-culturing a T cell and a monocyte or a macrophage with an agent selected from the group consisting of:

(a) an isolated attractin polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID
10 NO:18;

(b) a functional fragment of the attractin polypeptide; and

(c) the polypeptide or the functional fragment, but with at least one conservative amino acid
15 substitution.

8. A method of treating a mammal in need of an enhanced immune response, the method comprising delivering to a tissue of the mammal that contains T cells and macrophages or monocytes, an agent selected
20 from the group consisting of:

(a) an isolated attractin polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID
NO:18;

25 (b) a functional fragment of the attractin polypeptide; and

(c) the polypeptide or the functional fragment, but with at least one conservative amino acid substitution.

30 9. The method of claim 8, wherein the delivery comprises administration of the agent to the mammal.

- 55 -

10. The method of claim 8, wherein the delivery comprises administering to the mammal a nucleic acid encoding the agent.

11. The method of claim 8, wherein the mammal is
5 a human.

12. The method of claim 11, wherein the human is suspected of being immunodeficient.

13. The method of claim 11, wherein the human is suspected of having cancer.

10 14. The method of claim 13, wherein the method is performed before, during, or after chemotherapy or radiation therapy.

15 15. A method of inhibiting spreading of a macrophage or a monocyte in a mammal, the method comprising administering to the mammal an isolated compound that binds to an attractin polypeptide.

16. The method of claim 15, wherein the compound is an antibody.

17. The method of claim 15, wherein the mammal is
20 a human.

18. The method of claim 17, wherein the human is suspected of having an autoimmune disease.

19. The method of claim 17, wherein the human is a transplant recipient.

- 56 -

20. A vector comprising the isolated DNA of claim 1.

21. The vector of claim 20, wherein the nucleic acid sequence is operably linked to a regulatory element
5 which allows expression of said nucleic acid in a cell.

22. A cultured cell comprising the vector of claim 21.

23. A method of producing a polypeptide, the method comprising culturing the cell of claim 22 and
10 purifying the polypeptide from the cell.

24. A vector comprising the isolated nucleic acid of claim 6.

25. The vector of claim 24, wherein the nucleic acid is operably linked to a regulatory element which
15 allows expression of said nucleic acid in a cell.

26. A cell comprising the vector of claim 25.

27. A method of producing a fusion protein, the method comprising culturing the cell of claim 26 and purifying the fusion protein from the cell.

20 28. A method of identifying a compound that inhibits an immune response, the method comprising:
a) providing an isolated polypeptide comprising an amino acid sequence selected from the group consisting of
SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID
25 NO:18, or the amino acid sequence but with one or more conservative amino acid substitutions;

- 57 -

b) co-culturing a T cell and a macrophage or a monocyte with the isolated polypeptide and the test compound;

5 c) determining whether the test compound inhibits spreading of the macrophage or the monocyte, as an indication that the test compound inhibits an immune response.

29. A method of identifying a compound that enhances an immune response, the method comprising:

10 a) providing a test compound;

b) combining the test compound, a T cell, a macrophage or a monocyte, and an isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, 15 and SEQ ID NO:18, or the amino acid sequence with one or more conservative substitutions; and

c) determining whether the test compound enhances spreading of the macrophage or the monocyte, as an indication that the test compound inhibits an immune 20 response.

30. An antibody that binds to a polypeptide selected from the group consisting of SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:18, but that does not bind to CD26 or to a polypeptide with the sequence of SEQ ID 25 NO:2.

31. The antibody of claim 30, wherein the antibody is a single chain variable region fragment (scFv).

- 58 -

32. A method of treating a mammal in need of an enhanced immune response, the method comprising:

a) providing a recombinant cell which is the progeny of a cell obtained from the mammal and has been
5 transfected or transformed *ex vivo* with a nucleic acid encoding an agent or a functional fragment of the agent so that the cell expresses the agent or functional fragment; and

b) administering the cell to the mammal,
10 wherein the agent is selected from the group consisting of:

(i) an attractin polypeptide comprising an amino acid sequence selected from the group consisting of
SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID
15 NO:18;

(ii) a functional fragment of the attractin polypeptide; and

(iii) the polypeptide or the functional fragment, but with one or more conservative amino acid
20 substitutions.

33. An isolated functional attractin fragment comprising amino acid residues 31-104 of SEQ ID NO:12 or SEQ ID NO:18.

34. An isolated functional attractin fragment
25 comprising amino acid residues 1279-1301 of SEQ ID NO:12.

35. The isolated functional attractin fragment of claim 34, comprising amino acid residues 1219-1429 of SEQ ID NO:12.

36. An isolated functional attractin fragment
30 comprising amino acid residues 1302-1429 of SEQ ID NO:12.

- 59 -

37. The method of claim 12, wherein said human is suspected of having common variable immunodeficiency syndrome.




Fig 1A — 1F






Fig 1G - 1I

1 MVA AAAATEA RLRRRTAATA ALAGRSSGGPH CVNGGRCNPG TGQCVCPAGW
51 VGEQCQHC GG RFRLTGSSGF VTDGPGNYKY KTKCTWLIEG QPNRIMRLRF
101 NHFATECSWD HLYVYDGDSI YAPLVAAFSG LIVPERDGNE TVPEVVATSG
151 YALLHFFSDA AYNLTGFNIT YSFD MCPNNC SGRGECKISN SSETVECECS
201 ENWKGEACDI PHCTDNC GFP HRGICNSSDV RGCSCFSDWQ GPGCSVPVPA
251 NQSFWTREEY SNLKLPRASH KAVVNGNIMW VVGGYMFNHS DYNMVLAYDL
301 ASREWLP LNR SVNNVVVRYG HSLALYKDKI YMYGGKIDPT GNVTNELRVF
351 HIHNESWVLL TPKAKEQYAV VGHSAHIVTL KNGRVVMLVI FGHCPLYGYI
401 SNVQEYDL DK NTWSILHTQG ALVQGGYGHS SVYDHRTRAL YVHGGYKA FS
451 ANKYRLADDL YRYD VDTQ MW TILKDSRFFR YLHTAVIVSG TMLVFEGGNTH
501 NDTSM SHGAK CFSSDFMAYD IACDRWSVLP RPD LHHDVNR FGHS AVLHNS
551 TMYVFGGFNS LLLSDILVFT SEQCDHRSE AACLAAGPGI RCVWNTGSSQ
601 CISWALATDE QEEKLKSECF SKRTL DHDRC DQHTDCYSCT ANTNDCHWCN
651 DHCVPRNHSC SEGQISIFRY ENCPKDNPMY YCNKKTSCRS CALDQNCQWE
701 PRNQECIALP ENICGIGWHL VGNSCLKITT AKENYD NAKL FCRNHNALLA
751 SLTTQKKVEF VLKQLRIMQS SQSMSKLT LT PWVGLRKINV SYWCWEDMSP
801 FTNSLLQWMP SEPSDAGFCG ILSEPSTRGL KAATCINPLN GSV CERPANH
851 SAKQCRTPCA LRTACGDCTS GSSECMWCSN MKQCVDSNAY VASFPPGQCM
901 EWYTMSTCPP ENCSGYCTCS HCLEQPGCGW CTDPSNTGKG KCIEGSYKGP
951 VKMPSQAPTG NFYPQPLLNS SMCLEDSRYN WSFIHCPACQ CNGH SKCINQ
1001 SICEKCENLT TGKHCETCIS GFYGDPTNGG KCQPCKCNGH ASLCNTNTGK
1051 CFCTTKGVKG DECQLCEVEN RYQGNPLRGT CYYTLLIDYQ FTFSLSQEDD
1101 RYYTAINFVA TPDEQNRDL D MFINASKNFN LNITWAASF S AGTQAGEEMP
1151 VVSKTNIKEY KDSFSNEKFD FRNHPNITFF VYVSNFTWPI KIQVQTEQ






Fig. 3

A.



B



C



Minimum serine protease

**Prolyl oligo
peptidase**

Trypsin




Fig. 4





Fig. 5




Fig. 6






Fig. 7.

1 ATGGTGGCCG CAGCGGCGGC AACTGAGGCA AGGCTGAGGA GGAGGACGGC
51 GCGACGGCA GCGCTCGCGG GCAGGAGCGG CGGGCCGCAC TGTGTCAACG
101 GCGGTGCTG CAACCCTGGC ACCGGCCAGT GCGTCTGCCC CGCCGGCTGG
151 GTGGGCGAGC AATGCCAGCA CTGCGGGGGC CGCTTCAGAC TAACTGGATC
201 TTCTGGGTTT GTGACAGATG GACCTGGAAA TTATAAATAC AAAACGAAGT
251 GCACGTGGCT CATTGAAGGA CAGCCAAATA GAATAATGAG ACTTCGTTTC
301 AATCATTTTG CTACAGAGTG TAGTTGGGAC CATTTATATG TTTATGATGG
351 GGA CTCAATT TATGCACCGC TAGTTGCTGC ATTTAGTGGC CTCATTGTTC
401 CTGAGAGAGA TGGCAATGAG ACTGTCCCTG AGGTTGTTGC CACATCAGGT
451 TATGCCTTGC TGCATTTTTT TAGTGATGCT GCTTATAATT TGA CTGGATT
501 TAATATTACT TACAGTTTTG ATATGTGTcC AAATAACTGC TCAGGcCGAG
551 GAGAGTGTA GATCAGTAAT AGCAGCGAAA CTGTTGAATG TGAATGTTCT
601 GAAA ACTGGA AAGGTGAAGC ATGTGACATT CCTCACTGTA CAGACA ACTG
651 TGGTTTTCTT CATCGAGGCA TCTGCAATTC AAGTGATGTC AGAGGATGCT
701 CCTGCTTCTC AGACTGGCAG GGTCTGGAT GTTCAGTTCC TGTACCAGCT
751 AACCAGTCAT TTTGGACTCG AGAGGAATAT TCTAACTTAA AGCTCCCCAG
801 AGCATCTCAT AAAGCTGTGG TCAATGGAAA CATTATGTGG GTTGTGGAG
851 GATATATGTT CAACCACTCA GATTATAACA TGGTTCTAGC GTATGACCTT
901 GCTTCTAGGG AGTGGCTTCC ACTAAACCGT TCTGTGAACA ATGTGGTTGT
951 TAGATATGGT CATTCCTTGG CATTATACAA GGATAAAATT TACATGTATG
1001 GAGGAAAAAT TGATcCAACT GGAATGTGA CCAATGAGTT GAGAGTTTTT
1051 CACATTCATA ATGAGTCATG GGTGTTGTTG ACCCCTAAGG CAAAGGAGCA
1101 GTATGCAGTG GTTGGGCACT CTGCACACAT TGTTACACTG AAGAATGGCC
1151 GAGTGGTCAT GCTGGTCATC TTTGGTCACT GCCCTCTCTA TGGATATATA
1201 AGCAATGTGC AGGAATATGA TTTGGATAAG AACACATGGA GTATATTACA
1251 CACCCAGGGT GCCCTTGTGC AAGGGGGTTA CGGCCATAGC AGTGTTTACG
1301 ACCATAGGAC CAGGGCCCTA TACGTT CATG GTGGCTACAA GGCTTTCAGT

Fig. 8A

1351 GCCAATAAGT ACCGGCTTGC AGATGATCTC TACCGATATG ATGTGGATAC
1401 CCAGATGTGG ACCATTCTTA AGGACAGCCG ATTTTTCCTG TACTTGCACA
1451 CAGCTGTGAT AGTGAGTGGA ACCATGCTGG TGTTTGGGGG AAACACACAC
1501 AATGACACAT CTATGAGCCA TGGCGCCAAA TGCTTCTCTT CAGATTTTCAT
1551 GGCCTATGAC ATTGCCTGTG ACCGCTGGTC AGTGCTTCCC AGACCTGATC
1601 TCCACCATGA TGTCAACAGA TTTGGCCATT CAGCAGTCTT ACACAACAGC
1651 ACCATGTATG TGTTTCGGTGG TTTCAATAGT CTCCTCCTCA GCGACATCCT
1701 GGTATTCACC TCGGAACAGT GTGATGCGCA TCGGAGTGAA GCCGCTTGTT
1751 TAGCAGCAGG ACCTGGTATT CGGTGTGTGT GGAACACAGG GTCGTCTCAG
1801 TGTATCTCGT GGGCGCTGGC AACTGATGAA CAAGAAGAAA AGTTAAAATC
1851 AGAATGTTTT TCCAAAAGAA CTCTTGACCA TGACAGATGT GACCAGCACA
1901 CAGATTGTTA CAGCTGTACA GCCAACACCA ATGACTGCCA CTGGTGCAAT
1951 GACCATTGTG TCCCCAGGAA CCACAGCTGC TCAGAAGGCC AGATCTCCAT
2001 TTTTAGGTAT GAGAATTGCC CCAAGGATAA CCCcATGTAC TACTGTAACA
2051 AGAAGACCAG CTGCAGGAGC TGTGCCCTGG ACCAGAACTG CCAGTGGGAG
2101 CCCCgGAATC AGGAGTGCAT TGCCCTGCCC GAAAATATCT GTGGCATTGG
2151 CTGGCATTTG GTTGGAAGCT CATGTTTGAA AATTACTACT GCCAAGGAGA
2201 ATTATGACAA TGCTAAATTG TTCTGTAGGA ACCACAATGC CCTTTTGGCT
2251 TCTCTTACAA CCCAGAAGAA GGTAGAATTT GTCCTTAAGC AGCTGCGAAT
2301 AATGCAGTCA TCTCAGAGCA TGTCCAAGCT CACCTTAACC CCATGGGTCG
2351 GCCTTCGGAA GATCAATGTG TCCTACTGGT GCTGGGAAGA TATGTCCCCA
2401 TTTACAAATA GTTTACTACA GTGGATGCCG TCTGAGCCCA GTGATGCTGG
2451 ATTCTGTGGA ATTTTATCAG AACCCAGTAC TCGGGGACTG AAGGCTGCAA
2501 CCTGCATCAA CCCACTCAAT GGTAGTGTCT GTGAAAGGCC TGCAAACCAC
2551 AGTGCTAAGC AGTGCCGGAC ACCATGTGCC TTGAGGACAG CATGTGGAGA
2601 TTGCACCAGC GGCAGCTCTG AGTGCATGTG GTGCAGCAAC ATGAAGCAGT
2651 GTGTGGACTC CAATGCCTAT GTGGCCTCCT TCCCTTTTGG CCAGTGTATG

Fig. 8B

2701 GAATGGTATA CGATGAGCAC CTGCCCCCCT GAAAATTGTT CAGGCTACTG
2751 TACCTGTAGT CATTGCTTGG AGCAACCAGG CTGTGGCTGG TGTACTGATC
2801 CCAGCAATAC TGGCAAAGGG AAATGCATAG AGGGTTCCTA TAAAGGACCA
2851 GTGAAGATGC CTTCGCAAGC CCCTACAGGA AATTTCTATC CACAGCCCCT
2901 GCTCAATTCC AGCATGTGTC TAGAGGACAG CAGATACAAC TGGTCTTTCA
2951 TTCACTGTCC AGCTTGCCAA TGCAACGGCC ACAGTAAATG CATCAATCAG
3001 AGCATCTGTG AGAAGTGTGA GAACCTGACC ACAGGCAAGC ACTGCGAGAC
3051 CTGCATATCT GGCTTCTACG GTGATCCAC CAATGGAGGG AAATGTCAGC
3101 CATGCAAGTG CAATGGGCAC GCGTCTCTGT GCAACACCAA CACGGGCAAG
3151 TGCTTCTGCA CCACCAAGGG CGTCAAGGGG GACGAGTGCC AGCTATGTGA
3201 GGTAGAAAAT CGATACCAAG GAAACCCTCT CAGAGGAACA TGTATTATA
3251 CTCTTCTTAT TGACTATCAG TTCACCTTTA GTCTATCCCA GGAAGATGAT
3301 CGCTATTACA CAGCTATCAA TTTTGTGGCT ACTCCTGACG AACAAAACAG
3351 GGATTTGGAC ATGTTTCATCA ATGCCTCCAA GAATTTCAAC CTCAACATCA
3401 CCTGGGCTGC CAGTTTCTCA GCTGGAACCC AGGCTGGAGA AGAGATGCCT
3451 GTTGTTTCAA AAACCAACAT TAAGGAGTAC AAAGATAGTT TCTCTAATGA
3501 GAAGTTTGAT TTTCGCAACC ACCCAAATAT CACTTTCTTT GTTTATGTCA
3551 GTAATTTTAC CTGGCCCATC AAAATTCAGG TGCAAACCTGA ACAATGA

Fig. 8C

FIGURE 9

1	MVAAAAATEA	RLRRRTAATA	ALAGRSGGPH	CVNGGRCNPG	TGQCVCPAGW
51	VGEQCQHCGG	RFRLTGSSGF	VTDGPGNYKY	KTKCTWLI EG	QPNRIMRLRF
101	NHFATECSWD	HLVYVDGDSI	YAPLVAAFSG	LIVPERDGNE	TVPEVVATSG
151	YALLHFFSDA	AYNLTGFNIT	YSFDMCPMNC	SGRGECKISN	SSDTVECECS
201	ENWKGEACDI	PHCTDNCGFP	HRGICNSSDV	RGCSCFSDWQ	GPGCSVPVPA
251	NQSFWTREEY	SNLKLPRASH	KAVVNGNIMW	VVGGYMFNHS	DYNMVLAYDL
301	ASREWLPLNR	SVNNVVVRYG	HSLALYKDKI	YMYGGKIDST	GNVTNELRVF
351	HIHNESWVLL	TPKAKEQYAV	VGHSAHIVTL	KNGRVVMLVI	FGHCPLYGYI
401	SNVQEYDL DK	NTWSILHTQG	ALVQGGYGHS	SVYDHRTRAL	YVHGGYKA FS
451	ANKYRLAD DL	YRYDVDTQ MW	TILKDSRFFR	YLHTAVIVSG	TMLVFGGNTH
501	NDTSM SHGAK	CFSSDFMAYD	IACDRWSVLP	RPDLHHDVNR	FGHSAVLHNS
551	TMYVFGGFNS	LLLSDILVFT	SEQCDAHRSE	AACLAAGPGI	RCVWNTGSSQ
601	CISWALATDE	QEEKLKSECF	SKRTLDHDCR	DQHTDCYSCT	ANTNDCHWCN
651	DHCVPRNHSC	SEGQISIFRY	ENCPKDNPMY	YCNKKTSCRS	CALDQNCQWE
701	PRNQECIALP	ENICGIGWHL	VGNSCLKITT	AKENYDNAKL	FCRNHNALLA
751	SLTTQKKVEF	VLKQLRIMQS	SQSMSKLT LT	PWVGLRKINV	SYWCWEDMSP
801	FTNSLLQWMP	SEPSDAGFCG	ILSEPSTRGL	KAATCINPLN	GSVCERPANH
851	SAKQCRTPCA	LRTACGDCTS	GSSECMWC SN	MKQCVDSNAY	VASFPPGQCM
901	EWYTMSTCPP	ENCSGYCTCS	HCLEQPGCGW	CTDPSNTGKG	KCIEGSYKGP
951	VKMPSQAPTG	NFY PQPLLNS	SMCLEDSRYN	WSFIHCPACQ	CNGH SKCINQ
1001	SICEKCENLT	TGKHCETCIS	GFYGDPTNGG	KCQPCCKNGH	ASLCNTNTGK
1051	CFCTTKGVKG	DECQLCEVEN	RYQGNPLRGT	CYYTLLIDYQ	FTFSLSQEDD
1101	RYYTAINFVA	TPDEQNRDL D	MFINASKNFN	LNITWAASFS	AGTQAGEEMP
1151	VVSKTNIKEY	KDSFSNEKFD	FRNH PNITFF	VYVSNFTWPI	KIQIAFSQHS
1201	NFMDLVQFFV	TFFSCFLSLL	LVA AVWKIK	QSCWASRRRE	QLLREM QOMA
1251	SRPFASVNVA	LETDEEPPDL	IGGSIKTVPK	PIALEPCFGN	KAAVLSVFVR
1301	LPRGLGGIPP	PGQSGLAVAS	ALVDISQOMP	IVYKEKSGAV	RNRKQQPPAQ
1351	PGTCI				

FIGURE 10A

```

1      atggtggccg cagcggcggc aactgaggca aggctgagga ggaggacggc
51     ggcgacggca gcgctcgcg gcaggagcgg cgggcccgcac tgtgtcaacg
101    gcggtcgctg caaccctggc accggccagt gcgctcgccc cgccggctgg
151    gtgggcgagc aatgccagca ctgcgggggc cgcttcagac taactggatc
201    ttctgggttt gtgacagatg gacctggaaa ttataaatac aaaacgaagt
251    gcacgtggct cattgaagga cagccaaata gaataatgag acttcgtttc
301    aatcattttg ctacagagtg tagttgggac catttatatg tttatgatgg
351    ggactcaatt tatgcaccgc tagttgctgc attcagtggc ctcatgttc
401    ctgagagaga tggcaatgag actgtccctg aggttggttc cacatcaggt
451    tatgccttgc tgcatttttt tagtgatgct gcttataatt tgactggatt
501    taatattact tacagttttg atatgtgtcc aaataactgc tcaggccgag
551    gagagtgtaa gatcagtaat agcagcgata ctgttgaatg tgaatgttct
601    gaaaactgga aaggtgaagc atgtgacatt cctcactgta cagacaactg
651    tggttttcct catcgaggca tctgcaattc aagtgatgtc agaggatgct
701    cctgcttctc agactggcag ggtcctggat gttcagttcc tgtaccagct
751    aaccagtcac tttggactcg agaggaatat tctaacttaa agctccccag
801    agcatctcat aaagctgtgg tcaatggaaa cattatgtgg gttgttggag
851    gatatatgtt caaccactca gattataaca tgggtctagc grtgacctt
901    gcttctaggg agtggtctcc actaaaccgt tctgtgaaca atgtggttgt
951    tagatatggt cattcttttg cattatacaa ggataaaaatt tacatgtatg
1001   gagaaaaaat tgattcaact gggaatgtga ccaatgagtt gagagttttt
1051   cacattcata atgagtcatg ggtgttgttg acccctaagg caaaggagca
1101   gtatgcagtg gttgggcact ctgcacacat tgttacctg aagaatggcc
1151   gagtgggtcat gctgggtcatc tttgggtcact gccctctcta tggatatata
1201   agcaatgtgc aggaatatga tttggataag aacacatgga gtatattaca
1251   caccagggtg gcccttgtgc aaggggggta cggccatagc agtgtttacg
1301   accataggac cagggcccta tacgttcatg gtggctacaa ggctttcagt
1351   gccataaagt accggcttgc agatgatctc taccgatatg atgtggatac
1401   ccagatgtgg accattctta aggacagccg atttttccgt tacttgaca
1451   cagctgtgat agtgagtgga accatgctgg tgtttggggg aaacacacac
1501   aatgacacat ctatgagcca tggcgccaaa tgcttctctt cagatttcat
1551   ggccatgac attgcctgtg accgtgggtc agtgcttccc agacctgac
1601   tccaccatga tgtcaacaga tttggccatt cagcagctct acacaacagc
1651   accatgtatg tgttcggtgg tttcaatagt ctctcctca gcgacatcct
1701   ggtattcacc tcggaacagt gtgatgcgca tcggagtga ggcgcttgtt
1751   tagcagcagg acctggtatt cgggtgtgtg ggaacacagg gtcgtctcag
1801   tgtatctcgt gggcgctggc aactgatgaa caagaagaaa agttaaaatc
1851   agaatgtttt tccaaaagaa ctcttgacca tgacagatgt gaccagcaca
1901   cagattgtta cagctgcaca gccaacacca atgactgcca ctggtgcaat
1951   gaccattgtg tccccaggaa ccacagctgc tcagaaggcc agatctccat
2001   ttttaggtat gagaattgcc ccaaggataa ccctatgtac tactgtaaca
2051   agaagaccag ctgcaggagc tgtgccctgg accagaactg ccagtgggag
2101   ccccggaatc aggagtgcac tgccctgccc gaaaatatct gtggcattgg
2151   ctggcatttg gttggaaact catgtttgaa aattactact gccaggaga
2201   attatgacaa tgctaaattg ttctgtagga accacaatgc ccttttggct
2251   tctcttaciaa cccagaagaa ggtagaattt gtccttaagc agctgcgaat
2301   aatgcagtca tctcagagca tgtccaagct caccctaacc ccatgggtcg
2351   gccttcggaa gatcaatgtg tcctactggg gctgggaaga tatgtcccca
2401   tttacaaata gtttactaca gtggatgccg tctgagccca gtgatgctgg
2451   attctgtgga attttatcag aaccagtac tcggggactg aaggctgcaa
2501   cctgcatcaa cccactcaat ggtagtgtct gtgaaaggcc tgcaaacacc
2551   agtgctaagc agtgccggac accatgtgcc ttgaggacag catgtggaga
2601   ttgcaccagc ggcagctctg agtgcatgtg gtgcagcaac atgaagcagt

```

FIGURE 10B

```
2651 gtgtggactc caatgcctat gtggcctcct tcccttttgg ccagtgtatg
2701 gaatggtata cgatgagcac ctgccccctt gaaaattgtt caggctactg
2751 tacctgtagt cattgcttgg agcaaccagg ctgtggctgg tgtactgatc
2801 ccagcaatac tggcaaaggg aaatgcatag agggttccta taaaggacca
2851 gtgaagatgc cttcgcaagc cctacagga aatttctatc cacagcccct
2901 gctcaattcc agcatgtgtc tagaggacag cagatacaac tggctcttca
2951 ttcactgtcc agcttgccaa tgcaacggcc acagtaaagc catcaatcag
3001 agcatctgtg agaagtgtga gaacctgacc acaggcaagc actgcgagac
3051 ctgcatatct ggcttctacg gtgatcccac caatggaggg aaatgtcagc
3101 catgcaagtg caatgggcac gcgtctctgt gcaacaccaa cacgggcaag
3151 tgcttctgca ccaccaaggg cgtcaagggg gacgagtgcc agctatgtga
3201 ggtagaaaat cgataccaag gaaaccctct cagaggaaca tgttattata
3251 ctcttcttat tgactatcag ttcaccttta gtctatccca ggaagatgat
3301 cgctattaca cagctatcaa ttttgtggct actcctgacg aacaaaacag
3351 ggatttggac atgttcatca atgcctccaa gaatttcaac ctcaacatca
3401 cctgggctgc cagtttctca gctggaaccc aggctggaga agagatgcct
3451 gttgtttcaa aaaccaacat taaggagtac aaagatagtt tctctaataa
3501 gaagtgtgat tttcgcaacc acccaaatat cactttcttt gtttatgtca
3551 gtaatttcac ctggcccatc aaaattcaga ttgccttctc tcagcacagc
3601 aattttatgg acctggtaca gttcttctgt actttcttca gttgttctct
3651 ctctttgctc ctggtggctg ctgtggtttg gaagatcaaa caaagtgtgt
3701 gggcctccag acgtagagag caacttcttc gagagatgca acagatggcc
3751 agccgtccct ttgcctctgt aaatgtcgcc ttggaaacag atgaggagcc
3801 tcctgatctt attgggggga gtataaagac tgttcccaaa cccattgcac
3851 tggagccgtg ttttggcaac aaagccgctg tcctctctgt gtttgtgagg
3901 ctccctcgag gcctgggtgg catccctcct cctgggagcag caggtcttgc
3951 tgtggccagc gccctggtgg acatttctca gcagatgccg atagtgtaca
4001 aggagaagtc aggagccgtg agaaaccgga agcagcagcc ccctgcacag
4051 cctgggacct gcatctga
```

FIGURE 11

MVAAAAATEARLRRRTAATAALAGRSGGPHWDWDVTRAGRPGLGAGLRLPRLSPPLR
PRLLLLLLLLPPPLLLLLLPCEAEAAAAAAVSGSAAAEAKECDRPCVNGGRCPNPGTG
QCVCAPAGWVGEQCQHCGRFRLTGSSGFVTDGPGNYKYKTKCTWLIQGPNRIMRLRF
NHFATECSWDHLYVYDGDSIYAPLVAAFSGLIVPERDGNETVPEVVATSGYALLHFFS
DAAYNLTGFNITYSFDMPNNCSGRGECKISNSSETVECECSENWKGEACDIPHCTDN
CGFPHRGICNSSDVRGCSCFSDWQPGCSVPVPAQSFWTREEYSNLKLPRASHKAVV
NGNIMWVVGGMFNHSDYNMVLADLASREWLPLNRSVNNVVVRYGHSALALYDKIYM
YGGKIDPTGNVTNELRVFHIHNESWVLLTPKAKEQYAVVGHSAHIVTLKNGRVMLVI
FGHCPLYGYISNVQEYDLDKNTWSILHTQALVQGGYGHSSVYDHRTRALYVHGGYKA
FSANKYRLADDLYRYDVTQMTILKDSRFFRYLHTAVIVSGTMLVFGGNTHTDTSMS
HGAKCFSSDFMAYDIACDRWSVLPRPDLHHDVNRFGHSAVLHNSTMYVFGGFHSLLS
DILVFTSEQCDAHRSEACLAAGPGIRCWNTGSSQCISWALATDEQEEKLHSECFSK
RTLHDHRCDDQHTDCYSCTANTNDCHWCNDHCVPRNHSCSEGQISIFRYENCPEXDNPMY
YCNKKTSCRSCALDQNCQWEPRNQECIALPENICGIGWHLVGNSCLKITTAKENYDNA
KLFCRNHNALLASLTQKKVEFVLKQLRIMQSSQSMKLTLPWVGLRKINVSYWCWE
DMSPTNSLLQWMPSEPSDAGFCGILSEPSTRGLKAATCINPLNGSV CERPANHSAKQ
CRTPCALRTACGDCTSGSSECMWCSNMKQCVD SNAYVASFPFGQCMEWYTMSTCPPEN
CSGYCTCSHCLEQPGCGWCTDPSNTGKGKCIEGSYKGPVKMPSQAPTGNFYPOPLLNS
SMCLEDSRYNWSFIHCPACQCNGHSGKINQSI CEKCNLTGKHCETCISGFYGDPTN
GGKCQPCCKNGHASLCNTNTGKCFCTTKGVKGDECQLCEVENRYQGNPLRGTCYYTLL
IDYQFTFSLSQEDDRYYTAINFVATPDEQNRDLDMFINASKNFNLNITWAASF SAGTQ
AGEEMPVVSKTNIKEYKDSFSNEKFDFRNHPNITFFVYVSNFTWPIKIQVQTEQ

FIGURE 12

```

1   atggtggccg cagcggcggc aactgaggca aggctgagga ggaggacggc ggcgacggca
61  gcgctcgccg gcaggagcgg cgggcccgcac tgggactggg acgtgaccag ggctgggagg
121 ccgggggctgg gggccgggct gcgcctcccg cggctgctgt ctccaccgct gcggccacgg
181 ctgctgctgc tgctgttgtt gctcccgcg cggctgttgc tgctgctgct gccctgtgag
241 gccgaggccg cggcggcggc ggcggcggtg tcgggctcag ccgcagccga ggccaaggaa
301 tgtgaccggc cctgtgtcaa cggcggtcgc tgcaaccctg gcaccggcca gtgctctgc
361 cccgccggct ggggtggcga gcaatgccag cactgcgggg gccgttcag actaactgga
421 tcttctgggt ttgtgacaga tggacctgga aattataaat acaaaacgaa gtgcactgg
481 ctcatgtgag gacagccaaa tagaataatg agacttcgtt tcaatcattt tgctacagag
541 tgtagtggg accatttara tgtttatgat ggggactcaa tttatgcacc gctagtgtgt
601 gcatttagtg gcctcattgt tcctgagaga gatggcaatg agactgtccc tgagggtgtt
661 gccacatcag gttatgcctt gctgcatttt tttagtgtg ctgcttataa tttgactgga
721 tttaatatta cttacagttt tgatatgtgt ccaaataaact gctcaggccg aggaggtgt
781 aagatcagta atagcagcga aactgttgaa tgtgaatgtt ctgaaaactg gaaagggtgaa
841 gcatgtgaca ttctcactg tacagacaac tgtggttttc ctcatcgagg catctgcaat
901 tcaagtgtg tcagaggatg ctctgtcttc tcagactggc agggctcctg atgttcagtt
961 cctgtaccag ctaaccagtc attttggact cgagaggaaat attctaactt aaagctcccc
1021 agagcatctc ataaagctgt ggtcaatgga aacattatgt ggggtgttgg aggtatgtatg
1081 ttcaaccact cagattataa catggttcta gcgtatgacc ttgcttctag ggagtggctt
1141 cactaaacc gttctgtgaa caatgtggtt gttagatattg gtcattcttt ggcatatatac
1201 aaggataaaa ttacatgta tggaggaaaa attgatccaa ctgggaattg gaccaatgag
1261 ttgagagttt ttcacattca taatgagtc tgggtgttgt tgaccttaa ggcaaaggag
1321 cagratgcag tgggtgggca ctctgcacac attgttacac tgaagaatgg ccgagtggctc
1381 atgctggta tctttggta ctgccccttc tatggatata taagcaatgt gcaggaatat
1441 gatttggata agaacacatg gagtatatta cacaccagg gtgcccctgt gcaaggggtt
1501 tacggccata gcagtgttta cgaccatagg accagggcc tatacgttca tgggtggctac
1561 aaggctttca gtgccaataa gtaccggctt gcagatgatc tctaccgata tgatgtggat
1621 acccagatgt ggaccattct taaggacagc cgatttttcc gttacttgca cacagctgtg
1681 atagtgtgtg gaaccatgct ggtgtttggg ggaaacacac acaatgacac atctatgagc
1741 catggcgcca aatgcttctc ttcagatttc attggcctatg acattgcctg tgaccgctgg
1801 tcagtgtctc ccagacctga tctccaccat gatgtcaaca gatttggcca ttcagcagtc
1861 ttacacaaca gcaccatgta tgtgttcggt ggtttcaata gtctcctcct cagcgacatc
1921 ctggtattca cctcggaaca gtgtgatgcg catcggagtg aagccgcttg tttagcagca
1981 ggactggta ttcggtgtgt gtggaacaca gggctcgtctc agtgtatctc gtgggcgctg
2041 gcaactgtg aacaagaaga aaagttaaaa tcagaatgtt tttccaaaag aactcttgac
2101 catgacagat gtgaccagca cacagattgt tacagctgta cagccaacac caatgactgc
2161 cactggtgca atgaccattg tgtccccagg aaccacagct gctcagaagg ccagatctcc
2221 attttttagt atgagaattg ccccaaggat aaccccatgt actactgtaa caagaagacc
2281 agctgcagg gctgtgccct ggaccagaac tgccagtggg agccccgaa tcaggatgc
2341 attgccctgc ccgaaaarat ctgtggcatt ggctggcatt tgggtggaaa ctcatgtttg
2401 aaaattacta ctgccaaagg gaattatgac aatgctaaat tgttctgtag gaaccacaat
2461 gcccttttgg cttctcttac aaccagaag aaggtagaat ttgtccttaa gcagctgcga
2521 ataatgcagt catctcagag catgtccaaag ctcaccttaa ccccatgggt cggccttcgg
2581 aagatcaatg tgtcctactg gtgtgggaa gatattgtccc catttacta tagtttacta
2641 cagtggatgc cgtctgagcc cagtgtgct ggattctgtg gaattttatc agaaccagt
2701 actcggggac tgaaggctgc aacctgcac aacccactca atggtagtgt ctgtgaaagg
2761 cctgcaaacc acagtgtcaa gcagtgcggc acaccatgtg ccttgaggac agcatgtgga
2821 gattgcacca gcggcagctc tgagtgcatt tgggtgcagca acatgaagca gtgtgtggac
2881 tccaatgct atgtggcctc cttccctttt ggccagtgtg tggaaatggta tacgatgagc
2941 acctgcccc ctgaaaattg ttcaggctac tgtacctgta gtcattgctt ggagcaacca
3001 ggctgtggct ggtgtactga tcccagcaat actggcaaag ggaaatgcat agaggggtcc
3061 tataaaggac cagtgaagat gccttcgcaa gccctacag gaaatttcta tccacagccc
3121 ctgctcaatt ccagcatgtg tctagaggac agcagataca actggctctt cattcactgt
3181 ccagcttgcc aatgcaacgg ccacagtaaa tgcataatc agagcatctg tgagaagtgt
3241 gagaacctga ccacaggcaa gcactgcag acctgcata ctggcttcta cgggtgatccc
3301 accaatggag ggaatgtca gccatgcaag tgcaatgggc acgcgtctct gtgcaacacc
3361 aacacgggca agtgcttctg caccaccaag ggcgtcaagg gggacgagt gcagctatgt
3421 gaggtagaaa atcgatacca aggaaccct ctcagaggaa catgttatta tactcttctt
3481 attgactatc agttcacct tagtctatcc caggaagatg atcgctatta cacagctatc
3541 aattttgtg ctactctgt cgaacaaaac agggatttgg acatgttcat caatgcctcc
3601 aagaatttca acctcaacat cacctgggt cccagtttct cagctggaac ccaggctgga
3661 gaagagatgc ctgttgtttc aaaaaccaac attaaggagt acaaagatag tttctctaatt
3721 gagaagtgtg attttcgcaa ccacccaaat atcactttct ttgtttatgt cagtaatttc
3781 acctggccca tcaaaattca ggtgcaaact gaacaatga

```

FIGURE 13

1	MVAAAAATEA	RLRRRTAATA	ALAGRSGGPH	WDWDVTPAGR	PGLGAGLRLP
51	RLLSPPLRPR	LLLLLLLLLP	PLLLLLLLPCE	AEAAAAAAAV	SGSAAAEAKE
101	CDRPCVNGGR	CNPGTGQVC	PAGWVGEQCQ	HCGGRFRLTG	SSGFVTDGPG
151	NYKYKTKCTW	LIEGQPNRIM	RLRFNHFATE	CSWDHLYVYD	GDSIYAPLVA
201	AFSGLIVPER	DGNETVPEVV	ATSGYALLHF	FSDAAYNLTG	FNITYSFDMC
251	PNNCSEGRGEC	KISNSSETVE	CECSENWKGE	ACDIPHCTDN	CGFPHRGICN
301	SSDVRGCSCF	SDWQGP GCSV	PVPANQSFWT	REEYSNLKLP	RASHKAVVNG
351	NIMWVVG GYM	FNHSDYNMVL	AYDLASREW	PLNRSVNNV	VRYGHSALY
401	KDKIYMYGGK	IDPTGNVTNE	LRVFHINHES	WVLLTPKAKE	QYAVVG HSAH
451	IVTLKNGRVV	MLVIFGHCP	YGYISNVQ EY	DLDKNTWSIL	HTQALVQGG
501	YGHSSVYDHR	TRALYVHGGY	KAFSANKYRL	ADDLYRYDVD	TQMWTILKDS
551	FFFYRLHTAV	IVSGTMLVFG	GNTHNDTSMS	HGAKCFSSDF	MAYDIACDRW
601	SVLPRPDLHH	DVNRFGHSAV	LHNSTMVYFG	GFNSLLLSDI	LVFTSEQCDA
651	HRSEAACLAA	GPGIRCVWNT	GSSQCISWAL	ATDEQEEKLK	SECFSKRTLD
701	HDRCDQHTDC	YSCTANTNDC	HWCNDHCVPR	NHSCSEGQIS	IFRYENCPKD
751	NPMYYCNKKT	SCRSCALDQN	CQWEPRNQEC	IALPENICGI	GWHLVGN SCL
801	KITTAKENYD	NAKLFCRNHN	ALLASLT TQK	KVEFVLKQLR	IMQSSQSMSK
851	LTLTPWVGLR	KINVS YWCWE	DMSPFTNSLL	QWMPSEPSDA	GFCGILSEPS
901	TRGLKAATCI	NPLNGSV CER	PANHSAKQCR	TPCALRTACG	DCTSGSSECM
951	WCSNMKQCVD	SNAYVASFPF	GQCMEWYTMS	TCPPENC SGY	CTCSHCLEQP
1001	GCGWCTDPSN	TGKGKCI EGS	YKGPVKMPSQ	APTGNFY PQP	LLNSSMCLED
1051	SRYNWSFIHC	PACQCNGH SK	CINQSICEKC	ENLTTGKHCE	TCISGFY GPD
1101	TNGGKCQPCK	CNGHASLCNT	NTGKCFCTTK	GVKGDECQLC	EVENRYQGNP
1151	LRGTCYYTLL	IDYQFTFSL S	QEDDRYYTAI	NFVATPDEQN	RDLDMFINAS
1201	KNFNLNITWA	ASFSAGTQAG	EEMPVVS KTN	IKEYKDSFSN	EKFDFRNHPN
1251	ITFFVYVS NF	TWPIKIQIAF	SQHSNFMDLV	QFFVTFFSCF	LSLLLVA AVV
1301	WKIKQSCWAS	RRREQLLREM	QQMASRPFAS	VNVALETDEE	PPDLIGGSIK
1351	TVPKPIALEP	CFGNKAAVLS	VFVRLPRGLG	GIPPPGQ SGL	AVASALVDIS
1401	QQMPIVYKEK	SGAVRNRKQQ	PPAQPGTCI		

FIGURE 14A

```
1   atggtggccg cagcggcggc aactgaggca aggctgagga ggaggacggc
51  ggcgacggca gcgctcgcgg gcaggagcgg cgggccgcac tgggactggg
101 acgtgaccag ggctgggagg ccggggctgg gggccgggct gcgcctcccg
151 cggctgctgt ctccaccgct gcggccacgg ctgctgctgc tgcgtgtgtt
201 gctcccgcgg ccgctgttgc tgctgctgct gccctgtgag gccgaggccg
251 cggcggcggc ggcggcgggt tcgggctcag ccgcagccga ggccaaggaa
301 tgtgaccggc cctgtgtcaa cggcgggtcgc tgcaaccctg gcaccggcca
351 gtgcgtctgc cccgccgggt ggggtgggca gcaatgccag cactgcgggg
401 gccgcttcag actaactgga tcttctgggt ttgtgacaga tggacctgga
451 aattataaat acaaaacgaa gtgcacgtgg ctcatgaag gacagccaaa
501 tagaataatg agacttcggt tcaatcattt tgctacagag tgtagtggg
551 accatttata tgtttatgat ggggactcaa tttatgcacc gctagtgtct
601 gcatttagtg gcctcattgt tccgagaga gatggcaatg agactgtccc
651 tgagggtgtt gccacatcag gttatgcctt gctgcatttt tttagtgtg
701 ctgcttataa tttgactgga tttaataatta cttacagttt tgatatgtgt
751 ccaaataact gctcaggccg aggagagtgt aagatcagta atagcagcga
801 aactgttgaa tgtgaatgtt ctgaaaactg gaaaggcgaa gcatgtgaca
851 ttcctcactg tacagacaac tgtggttttc ctcatcgagg catctgcaat
901 tcaagtgatg tcagaggatg ctcttgcttc tcagactggc agggctctgg
951 atgttcagtt cctgtaccag ctaaccagtc attttgact cgagaggaat
1001 attctaactt aaagctcccc agagcatctc ataaagctgt ggtcaatgga
1051 aacattatgt gggttgttgg aggatatatg ttcaaccact cagattataa
1101 catggttcta gcgtatgacc ttgcttctag ggagtggctt ccactaaacc
1151 gttctgtgaa caatgtggtt gttagatatg gtcattcttt ggcattatac
1201 aaggataaaa ttacatgta tggaggaaaa attgatccaa ctgggaatgt
1251 gaccaatgag ttgagagttt ttcacattca taatgagtca tgggtgttgt
1301 tgacccttaa ggcaaaggag cagtatgcag tgggtgggca ctctgcacac
1351 attgttacac tgaagaatgg ccgagtggtc atgctgggtc tctttgggtc
1401 ctgccctctc tatggatata taagcaatgt gcaggaatat gatttggata
1451 agaacacatg gagtatatta cacaccaggg gtgcccttgt gcaagggggg
1501 tacggccata gcagtgttta cgaccatagg accagggccc tatacgttca
1551 tgggtggctac aaggctttca gtgccataaa gtaccggctt gcagatgatc
1601 tctaccgata tgatgtggat acccagatgt ggaccaattc taaggacagc
1651 cgattttttcc gttacttgca cacagctgtg atagtgagtg gaaccatgct
1701 ggtgtttggg ggaaacacac acaatgacac atctatgagc catggcgcca
1751 aatgcttctc ttcagatttc atggcctatg acattgcctg tgaccgctgg
1801 tcagtgtctc ccagacctga tctccaccat gatgtcaaca gatttggcca
1851 ttcagcagtc ttacacaaca gcaccatgta tgtgttcggt ggtttcaata
1901 gtctcctcct cagcgacatc ctggtattca cctcggaaca gtgtgatgcg
1951 catcggagtg aagccgcttg tttagcagca ggacctggtt ttcgggtgtg
2001 gtggaacaca gggtcgtctc agtgtatctc gtgggcgctg gcaactgatg
2051 aacaagaaga aaagttaaaa tcagaatgtt tttccaaaag aactcttgac
2101 catgacagat gtgaccagca cacagattgt tacagctgta cagccaacac
2151 caatgactgc cactgggtgca atgaccattg tgtccccagg aaccacagct
2201 gctcagaagg ccagatctcc atttttagggt atgagaattg cccaaggat
2251 aaccccatgt actactgtaa caagaagacc agctgcagga gctgtgccct
2301 ggaccagaac tgccagtggg agccccggaa tcaggagtgc attgccctgc
2351 ccgaaaatat ctgtggcatt ggctggcatt tggttggaaa ctcatgtttg
2401 aaaattacta ctgccaaagg gaattatgac aatgctaaat tgttctgtag
2451 gaaccacaat gcccttttgg cttctcttac aaccagaag aaggtagaat
2501 ttgtccttaa gcagctcgga ataatgcagt catctcagag catgtccaag
2551 ctcaccttaa ccccatgggt cggccttcgg aagatcaatg tgtcctactg
2601 gtgctgggaa gatatgtccc catttacaaa tagtttacta cagtggatgc
```

Figure 14B

2651	cgtctgagcc	cagtgatgct	ggattctgtg	gaattttatc	agaacccagt
2701	actcggggac	tgaaggctgc	aacctgcatc	aaccactca	atggtagtgt
2751	ctgtgaaagg	cctgcaaacc	acagtgctaa	gcagtgccgg	acaccatgtg
2801	ccttgaggac	agcatgtgga	gattgcacca	gcggcagctc	tgagtgcattg
2851	tgggtgcagca	acatgaagca	gtgtgtggac	tccaatgcct	atgtggcctc
2901	cttccctttt	ggccagtgtg	tggaaatggta	tacgatgagc	acctgcccc
2951	ctgaaaattg	tccaggctac	tgtacctgta	gtcattgctt	ggagcaacca
3001	ggctgtggct	ggtgtactga	tcccagcaat	actggcaaag	ggaaatgcat
3051	agaggggttc	tataaaggac	cagtgaagat	gccttcgcaa	gcccctacag
3101	gaaattttcta	tccacagccc	ctgctcaatt	ccagcatgtg	tctagaggac
3151	agcagataca	actgggtcttt	cattcactgt	ccagcttgcc	aatgcaacgg
3201	ccacagtaaa	tgcattcaatc	agagcatctg	tgagaagtgt	gagaacctga
3251	ccacaggcaa	gcactgagag	acctgcata	ctggcttcta	cggtagatccc
3301	accaatggag	ggaaatgtca	gccatgcaag	tgcaatgggc	acgcgtctct
3351	gtgcaacacc	aacacgggca	agtgtctctg	caccaccaag	ggcgtcaagg
3401	gggacgagtg	ccagctatgt	gaggtagaaa	atcgatacca	aggaaacctt
3451	ctcagaggaa	catgttatta	tactcttctt	attgactatc	agttcacctt
3501	tagtctatcc	caggaagatg	atcgctatta	cacagctatc	aattttgtgg
3551	ctactcctga	cgaacaaaac	agggattttg	acatgttcat	caatgcctcc
3601	aagaattttca	acctcaacat	cacctgggct	gccagtttct	cagctggaac
3651	ccaggctgga	gaagagatgc	ctgttggttc	aaaaaccaac	attaaggagt
3701	acaaagatag	tttctcta	gagaagtttg	attttcgcaa	ccacccaaat
3751	atcactttct	ttgtttatgt	cagtaatttc	acctggccca	tcaaaattca
3801	gattgccttc	tctcagcaca	gcaattttat	ggacctggta	cagttcttcg
3851	tgactttctt	cagttgtttc	ctctctttgc	tcctgggtggc	tgctgtgggt
3901	tggaagatca	aacaaagtgt	ttgggcctcc	agacgtagag	agcaacttct
3951	tcgagagatg	caacagatgg	ccagccgtcc	ctttgcctct	gtaaatgtcg
4001	ccttggaaac	agatgaggag	cctcctgatc	ttattggggg	gagtataaag
4051	actgttccca	aaccatttgc	actggagccg	tgttttggca	acaaagccgc
4101	tgctctctct	gtgtttgtga	ggctccctcg	aggcctgggt	ggcatccctc
4151	ctcctgggca	gtcaggtctt	gctgtggcca	gcgccctggg	ggacatttct
4201	cagcagatgc	cgatagtgtg	caaggagaag	tcaggagccg	tgagaaaccg
4251	gaagcagcag	ccccctgcac	agcctgggac	ctgcatctga	




Fig. 15

SEQUENCE LISTING

<110> Dana-Farber Cancer Institute, Inc.

<120> REGULATION OF IMMUNE RESPONSES BY ATTRACTIN

<130> 00530/089WO1

<150> US 60/100,137

<151> 1998-09-14

<160> 25

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 3597

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)...(3594)

<400> 1

atg gtg gcc gca gcg gcg gca act gag gca agg ctg agg agg agg acg	48
Met Val Ala Ala Ala Ala Ala Thr Glu Ala Arg Leu Arg Arg Arg Thr	
1 5 10 15	
gcg gcg acg gca gcg ctc gcg ggc agg agc ggc ggg ccg cac tgt gtc	96
Ala Ala Thr Ala Ala Leu Ala Gly Arg Ser Gly Gly Pro His Cys Val	
20 25 30	
aac ggc ggt cgc tgc aac cct ggc acc ggc cag tgc gtc tgc ccc gcc	144
Asn Gly Gly Arg Cys Asn Pro Gly Thr Gly Gln Cys Val Cys Pro Ala	
35 40 45	
ggc tgg gtg ggc gag caa tgc cag cac tgc ggc ggc cgc ttc aga cta	192
Gly Trp Val Gly Glu Gln Cys Gln His Cys Gly Gly Arg Phe Arg Leu	
50 55 60	
act gga tct tct ggg ttt gtg aca gat gga cct gga aat tat aaa tac	240
Thr Gly Ser Ser Gly Phe Val Thr Asp Gly Pro Gly Asn Tyr Lys Tyr	
65 70 75 80	
aaa acg aag tgc acg tgg ctc att gaa gga cag cca aat aga ata atg	288
Lys Thr Lys Cys Thr Trp Leu Ile Glu Gly Gln Pro Asn Arg Ile Met	
85 90 95	
aga ctt cgt ttc aat cat ttt gct aca gag tgt agt tgg gac cat tta	336
Arg Leu Arg Phe Asn His Phe Ala Thr Glu Cys Ser Trp Asp His Leu	
100 105 110	
tat gtt tat gat ggg gac tca att tat gca ccg cta gtt gct gca ttt	384
Tyr Val Tyr Asp Gly Asp Ser Ile Tyr Ala Pro Leu Val Ala Ala Phe	
115 120 125	
agt ggc ctc att gtt cct gag aga gat ggc aat gag act gtc cct gag	432
Ser Gly Leu Ile Val Pro Glu Arg Asp Gly Asn Glu Thr Val Pro Glu	
130 135 140	
gtt gtt gcc aca tca ggt tat gcc ttg ctg cat ttt ttt agt gat gct	480
Val Val Ala Thr Ser Gly Tyr Ala Leu Leu His Phe Phe Ser Asp Ala	
145 150 155 160	

gct tat aat ttg act gga ttt aat att act tac agt ttt gat atg tgt Ala Tyr Asn Leu Thr Gly Phe Asn Ile Thr Tyr Ser Phe Asp Met Cys 165 170 175	528
cca aat aac tgc tca ggc cga gga gag tgt aag atc agt aat agc agc Pro Asn Asn Cys Ser Gly Arg Gly Glu Cys Lys Ile Ser Asn Ser Ser 180 185 190	576
gat act gtt gaa tgt gaa tgt tct gaa aac tgg aaa ggt gaa gca tgt Asp Thr Val Glu Cys Glu Cys Ser Glu Asn Trp Lys Gly Glu Ala Cys 195 200 205	624
gac att cct cac tgt aca gac aac tgt ggt ttt cct cat cga ggc atc Asp Ile Pro His Cys Thr Asp Asn Cys Gly Phe Pro His Arg Gly Ile 210 215 220	672
tgc aat tca agt gat gtc aga gga tgc tcc tgc ttc tca gac tgg cag Cys Asn Ser Ser Asp Val Arg Gly Cys Ser Cys Phe Ser Asp Trp Gln 225 230 235 240	720
ggt cct gga tgt tca gtt cct gta cca gct aac cag tca ttt tgg act Gly Pro Gly Cys Ser Val Pro Val Pro Ala Asn Gln Ser Phe Trp Thr 245 250 255	768
cga gag gaa tat tct aac tta aag ctc ccc aga gca tct cat aaa gct Arg Glu Glu Tyr Ser Asn Leu Lys Leu Pro Arg Ala Ser His Lys Ala 260 265 270	816
gtg gtc aat gga aac att atg tgg gtt gtt gga gga tat atg ttc aac Val Val Asn Gly Asn Ile Met Trp Val Val Gly Gly Tyr Met Phe Asn 275 280 285	864
cac tca gat tat aac atg gtt cta gcg tat gac ctt gct tct agg gag His Ser Asp Tyr Asn Met Val Leu Ala Tyr Asp Leu Ala Ser Arg Glu 290 295 300	912
tgg ctt cca cta aac cgt tct gtg aac aat gtg gtt gtt aga tat ggt Trp Leu Pro Leu Asn Arg Ser Val Asn Asn Val Val Val Arg Tyr Gly 305 310 315 320	960
cat tct ttg gca tta tac aag gat aaa att tac atg tat gga gga aaa His Ser Leu Ala Leu Tyr Lys Asp Lys Ile Tyr Met Tyr Gly Gly Lys 325 330 335	1008
att gat tca act ggg aat gtg acc aat gag ttg aga gtt ttt cac att Ile Asp Ser Thr Gly Asn Val Thr Asn Glu Leu Arg Val Phe His Ile 340 345 350	1056
cat aat gag tca tgg gtg ttg ttg acc cct aag gca aag gag cag tat His Asn Glu Ser Trp Val Leu Leu Thr Pro Lys Ala Lys Glu Gln Tyr 355 360 365	1104
gca gtg gtt ggg cac tct gca cac att gtt aca ctg aag aat ggc cga Ala Val Val Gly His Ser Ala His Ile Val Thr Leu Lys Asn Gly Arg 370 375 380	1152
gtg gtc atg ctg gtc atc ttt ggt cac tgc cct ctc tat gga tat ata Val Val Met Leu Val Ile Phe Gly His Cys Pro Leu Tyr Gly Tyr Ile 385 390 395 400	1200
agc aat gtg cag gaa tat gat ttg gat aag aac aca tgg agt ata tta Ser Asn Val Gln Glu Tyr Asp Leu Asp Lys Asn Thr Trp Ser Ile Leu 405 410 415	1248
cac acc cag ggt gcc ctt gtg caa ggg ggt tac ggc cat agc agt gtt His Thr Gln Gly Ala Leu Val Gln Gly Gly Tyr Gly His Ser Ser Val 420 425 430	1296

tac gac cat agg acc agg gcc cta tac gtt cat ggt ggc tac aag gct Tyr Asp His Arg Thr Arg Ala Leu Tyr Val His Gly Gly Tyr Lys Ala 435 440 445	1344
ttc agt gcc aat aag tac cgg ctt gca gat gat ctc tac cga tat gat Phe Ser Ala Asn Lys Tyr Arg Leu Ala Asp Asp Leu Tyr Arg Tyr Asp 450 455 460	1392
gtg gat acc cag atg tgg acc att ctt aag gac agc cga ttt ttc cgt Val Asp Thr Gln Met Trp Thr Ile Leu Lys Asp Ser Arg Phe Phe Arg 465 470 475 480	1440
tac ttg cac aca gct gtg ata gtg agt gga acc atg ctg gtg ttt ggg Tyr Leu His Thr Ala Val Ile Val Ser Gly Thr Met Leu Val Phe Gly 485 490 495	1488
gga aac aca cac aat gac aca tct atg agc cat ggc gcc aaa tgc ttc Gly Asn Thr His Asn Asp Thr Ser Met Ser His Gly Ala Lys Cys Phe 500 505 510	1536
tct tca gat ttc atg gcc tat gac att gcc tgt gac cgc tgg tca gtg Ser Ser Asp Phe Met Ala Tyr Asp Ile Ala Cys Asp Arg Trp Ser Val 515 520 525	1584
ctt ccc aga cct gat tcc acc atg atg tca aca gat ttg gcc att cca Leu Pro Arg Pro Asp Ser Thr Met Met Ser Thr Asp Leu Ala Ile Pro 530 535 540	1632
gca gtc tta cac aac agc acc atg tat gtg ttc ggt ggt ttc aat agt Ala Val Leu His Asn Ser Thr Met Tyr Val Phe Gly Gly Phe Asn Ser 545 550 555 560	1680
ctc ctc ctc agc gac atc ctg gta ttc acc tcg gaa cag tgt gat gcg Leu Leu Leu Ser Asp Ile Leu Val Phe Thr Ser Glu Gln Cys Asp Ala 565 570 575	1728
cat cgg agt gaa gcc gct tgt tta gca gca gga cct ggt att cgg tgt His Arg Ser Glu Ala Ala Cys Leu Ala Ala Gly Pro Gly Ile Arg Cys 580 585 590	1776
gtg tgg aac aca ggg tcg tct cag tgt atc tcg tgg gcg ctg gca act Val Trp Asn Thr Gly Ser Ser Gln Cys Ile Ser Trp Ala Leu Ala Thr 595 600 605	1824
gat gaa caa gaa gaa aag tta aaa tca gaa tgt ttt tcc aaa aga act Asp Glu Gln Glu Glu Lys Leu Lys Ser Glu Cys Phe Ser Lys Arg Thr 610 615 620	1872
ctt gac cat gac aga tgt gac cag cac aca gat tgt tac agc tgc aca Leu Asp His Asp Arg Cys Asp Gln His Thr Asp Cys Tyr Ser Cys Thr 625 630 635 640	1920
gcc aac acc aat gac tgc cac tgg tgc aat gac cat tgt gtc ccc agg Ala Asn Thr Asn Asp Cys His Trp Cys Asn Asp His Cys Val Pro Arg 645 650 655	1968
aac cac agc tgc tca gaa ggc cag atc tcc att ttt agg tat gag aat Asn His Ser Cys Ser Glu Gly Gln Ile Ser Ile Phe Arg Tyr Glu Asn 660 665 670	2016
tgc ccc aag gat aac cct atg tac tac tgt aac aag aag acc agc tgc Cys Pro Lys Asp Asn Pro Met Tyr Tyr Cys Asn Lys Lys Thr Ser Cys 675 680 685	2064

agg agc tgt gcc ctg gac cag aac tgc cag tgg gag ccc cgg aat cag Arg Ser Cys Ala Leu Asp Gln Asn Cys Gln Trp Glu Pro Arg Asn Gln 690 695 700	2112
gag tgc att gcc ctg ccc gaa aat atc tgt ggc att ggc tgg cat ttg Glu Cys Ile Ala Leu Pro Glu Asn Ile Cys Gly Ile Gly Trp His Leu 705 710 715 720	2160
gtt gga aac tca tgt ttg aaa att act act gcc aag gag aat tat gac Val Gly Asn Ser Cys Leu Lys Ile Thr Thr Ala Lys Glu Asn Tyr Asp 725 730 735	2208
aat gct aaa ttg ttc tgt agg aac cac aat gcc ctt ttg gct tct ctt Asn Ala Lys Leu Phe Cys Arg Asn His Asn Ala Leu Leu Ala Ser Leu 740 745 750	2256
aca acc cag aag aag gta gaa ttt gtc ctt aag cag ctg cga ata atg Thr Thr Gln Lys Lys Val Glu Phe Val Leu Lys Gln Leu Arg Ile Met 755 760 765	2304
cag tca tct cag agc atg tcc aag ctc acc tta acc cca tgg gtc ggc Gln Ser Ser Gln Ser Met Ser Lys Leu Thr Leu Thr Pro Trp Val Gly 770 775 780	2352
ctt cgg aag atc aat gtg tcc tac tgg tgc tgg gaa gat atg tcc cca Leu Arg Lys Ile Asn Val Ser Tyr Trp Cys Trp Glu Asp Met Ser Pro 785 790 800	2400
ttt aca aat agt tta cta cag tgg atg ccg tct gag ccc agt gat gct Phe Thr Asn Ser Leu Gln Trp Met Pro Ser Glu Pro Ser Asp Ala 805 810 815	2448
gga ttc tgt gga att tta tca gaa ccc agt act cgg gga ctg aag gct Gly Phe Cys Gly Ile Leu Ser Glu Pro Ser Thr Arg Gly Leu Lys Ala 820 825 830	2496
gca acc tgc atc aac cca ctc aat ggt agt gtc tgt gaa agg cct gca Ala Thr Cys Ile Asn Pro Leu Asn Gly Ser Val Cys Glu Arg Pro Ala 835 840 845	2544
aac cac agt gct aag cag tgc cgg aca cca tgt gcc ttg agg aca gca Asn His Ser Ala Lys Gln Cys Arg Thr Pro Cys Ala Leu Arg Thr Ala 850 855 860	2592
tgt gga gat tgc acc agc ggc agc tct gag tgc atg tgg tgc agc aac Cys Gly Asp Cys Thr Ser Gly Ser Ser Glu Cys Met Trp Cys Ser Asn 865 870 875 880	2640
atg aag cag tgt gtg gac tcc aat gcc tat gtg gcc tcc ttc cct ttt Met Lys Gln Cys Val Asp Ser Asn Ala Tyr Val Ala Ser Phe Pro Phe 885 890 895	2688
ggc cag tgt atg gaa tgg tat acg atg agc acc tgc ccc cct gaa aat Gly Gln Cys Met Glu Trp Tyr Thr Met Ser Thr Cys Pro Pro Glu Asn 900 905 910	2736
tgt tca ggc tac tgt acc tgt agt cat tgc ttg gag caa cca ggc tgt Cys Ser Gly Tyr Cys Thr Cys Ser His Cys Leu Glu Gln Pro Gly Cys 915 920 925	2784
ggc tgg tgt act gat ccc agc aat act ggc aaa ggg aaa tgc ata gag Gly Trp Cys Thr Asp Pro Ser Asn Thr Gly Lys Gly Lys Cys Ile Glu 930 935 940	2832
ggt tcc tat aaa gga cca gtg aag atg cct tcg caa gcc cct aca gga Gly Ser Tyr Lys Gly Pro Val Lys Met Pro Ser Gln Ala Pro Thr Gly 945 950 955 960	2880

aat ttc tat cca cag ccc ctg ctc aat tcc agc atg tgt cta gag gac Asn Phe Tyr Pro Gln Pro Leu Leu Asn Ser Ser Met Cys Leu Glu Asp 965 970 975	2928
agc aga tac aac tgg tct ttc att cac tgt cca gct tgc caa tgc aac Ser Arg Tyr Asn Trp Ser Phe Ile His Cys Pro Ala Cys Gln Cys Asn 980 985 990	2976
ggc cac agt aaa tgc atc aat cag agc atc tgt gag aag tgt gag aac Gly His Ser Lys Cys Ile Asn Gln Ser Ile Cys Glu Lys Cys Glu Asn 995 1000 1005	3024
ctg acc aca ggc aag cac tgc gag acc tgc ata tct ggc ttc tac ggt Leu Thr Gly Lys His Cys Glu Thr Cys Ile Ser Gly Phe Tyr Gly 1010 1015 1020	3072
gat ccc acc aat gga ggg aaa tgt cag cca tgc aag tgc aat ggg cac Asp Pro Thr Asn Gly Gly Lys Cys Gln Pro Cys Lys Cys Asn Gly His 1025 1030 1035 1040	3120
gcg tct ctg tgc aac acc aac acg ggc aag tgc ttc tgc acc acc aag Ala Ser Leu Cys Asn Thr Asn Thr Gly Lys Cys Phe Cys Thr Thr Lys 1045 1050 1055	3168
ggc gtc aag ggg gac gag tgc cag cta tgt gag gta gaa aat cga tac Gly Val Lys Gly Asp Glu Cys Gln Leu Cys Glu Val Glu Asn Arg Tyr 1060 1065 1070	3216
caa gga aac cct ctc aga gga aca tgt tat tat act ctt ctt att gac Gln Gly Asn Pro Leu Arg Gly Thr Cys Tyr Tyr Thr Leu Leu Ile Asp 1075 1080 1085	3264
tat cag ttc acc ttt agt cta tcc cag gaa gat gat cgc tat tac aca Tyr Gln Phe Thr Phe Ser Leu Ser Gln Glu Asp Asp Arg Tyr Tyr Thr 1090 1095 1100	3312
gct atc aat ttt gtg gct act cct gac gaa caa aac agg gat ttg gac Ala Ile Asn Phe Val Ala Thr Pro Asp Glu Gln Asn Arg Asp Leu Asp 1105 1110 1115 1120	3360
atg ttc atc aat gcc tcc aag aat ttc aac ctc aac atc acc tgg gct Met Phe Ile Asn Ala Ser Lys Asn Phe Asn Leu Asn Ile Thr Trp Ala 1125 1130 1135	3408
gcc agt ttc tca gct gga acc cag gct gga gaa gag atg cct gtt gtt Ala Ser Phe Ser Ala Gly Thr Gln Ala Gly Glu Glu Met Pro Val Val 1140 1145 1150	3456
tca aaa acc aac att aag gag tac aaa gat agt ttc tct aat gag aag Ser Lys Thr Asn Ile Lys Glu Tyr Lys Asp Ser Phe Ser Asn Glu Lys 1155 1160 1165	3504
ttt gat ttt cgc aac cac cca aat atc act ttc ttt gtt tat gtc agt Phe Asp Phe Arg Asn His Pro Asn Ile Thr Phe Phe Val Tyr Val Ser 1170 1175 1180	3552
aat ttc acc tgg ccc atc aaa att cag gtg caa act gaa caa Asn Phe Thr Trp Pro Ile Lys Ile Gln Val Gln Thr Glu Gln 1185 1190 1195	3594
tga	3597
<210> 2	
<211> 1198	
<212> PRT	
<213> Homo sapiens	

<400> 2

Met Val Ala Ala Ala Ala Thr Glu Ala Arg Leu Arg Arg Arg Thr
1 5 10 15
Ala Ala Thr Ala Ala Leu Ala Gly Arg Ser Gly Gly Pro His Cys Val
20 25 30
Asn Gly Gly Arg Cys Asn Pro Gly Thr Gly Gln Cys Val Cys Pro Ala
35 40 45
Gly Trp Val Gly Glu Gln Cys Gln His Cys Gly Gly Arg Phe Arg Leu
50 55 60
Thr Gly Ser Ser Gly Phe Val Thr Asp Gly Pro Gly Asn Tyr Lys Tyr
65 70 75 80
Lys Thr Lys Cys Thr Trp Leu Ile Glu Gly Gln Pro Asn Arg Ile Met
85 90 95
Arg Leu Arg Phe Asn His Phe Ala Thr Glu Cys Ser Trp Asp His Leu
100 105 110
Tyr Val Tyr Asp Gly Asp Ser Ile Tyr Ala Pro Leu Val Ala Ala Phe
115 120 125
Ser Gly Leu Ile Val Pro Glu Arg Asp Gly Asn Glu Thr Val Pro Glu
130 135 140
Val Val Ala Thr Ser Gly Tyr Ala Leu Leu His Phe Phe Ser Asp Ala
145 150 155 160
Ala Tyr Asn Leu Thr Gly Phe Asn Ile Thr Tyr Ser Phe Asp Met Cys
165 170 175
Pro Asn Asn Cys Ser Gly Arg Gly Glu Cys Lys Ile Ser Asn Ser Ser
180 185 190
Asp Thr Val Glu Cys Glu Cys Ser Glu Asn Trp Lys Gly Glu Ala Cys
195 200 205
Asp Ile Pro His Cys Thr Asp Asn Cys Gly Phe Pro His Arg Gly Ile
210 215 220
Cys Asn Ser Ser Asp Val Arg Gly Cys Ser Cys Phe Ser Asp Trp Gln
225 230 235 240
Gly Pro Gly Cys Ser Val Pro Val Pro Ala Asn Gln Ser Phe Trp Thr
245 250 255
Arg Glu Glu Tyr Ser Asn Leu Lys Leu Pro Arg Ala Ser His Lys Ala
260 265 270
Val Val Asn Gly Asn Ile Met Trp Val Val Gly Gly Tyr Met Phe Asn
275 280 285
His Ser Asp Tyr Asn Met Val Leu Ala Tyr Asp Leu Ala Ser Arg Glu
290 295 300
Trp Leu Pro Leu Asn Arg Ser Val Asn Asn Val Val Val Arg Tyr Gly
305 310 315 320
His Ser Leu Ala Leu Tyr Lys Asp Lys Ile Tyr Met Tyr Gly Gly Lys
325 330 335
Ile Asp Ser Thr Gly Asn Val Thr Asn Glu Leu Arg Val Phe His Ile
340 345 350
His Asn Glu Ser Trp Val Leu Leu Thr Pro Lys Ala Lys Glu Gln Tyr
355 360 365
Ala Val Val Gly His Ser Ala His Ile Val Thr Leu Lys Asn Gly Arg
370 375 380
Val Val Met Leu Val Ile Phe Gly His Cys Pro Leu Tyr Gly Tyr Ile
385 390 395 400
Ser Asn Val Gln Glu Tyr Asp Leu Asp Lys Asn Thr Trp Ser Ile Leu
405 410 415
His Thr Gln Gly Ala Leu Val Gln Gly Gly Tyr Gly His Ser Ser Val
420 425 430
Tyr Asp His Arg Thr Arg Ala Leu Tyr Val His Gly Gly Tyr Lys Ala
435 440 445
Phe Ser Ala Asn Lys Tyr Arg Leu Ala Asp Asp Leu Tyr Arg Tyr Asp
450 455 460
Val Asp Thr Gln Met Trp Thr Ile Leu Lys Asp Ser Arg Phe Phe Arg
465 470 475 480
Tyr Leu His Thr Ala Val Ile Val Ser Gly Thr Met Leu Val Phe Gly
485 490 495
Gly Asn Thr His Asn Asp Thr Ser Met Ser His Gly Ala Lys Cys Phe
500 505 510
Ser Ser Asp Phe Met Ala Tyr Asp Ile Ala Cys Asp Arg Trp Ser Val
515 520 525

Leu Pro Arg Pro Asp Ser Thr Met Met Ser Thr Asp Leu Ala Ile Pro
 530 535 540
 Ala Val Leu His Asn Ser Thr Met Tyr Val Phe Gly Gly Phe Asn Ser
 545 550 555 560
 Leu Leu Leu Ser Asp Ile Leu Val Phe Thr Ser Glu Gln Cys Asp Ala
 565 570 575
 His Arg Ser Glu Ala Ala Cys Leu Ala Ala Gly Pro Gly Ile Arg Cys
 580 585 590
 Val Trp Asn Thr Gly Ser Ser Gln Cys Ile Ser Trp Ala Leu Ala Thr
 595 600 605
 Asp Glu Gln Glu Glu Lys Leu Lys Ser Glu Cys Phe Ser Lys Arg Thr
 610 615 620
 Leu Asp His Asp Arg Cys Asp Gln His Thr Asp Cys Tyr Ser Cys Thr
 625 630 635 640
 Ala Asn Thr Asn Asp Cys His Trp Cys Asn Asp His Cys Val Pro Arg
 645 650 655
 Asn His Ser Cys Ser Glu Gly Gln Ile Ser Ile Phe Arg Tyr Glu Asn
 660 665 670
 Cys Pro Lys Asp Asn Pro Met Tyr Tyr Cys Asn Lys Lys Thr Ser Cys
 675 680 685
 Arg Ser Cys Ala Leu Asp Gln Asn Cys Gln Trp Glu Pro Arg Asn Gln
 690 695 700
 Glu Cys Ile Ala Leu Pro Glu Asn Ile Cys Gly Ile Gly Trp His Leu
 705 710 715 720
 Val Gly Asn Ser Cys Leu Lys Ile Thr Thr Ala Lys Glu Asn Tyr Asp
 725 730 735
 Asn Ala Lys Leu Phe Cys Arg Asn His Asn Ala Leu Leu Ala Ser Leu
 740 745 750
 Thr Thr Gln Lys Lys Val Glu Phe Val Leu Lys Gln Leu Arg Ile Met
 755 760 765
 Gln Ser Ser Gln Ser Met Ser Lys Leu Thr Leu Thr Pro Trp Val Gly
 770 775 780
 Leu Arg Lys Ile Asn Val Ser Tyr Trp Cys Trp Glu Asp Met Ser Pro
 785 790 795 800
 Phe Thr Asn Ser Leu Leu Gln Trp Met Pro Ser Glu Pro Ser Asp Ala
 805 810 815
 Gly Phe Cys Gly Ile Leu Ser Glu Pro Ser Thr Arg Gly Leu Lys Ala
 820 825 830
 Ala Thr Cys Ile Asn Pro Leu Asn Gly Ser Val Cys Glu Arg Pro Ala
 835 840 845
 Asn His Ser Ala Lys Gln Cys Arg Thr Pro Cys Ala Leu Arg Thr Ala
 850 855 860
 Cys Gly Asp Cys Thr Ser Gly Ser Ser Glu Cys Met Trp Cys Ser Asn
 865 870 875 880
 Met Lys Gln Cys Val Asp Ser Asn Ala Tyr Val Ala Ser Phe Pro Phe
 885 890 895
 Gly Gln Cys Met Glu Trp Tyr Thr Met Ser Thr Cys Pro Pro Glu Asn
 900 905 910
 Cys Ser Gly Tyr Cys Thr Cys Ser His Cys Leu Glu Gln Pro Gly Cys
 915 920 925
 Gly Trp Cys Thr Asp Pro Ser Asn Thr Gly Lys Gly Lys Cys Ile Glu
 930 935 940
 Gly Ser Tyr Lys Gly Pro Val Lys Met Pro Ser Gln Ala Pro Thr Gly
 945 950 955 960
 Asn Phe Tyr Pro Gln Pro Leu Leu Asn Ser Ser Met Cys Leu Glu Asp
 965 970 975
 Ser Arg Tyr Asn Trp Ser Phe Ile His Cys Pro Ala Cys Gln Cys Asn
 980 985 990
 Gly His Ser Lys Cys Ile Asn Gln Ser Ile Cys Glu Lys Cys Glu Asn
 995 1000 1005
 Leu Thr Thr Gly Lys His Cys Glu Thr Cys Ile Ser Gly Phe Tyr Gly
 1010 1015 1020
 Asp Pro Thr Asn Gly Gly Lys Cys Gln Pro Cys Lys Cys Asn Gly His
 1025 1030 1035 1040
 Ala Ser Leu Cys Asn Thr Asn Thr Gly Lys Cys Phe Cys Thr Thr Lys
 1045 1050 1055

Gly Val Lys Gly Asp Glu Cys Gln Leu Cys Glu Val Glu Asn Arg Tyr
 1060 1065 1070
 Gln Gly Asn Pro Leu Arg Gly Thr Cys Tyr Tyr Thr Leu Leu Ile Asp
 1075 1080 1085
 Tyr Gln Phe Thr Phe Ser Leu Ser Gln Glu Asp Asp Arg Tyr Tyr Thr
 1090 1095 1100
 Ala Ile Asn Phe Val Ala Thr Pro Asp Glu Gln Asn Arg Asp Leu Asp
 1105 1110 1115 1120
 Met Phe Ile Asn Ala Ser Lys Asn Phe Asn Leu Asn Ile Thr Trp Ala
 1125 1130 1135
 Ala Ser Phe Ser Ala Gly Thr Gln Ala Gly Glu Glu Met Pro Val Val
 1140 1145 1150
 Ser Lys Thr Asn Ile Lys Glu Tyr Lys Asp Ser Phe Ser Asn Glu Lys
 1155 1160 1165
 Phe Asp Phe Arg Asn His Pro Asn Ile Thr Phe Phe Val Tyr Val Ser
 1170 1175 1180
 Asn Phe Thr Trp Pro Ile Lys Ile Gln Val Gln Thr Glu Gln
 1185 1190 1195

<210> 3
 <211> 34
 <212> DNA
 <213> Homo sapiens

<400> 3
 cccaagcttg ggatgggtgt cgggctcagc ccgc

34

<210> 4
 <211> 41
 <212> DNA
 <213> Homo sapiens

<400> 4
 ataagaatgc ggcgctaaac tcattgttca gtttcgacct g

41

<210> 5
 <211> 32
 <212> DNA
 <213> Homo sapiens

<400> 5
 cccaagcttg ggatggtggc cgcagcggcg gc

32

<210> 6
 <211> 25
 <212> DNA
 <213> Homo sapiens

<400> 6
 ccaggtccat ctgtcacaaa ccag

25

<210> 7
 <211> 38
 <212> DNA
 <213> Homo sapiens

<400> 7
 gtgcgtgaag cttgtaccgg caactgaggc aaggctga

38

<210> 8
 <211> 39
 <212> DNA
 <213> Homo sapiens

<400> 8
 gtagtttta gtaggtgttt gacttcgccg gcgtgcgtg

39

<210> 9
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> synthetically generated

<400> 9
 Gly Ala Pro Val Pro Tyr Pro Asp Pro Leu Glu Pro Arg Ala Ala
 1 5 10 15

<210> 10
 <211> 1355
 <212> PRT
 <213> Homo sapiens

<400> 10
 Met Val Ala Ala Ala Ala Thr Glu Ala Arg Leu Arg Arg Arg Thr
 1 5 10 15
 Ala Ala Thr Ala Ala Leu Ala Gly Arg Ser Gly Gly Pro His Cys Val
 20 25 30
 Asn Gly Gly Arg Cys Asn Pro Gly Thr Gly Gln Cys Val Cys Pro Ala
 35 40 45
 Gly Trp Val Gly Glu Gln Cys Gln His Cys Gly Gly Arg Phe Arg Leu
 50 55 60
 Thr Gly Ser Ser Gly Phe Val Thr Asp Gly Pro Gly Asn Tyr Lys Tyr
 65 70 75 80
 Lys Thr Lys Cys Thr Trp Leu Ile Glu Gly Gln Pro Asn Arg Ile Met
 85 90 95
 Arg Leu Arg Phe Asn His Phe Ala Thr Glu Cys Ser Trp Asp His Leu
 100 105 110
 Tyr Val Tyr Asp Gly Asp Ser Ile Tyr Ala Pro Leu Val Ala Ala Phe
 115 120 125
 Ser Gly Leu Ile Val Pro Glu Arg Asp Gly Asn Glu Thr Val Pro Glu
 130 135 140
 Val Val Ala Thr Ser Gly Tyr Ala Leu Leu His Phe Phe Ser Asp Ala
 145 150 155 160
 Ala Tyr Asn Leu Thr Gly Phe Asn Ile Thr Tyr Ser Phe Asp Met Cys
 165 170 175
 Pro Asn Asn Cys Ser Gly Arg Gly Glu Cys Lys Ile Ser Asn Ser Ser
 180 185 190
 Asp Thr Val Glu Cys Glu Cys Ser Glu Asn Trp Lys Gly Glu Ala Cys
 195 200 205
 Asp Ile Pro His Cys Thr Asp Asn Cys Gly Phe Pro His Arg Gly Ile
 210 215 220
 Cys Asn Ser Ser Asp Val Arg Gly Cys Ser Cys Phe Ser Asp Trp Gln
 225 230 235 240
 Gly Pro Gly Cys Ser Val Pro Val Pro Ala Asn Gln Ser Phe Trp Thr
 245 250 255
 Arg Glu Glu Tyr Ser Asn Leu Lys Leu Pro Arg Ala Ser His Lys Ala
 260 265 270
 Val Val Asn Gly Asn Ile Met Trp Val Val Gly Gly Tyr Met Phe Asn
 275 280 285
 His Ser Asp Tyr Asn Met Val Leu Ala Tyr Asp Leu Ala Ser Arg Glu
 290 295 300
 Trp Leu Pro Leu Asn Arg Ser Val Asn Asn Val Val Val Arg Tyr Gly
 305 310 315 320
 His Ser Leu Ala Leu Tyr Lys Asp Lys Ile Tyr Met Tyr Gly Gly Lys
 325 330 335
 Ile Asp Ser Thr Gly Asn Val Thr Asn Glu Leu Arg Val Phe His Ile
 340 345 350
 His Asn Glu Ser Trp Val Leu Leu Thr Pro Lys Ala Lys Glu Gln Tyr
 355 360 365
 Ala Val Val Gly His Ser Ala His Ile Val Thr Leu Lys Asn Gly Arg
 370 375 380

10.

Val Val Met Leu Val Ile Phe Gly His Cys Pro Leu Tyr Gly Tyr Ile
 385 390 395 400
 Ser Asn Val Gln Glu Tyr Asp Leu Asp Lys Asn Thr Trp Ser Ile Leu
 405 410 415
 His Thr Gln Gly Ala Leu Val Gln Gly Gly Tyr Gly His Ser Ser Val
 420 425 430
 Tyr Asp His Arg Thr Arg Ala Leu Tyr Val His Gly Gly Tyr Lys Ala
 435 440 445
 Phe Ser Ala Asn Lys Tyr Arg Leu Ala Asp Asp Leu Tyr Arg Tyr Asp
 450 455 460
 Val Asp Thr Gln Met Trp Thr Ile Leu Lys Asp Ser Arg Phe Phe Arg
 465 470 475 480
 Tyr Leu His Thr Ala Val Ile Val Ser Gly Thr Met Leu Val Phe Gly
 485 490 495
 Gly Asn Thr His Asn Asp Thr Ser Met Ser His Gly Ala Lys Cys Phe
 500 505 510
 Ser Ser Asp Phe Met Ala Tyr Asp Ile Ala Cys Asp Arg Trp Ser Val
 515 520 525
 Leu Pro Arg Pro Asp Leu His His Asp Val Asn Arg Phe Gly His Ser
 530 535 540
 Ala Val Leu His Asn Ser Thr Met Tyr Val Phe Gly Gly Phe Asn Ser
 545 550 555 560
 Leu Leu Leu Ser Asp Ile Leu Val Phe Thr Ser Glu Gln Cys Asp Ala
 565 570 575
 His Arg Ser Glu Ala Ala Cys Leu Ala Ala Gly Pro Gly Ile Arg Cys
 580 585 590
 Val Trp Asn Thr Gly Ser Ser Gln Cys Ile Ser Trp Ala Leu Ala Thr
 595 600 605
 Asp Glu Gln Glu Glu Lys Leu Lys Ser Glu Cys Phe Ser Lys Arg Thr
 610 615 620
 Leu Asp His Asp Arg Cys Asp Gln His Thr Asp Cys Tyr Ser Cys Thr
 625 630 635 640
 Ala Asn Thr Asn Asp Cys His Trp Cys Asn Asp His Cys Val Pro Arg
 645 650 655
 Asn His Ser Cys Ser Glu Gly Gln Ile Ser Ile Phe Arg Tyr Glu Asn
 660 665 670
 Cys Pro Lys Asp Asn Pro Met Tyr Tyr Cys Asn Lys Lys Thr Ser Cys
 675 680 685
 Arg Ser Cys Ala Leu Asp Gln Asn Cys Gln Trp Glu Pro Arg Asn Gln
 690 695 700
 Glu Cys Ile Ala Leu Pro Glu Asn Ile Cys Gly Ile Gly Trp His Leu
 705 710 715 720
 Val Gly Asn Ser Cys Leu Lys Ile Thr Thr Ala Lys Glu Asn Tyr Asp
 725 730 735
 Asn Ala Lys Leu Phe Cys Arg Asn His Asn Ala Leu Leu Ala Ser Leu
 740 745 750
 Thr Thr Gln Lys Lys Val Glu Phe Val Leu Lys Gln Leu Arg Ile Met
 755 760 765
 Gln Ser Ser Gln Ser Met Ser Lys Leu Thr Leu Thr Pro Trp Val Gly
 770 775 780
 Leu Arg Lys Ile Asn Val Ser Tyr Trp Cys Trp Glu Asp Met Ser Pro
 785 790 795 800
 Phe Thr Asn Ser Leu Leu Gln Trp Met Pro Ser Glu Pro Ser Asp Ala
 805 810 815
 Gly Phe Cys Gly Ile Leu Ser Glu Pro Ser Thr Arg Gly Leu Lys Ala
 820 825 830
 Ala Thr Cys Ile Asn Pro Leu Asn Gly Ser Val Cys Glu Arg Pro Ala
 835 840 845
 Asn His Ser Ala Lys Gln Cys Arg Thr Pro Cys Ala Leu Arg Thr Ala
 850 855 860
 Cys Gly Asp Cys Thr Ser Gly Ser Ser Glu Cys Met Trp Cys Ser Asn
 865 870 875 880
 Met Lys Gln Cys Val Asp Ser Asn Ala Tyr Val Ala Ser Phe Pro Phe
 885 890 895
 Gly Gln Cys Met Glu Trp Tyr Thr Met Ser Thr Cys Pro Pro Glu Asn
 900 905 910

11

Cys Ser Gly Tyr Cys Thr Cys Ser His Cys Leu Glu Gln Pro Gly Cys
 915 920 925
 Gly Trp Cys Thr Asp Pro Ser Asn Thr Gly Lys Gly Lys Cys Ile Glu
 930 935 940
 Gly Ser Tyr Lys Gly Pro Val Lys Met Pro Ser Gln Ala Pro Thr Gly
 945 950 955 960
 Asn Phe Tyr Pro Gln Pro Leu Leu Asn Ser Ser Met Cys Leu Glu Asp
 965 970 975
 Ser Arg Tyr Asn Trp Ser Phe Ile His Cys Pro Ala Cys Gln Cys Asn
 980 985 990
 Gly His Ser Lys Cys Ile Asn Gln Ser Ile Cys Glu Lys Cys Glu Asn
 995 1000 1005
 Leu Thr Thr Gly Lys His Cys Glu Thr Cys Ile Ser Gly Phe Tyr Gly
 1010 1015 1020
 Asp Pro Thr Asn Gly Gly Lys Cys Gln Pro Cys Lys Cys Asn Gly His
 1025 1030 1035 1040
 Ala Ser Leu Cys Asn Thr Asn Thr Gly Lys Cys Phe Cys Thr Thr Lys
 1045 1050 1055
 Gly Val Lys Gly Asp Glu Cys Gln Leu Cys Glu Val Glu Asn Arg Tyr
 1060 1065 1070
 Gln Gly Asn Pro Leu Arg Gly Thr Cys Tyr Tyr Thr Leu Leu Ile Asp
 1075 1080 1085
 Tyr Gln Phe Thr Phe Ser Leu Ser Gln Glu Asp Asp Arg Tyr Tyr Thr
 1090 1095 1100
 Ala Ile Asn Phe Val Ala Thr Pro Asp Glu Gln Asn Arg Asp Leu Asp
 1105 1110 1115 1120
 Met Phe Ile Asn Ala Ser Lys Asn Phe Asn Leu Asn Ile Thr Trp Ala
 1125 1130 1135
 Ala Ser Phe Ser Ala Gly Thr Gln Ala Gly Glu Glu Met Pro Val Val
 1140 1145 1150
 Ser Lys Thr Asn Ile Lys Glu Tyr Lys Asp Ser Phe Ser Asn Glu Lys
 1155 1160 1165
 Phe Asp Phe Arg Asn His Pro Asn Ile Thr Phe Phe Val Tyr Val Ser
 1170 1175 1180
 Asn Phe Thr Trp Pro Ile Lys Ile Gln Ile Ala Phe Ser Gln His Ser
 1185 1190 1195 1200
 Asn Phe Met Asp Leu Val Gln Phe Phe Val Thr Phe Phe Ser Cys Phe
 1205 1210 1215
 Leu Ser Leu Leu Leu Val Ala Ala Val Val Trp Lys Ile Lys Gln Ser
 1220 1225 1230
 Cys Trp Ala Ser Arg Arg Arg Glu Gln Leu Leu Arg Glu Met Gln Gln
 1235 1240 1245
 Met Ala Ser Arg Pro Phe Ala Ser Val Asn Val Ala Leu Glu Thr Asp
 1250 1255 1260
 Glu Glu Pro Pro Asp Leu Ile Gly Gly Ser Ile Lys Thr Val Pro Lys
 1265 1270 1275 1280
 Pro Ile Ala Leu Glu Pro Cys Phe Gly Asn Lys Ala Ala Val Leu Ser
 1285 1290 1295
 Val Phe Val Arg Leu Pro Arg Gly Leu Gly Gly Ile Pro Pro Pro Gly
 1300 1305 1310
 Gln Ser Gly Leu Ala Val Ala Ser Ala Leu Val Asp Ile Ser Gln Gln
 1315 1320 1325
 Met Pro Ile Val Tyr Lys Glu Lys Ser Gly Ala Val Arg Asn Arg Lys
 1330 1335 1340
 Gln Gln Pro Pro Ala Gln Pro Gly Thr Cys Ile
 1345 1350 1355

<210> 11
 <211> 4068
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(4065)

<400> 11															
atg	gtg	gcc	gca	gcg	gca	gca	act	gag	gca	agg	ctg	agg	agg	agg	acg
Met	Val	Ala	Ala	Ala	Ala	Ala	Thr	Glu	Ala	Arg	Leu	Arg	Arg	Arg	Thr
1				5				10					15		48
gcg	gca	acg	gca	gca	ctc	gca	ggc	agg	agc	ggc	ggg	ccg	cac	tgt	gtc
Ala	Ala	Thr		20	Ala	Leu	Ala	Gly	Arg	Ser	Gly	Gly	Pro	His	Cys
								25					30	Val	
aac	ggc	ggt	cgc	tgc	aac	cct	ggc	acc	ggc	cag	tgc	gtc	tgc	ccc	gcc
Asn	Gly		35	Arg	Cys	Asn	Pro	Gly	Thr	Gly	Gln	Cys	Val	Cys	Pro
								40					45	Ala	
ggc	tgg	gtg	ggc	gag	caa	tgc	cag	cac	tgc	ggg	ggc	cgc	ttc	aga	cta
Gly	Trp	Val	Gly	Glu	Gln	Cys	Gln	His	Cys	Gly	Gly	Arg	Phe	Arg	Leu
50					55					60					
act	gga	tct	tct	ggg	ttt	gtg	aca	gat	gga	cct	gga	aat	tat	aaa	tac
Thr	Gly	Ser	Ser	Gly	Phe	Val	Thr	Asp	Gly	Pro	Gly	Asn	Tyr	Lys	Tyr
65					70					75					80
aaa	acg	aag	tgc	acg	tgg	ctc	att	gaa	gga	cag	cca	aat	aga	ata	atg
Lys	Thr	Lys	Cys	Thr	Trp	Leu	Ile	Glu	Gly	Gln	Pro	Asn	Arg	Ile	Met
				85					90					95	
aga	ctt	cgt	ttc	aat	cat	ttt	gct	aca	gag	tgt	agt	tgg	gac	cat	tta
Arg	Leu	Arg	Phe	Asn	His	Phe	Ala	Thr	Glu	Cys	Ser	Trp	Asp	His	Leu
			100					105					110		
tat	gtt	tat	gat	ggg	gac	tca	att	tat	gca	ccg	cta	gtt	gct	gca	ttt
Tyr	Val	Tyr	Asp	Gly	Asp	Ser	Ile	Tyr	Ala	Pro	Leu	Val	Ala	Ala	Phe
		115					120					125			
agt	ggc	ctc	att	gtt	cct	gag	aga	gat	ggc	aat	gag	act	gtc	cct	gag
Ser	Gly	Leu	Ile	Val	Pro	Glu	Arg	Asp	Gly	Asn	Glu	Thr	Val	Pro	Glu
130						135					140				
gtt	gtt	gcc	aca	tca	ggt	tat	gcc	ttg	ctg	cat	ttt	ttt	agt	gat	gct
Val	Val	Ala	Thr	Ser	Gly	Tyr	Ala	Leu	Leu	His	Phe	Phe	Ser	Asp	Ala
145					150					155					160
gct	tat	aat	ttg	act	gga	ttt	aat	att	act	tac	agt	ttt	gat	atg	tgt
Ala	Tyr	Asn	Leu	Thr	Gly	Phe	Asn	Ile	Thr	Tyr	Ser	Phe	Asp	Met	Cys
				165				170					175		
cca	aat	aac	tgc	tca	ggc	cga	gga	gag	tgt	aag	atc	agt	aat	agc	agc
Pro	Asn	Asn	Cys	Ser	Gly	Arg	Gly	Glu	Cys	Lys	Ile	Ser	Asn	Ser	Ser
			180					185					190		
gat	act	gtt	gaa	tgt	gaa	tgt	tct	gaa	aac	tgg	aaa	ggt	gaa	gca	tgt
Asp	Thr	Val	Glu	Cys	Glu	Cys	Ser	Glu	Asn	Trp	Lys	Gly	Glu	Ala	Cys
		195					200					205			
gac	att	cct	cac	tgt	aca	gac	aac	tgt	ggt	ttt	cct	cat	cga	ggc	atc
Asp	Ile	Pro	His	Cys	Thr	Asp	Asn	Cys	Gly	Phe	Pro	His	Arg	Gly	Ile
	210					215					220				
tgc	aat	tca	agt	gat	gtc	aga	gga	tgc	tcc	tgc	ttc	tca	gac	tgg	cag
Cys	Asn	Ser	Ser	Asp	Val	Arg	Gly	Cys	Ser	Cys	Phe	Ser	Asp	Trp	Gln
225					230					235				240	
ggt	cct	gga	tgt	tca	gtt	cct	gta	cca	gct	aac	cag	tca	ttt	tgg	act
Gly	Pro	Gly	Cys	Ser	Val	Pro	Val	Pro	Ala	Asn	Gln	Ser	Phe	Trp	Thr
				245					250					255	

cga gag gaa tat tct aac tta aag ctc ccc aga gca tct cat aaa gct Arg Glu Glu Tyr Ser Asn Leu Lys Leu Pro Arg Ala Ser His Lys Ala 260 265 270	816
gtg gtc aat gga aac att atg tgg gtt gtt gga gga tat atg ttc aac Val Val Asn Gly Asn Ile Met Trp Val Val Gly Gly Tyr Met Phe Asn 275 280 285	864
cac tca gat tat aac atg gtt cta gcg tat gac ctt gct tct agg gag His Ser Asp Tyr Asn Met Val Leu Ala Tyr Asp Leu Ala Ser Arg Glu 290 295 300	912
tgg ctt cca cta aac cgt tct gtg aac aat gtg gtt gtt aga tat ggt Trp Leu Pro Leu Asn Arg Ser Val Asn Asn Val Val Val Arg Tyr Gly 305 310 315 320	960
cat tct ttg gca tta tac aag gat aaa att tac atg tat gga gga aaa His Ser Leu Ala Leu Tyr Lys Asp Lys Ile Tyr Met Tyr Gly Gly Lys 325 330 335	1008
att gat tca act ggg aat gtg acc aat gag ttg aga gtt ttt cac att Ile Asp Ser Thr Gly Asn Val Thr Asn Glu Leu Arg Val Phe His Ile 340 345 350	1056
cat aat gag tca tgg gtg ttg ttg acc cct aag gca aag gag cag tat His Asn Glu Ser Trp Val Leu Leu Thr Pro Lys Ala Lys Glu Gln Tyr 355 360 365	1104
gca gtg gtt ggg cac tct gca cac att gtt aca ctg aag aat ggc cga Ala Val Val Gly His Ser Ala His Ile Val Thr Leu Lys Asn Gly Arg 370 375 380	1152
gtg gtc atg ctg gtc atc ttt ggt cac tgc cct ctc tat gga tat ata Val Val Met Leu Val Ile Phe Gly His Cys Pro Leu Tyr Gly Tyr Ile 385 390 395 400	1200
agc aat gtg cag gaa tat gat ttg gat aag aac aca tgg agt ata tta Ser Asn Val Gln Glu Tyr Asp Leu Asp Lys Asn Thr Trp Ser Ile Leu 405 410 415	1248
cac acc cag ggt gcc ctt gtg caa ggg ggt tac ggc cat agc agt gtt His Thr Gln Gly Ala Leu Val Gln Gly Gly Tyr Gly His Ser Ser Val 420 425 430	1296
tac gac cat agg acc agg gcc cta tac gtt cat ggt ggc tac aag gct Tyr Asp His Arg Thr Arg Ala Leu Tyr Val His Gly Gly Tyr Lys Ala 435 440 445	1344
ttc agt gcc aat aag tac cgg ctt gca gat gat ctc tac cga tat gat Phe Ser Ala Asn Lys Tyr Arg Leu Ala Asp Asp Leu Tyr Arg Tyr Asp 450 455 460	1392
gtg gat acc cag atg tgg acc att ctt aag gac agc cga ttt ttc cgt Val Asp Thr Gln Met Trp Thr Ile Leu Lys Asp Ser Arg Phe Phe Arg 465 470 475 480	1440
tac ttg cac aca gct gtg ata gtg agt gga acc atg ctg gtg ttt ggg Tyr Leu His Thr Ala Val Ile Val Ser Gly Thr Met Leu Val Phe Gly 485 490 495	1488
gga aac aca cac aat gac aca tct atg agc cat ggc gcc aaa tgc ttc Gly Asn Thr His Asn Asp Thr Ser Met Ser His Gly Ala Lys Cys Phe 500 505 510	1536
tct tca gat ttc atg gcc tat gac att gcc tgt gac cgc tgg tca gtg Ser Ser Asp Phe Met Ala Tyr Asp Ile Ala Cys Asp Arg Trp Ser Val 515 520 525	1584

ctt ccc aga cct gat ctc cac cat gat gtc aac aga ttt ggc cat tca Leu Pro Arg Pro Asp Leu His His Asp Val Asn Arg Phe Gly His Ser 530 535 540	1632
gca gtc tta cac aac agc acc atg tat gtg ttc ggt ggt ttc aat agt Ala Val Leu His Asn Ser Thr Met Tyr Val Phe Gly Gly Phe Asn Ser 545 550 555 560	1680
ctc ctc ctc agc gac atc ctg gta ttc acc tcg gaa cag tgt gat gcg Leu Leu Leu Ser Asp Ile Leu Val Phe Thr Ser Glu Gln Cys Asp Ala 565 570 575	1728
cat cgg agt gaa gcc gct tgt tta gca gca gga cct ggt att cgg tgt His Arg Ser Glu Ala Ala Cys Leu Ala Ala Gly Pro Gly Ile Arg Cys 580 585 590	1776
gtg tgg aac aca ggg tcg tct cag tgt atc tcg tgg gcg ctg gca act Val Trp Asn Thr Gly Ser Ser Gln Cys Ile Ser Trp Ala Leu Ala Thr 595 600 605	1824
gat gaa caa gaa gaa aag tta aaa tca gaa tgt ttt tcc aaa aga act Asp Glu Gln Glu Glu Lys Leu Lys Ser Glu Cys Phe Ser Lys Arg Thr 610 615 620	1872
ctt gac cat gac aga tgt gac cag cac aca gat tgt tac agc tgc aca Leu Asp His Asp Arg Cys Asp Gln His Thr Asp Cys Tyr Ser Cys Thr 625 630 635 640	1920
gcc aac acc aat gac tgc cac tgg tgc aat gac cat tgt gtc ccc agg Ala Asn Thr Asn Asp Cys His Trp Cys Asn Asp His Cys Val Pro Arg 645 650 655	1968
aac cac agc tgc tca gaa ggc cag atc tcc att ttt agg tat gag aat Asn His Ser Cys Ser Glu Gly Gln Ile Ser Ile Phe Arg Tyr Glu Asn 660 665 670	2016
tgc ccc aag gat aac cct atg tac tac tgt aac aag aag acc agc tgc Cys Pro Lys Asp Asn Pro Met Tyr Tyr Cys Asn Lys Lys Thr Ser Cys 675 680 685	2064
agg agc tgt gcc ctg gac cag aac tgc cag tgg gag ccc cgg aat cag Arg Ser Cys Ala Leu Asp Gln Asn Cys Gln Trp Glu Pro Arg Asn Gln 690 695 700	2112
gag tgc att gcc ctg ccc gaa aat atc tgt ggc att ggc tgg cat ttg Glu Cys Ile Ala Leu Pro Glu Asn Ile Cys Gly Ile Gly Trp His Leu 705 710 715 720	2160
gtt gga aac tca tgt ttg aaa att act act gcc aag gag aat tat gac Val Gly Asn Ser Cys Leu Lys Ile Thr Thr Ala Lys Glu Asn Tyr Asp 725 730 735	2208
aat gct aaa ttg ttc tgt agg aac cac aat gcc ctt ttg gct tct ctt Asn Ala Lys Leu Phe Cys Arg Asn His Asn Ala Leu Leu Ala Ser Leu 740 745 750	2256
aca acc cag aag aag gta gaa ttt gtc ctt aag cag ctg cga ata atg Thr Thr Gln Lys Lys Val Glu Phe Val Leu Lys Gln Leu Arg Ile Met 755 760 765	2304
cag tca tct cag agc atg tcc aag ctc acc tta acc cca tgg gtc ggc Gln Ser Ser Gln Ser Met Ser Lys Leu Thr Leu Thr Pro Trp Val Gly 770 775 780	2352

ctt cgg aag atc aat gtg tcc tac tgg tgc tgg gaa gat atg tcc cca Leu Arg Lys Ile Asn Val Ser Tyr Trp Cys Trp Glu Asp Met Ser Pro 785 790 795 800	2400
ttt aca aat agt tta cta cag tgg atg ccg tct gag ccc agt gat gct Phe Thr Asn Ser Leu Leu Gln Trp Met Pro Ser Glu Pro Ser Asp Ala 805 810 815	2448
gga ttc tgt gga att tta tca gaa ccc agt act cgg gga ctg aag gct Gly Phe Cys Gly Ile Leu Ser Glu Pro Ser Thr Arg Gly Leu Lys Ala 820 825 830	2496
gca acc tgc atc aac cca ctc aat ggt agt gtc tgt gaa agg cct gca Ala Thr Cys Ile Asn Pro Leu Asn Gly Ser Val Cys Glu Arg Pro Ala 835 840 845	2544
aac cac agt gct aag cag tgc cgg aca cca tgt gcc ttg agg aca gca Asn His Ser Ala Lys Gln Cys Arg Thr Pro Cys Ala Leu Arg Thr Ala 850 855 860	2592
tgt gga gat tgc acc agc ggc agc tct gag tgc atg tgg tgc agc aac Cys Gly Asp Cys Thr Ser Gly Ser Ser Glu Cys Met Trp Cys Ser Asn 865 870 875 880	2640
atg aag cag tgt gtg gac tcc aat gcc tat gtg gcc tcc ttc cct ttt Met Lys Gln Cys Val Asp Ser Asn Ala Tyr Val Ala Ser Phe Pro Phe 885 890 895	2688
ggc cag tgt atg gaa tgg tat acg atg agc acc tgc ccc cct gaa aat Gly Gln Cys Met Glu Trp Tyr Thr Met Ser Thr Cys Pro Pro Glu Asn 900 905 910	2736
tgt tca ggc tac tgt acc tgt agt cat tgc ttg gag caa cca ggc tgt Cys Ser Gly Tyr Cys Thr Cys Ser His Cys Leu Glu Gln Pro Gly Cys 915 920 925	2784
ggc tgg tgt act gat ccc agc aat act ggc aaa ggg aaa tgc ata gag Gly Trp Cys Thr Asp Pro Ser Asn Thr Gly Lys Gly Lys Cys Ile Glu 930 935 940	2832
ggt tcc tat aaa gga cca gtg aag atg cct tgc caa gcc cct aca gga Gly Ser Tyr Lys Gly Pro Val Lys Met Pro Ser Gln Ala Pro Thr Gly 945 950 955 960	2880
aat ttc tat cca cag ccc ctg ctc aat tcc agc atg tgt cta gag gac Asn Phe Tyr Pro Gln Pro Leu Leu Asn Ser Ser Met Cys Leu Glu Asp 965 970 975	2928
agc aga tac aac tgg tct ttc att cac tgt cca gct tgc caa tgc aac Ser Arg Tyr Asn Trp Ser Phe Ile His Cys Pro Ala Cys Gln Cys Asn 980 985 990	2976
ggc cac agt aaa tgc atc aat cag agc atc tgt gag aag tgt gag aac Gly His Ser Lys Cys Ile Asn Gln Ser Ile Cys Glu Lys Cys Glu Asn 995 1000 1005	3024
ctg acc aca ggc aag cac tgc gag acc tgc ata tct ggc ttc tac ggt Leu Thr Thr Gly Lys His Cys Glu Thr Cys Ile Ser Gly Phe Tyr Gly 1010 1015 1020	3072
gat ccc acc aat gga ggg aaa tgt cag cca tgc aag tgc aat ggg cac Asp Pro Thr Asn Gly Gly Lys Cys Gln Pro Cys Lys Cys Asn Gly His 1025 1030 1035 1040	3120
gcg tct ctg tgc aac acc aac acg ggc aag tgc ttc tgc acc acc aag Ala Ser Leu Cys Asn Thr Asn Thr Gly Lys Cys Phe Cys Thr Thr Lys 1045 1050 1055	3168

ggc gtc aag ggg gac gag tgc cag cta tgt gag gta gaa aat cga tac Gly Val Lys Gly Asp Glu Cys Gln Leu Cys Glu Val Glu Asn Arg Tyr 1060 1065 1070	3216
caa gga aac cct ctc aga gga aca tgt tat tat act ctt ctt att gac Gln Gly Asn Pro Leu Arg Gly Thr Cys Tyr Tyr Thr Leu Leu Ile Asp 1075 1080 1085	3264
tat cag ttc acc ttt agt cta tcc cag gaa gat gat cgc tat tac aca Tyr Gln Phe Thr Phe Ser Leu Ser Gln Glu Asp Asp Arg Tyr Tyr Thr 1090 1095 1100	3312
gct atc aat ttt gtg gct act cct gac gaa caa aac agg gat ttg gac Ala Ile Asn Phe Val Ala Thr Pro Asp Glu Gln Asn Arg Asp Leu Asp 1105 1110 1115 1120	3360
atg ttc atc aat gcc tcc aag aat ttc aac ctc aac atc acc tgg gct Met Phe Ile Asn Ala Ser Lys Asn Phe Asn Leu Asn Ile Thr Trp Ala 1125 1130 1135	3408
gcc agt ttc tca gct gga acc cag gct gga gaa gag atg cct gtt gtt Ala Ser Phe Ser Ala Gly Thr Gln Ala Gly Glu Glu Met Pro Val Val 1140 1145 1150	3456
tca aaa acc aac att aag gag tac aaa gat agt ttc tct aat gag aag Ser Lys Thr Asn Ile Lys Glu Tyr Lys Asp Ser Phe Ser Asn Glu Lys 1155 1160 1165	3504
ttt gat ttt cgc aac cac cca aat atc act ttc ttt gtt tat gtc agt Phe Asp Phe Arg Asn His Pro Asn Ile Thr Phe Phe Val Tyr Val Ser 1170 1175 1180	3552
aat ttc acc tgg ccc atc aaa att cag att gcc ttc tct cag cac agc Asn Phe Thr Trp Pro Ile Lys Ile Gln Ile Ala Phe Ser Gln His Ser 1185 1190 1195 1200	3600
aat ttt atg gac ctg gta cag ttc ttc gtg act ttc ttc agt tgt ttc Asn Phe Met Asp Leu Val Gln Phe Phe Val Thr Phe Phe Ser Cys Phe 1205 1210 1215	3648
ctc tct ttg ctc ctg gtg gct gct gtg gtt tgg aag atc aaa caa agt Leu Ser Leu Leu Val Ala Ala Val Val Trp Lys Ile Lys Gln Ser 1220 1225 1230	3696
tgt tgg gcc tcc aga cgt aga gag caa ctt ctt cga gag atg caa cag Cys Trp Ala Ser Arg Arg Arg Glu Gln Leu Leu Arg Glu Met Gln Gln 1235 1240 1245	3744
atg gcc agc cgt ccc ttt gcc tct gta aat gtc gcc ttg gaa aca gat Met Ala Ser Arg Pro Phe Ala Ser Val Asn Val Ala Leu Glu Thr Asp 1250 1255 1260	3792
gag gag cct cct gat ctt att ggg ggg agt ata aag act gtt ccc aaa Glu Glu Pro Pro Asp Leu Ile Gly Gly Ser Ile Lys Thr Val Pro Lys 1265 1270 1275 1280	3840
ccc att gca ctg gag ccg tgt ttt ggc aac aaa gcc gct gtc ctc tct Pro Ile Ala Leu Glu Pro Cys Phe Gly Asn Lys Ala Ala Val Leu Ser 1285 1290 1295	3888
gtg ttt gtg agg ctc cct cga ggc ctg ggt ggc atc cct cct cct ggg Val Phe Val Arg Leu Pro Arg Gly Leu Gly Gly Ile Pro Pro Pro Gly 1300 1305 1310	3936
cag tca ggt ctt gct gtg gcc agc gcc ctg gtg gac att tct cag cag Gln Ser Gly Leu Ala Val Ala Ser Ala Leu Val Asp Ile Ser Gln Gln	3984

1315	1320	1325	
atg ccg ata gtg tac aag gag aag tca gga gcc gtg aga aac cgg aag			4032
Met Pro Ile Val Tyr Lys Glu Lys Ser Gly Ala Val Arg Asn Arg Lys			
1330	1335	1340	
cag cag ccc cct gca cag cct ggg acc tgc atc tga			4068
Gln Gln Pro Pro Ala Gln Pro Gly Thr Cys Ile			
1345	1350	1355	

<210> 12
 <211> 1429
 <212> PRT
 <213> Homo sapiens

<400> 12

Met	Val	Ala	Ala	Ala	Ala	Ala	Thr	Glu	Ala	Arg	Leu	Arg	Arg	Arg	Thr
1				5					10					15	
Ala	Ala	Thr	Ala	Ala	Leu	Ala	Gly	Arg	Ser	Gly	Gly	Pro	His	Trp	Asp
			20					25					30		
Trp	Asp	Val	Thr	Arg	Ala	Gly	Arg	Pro	Gly	Leu	Gly	Ala	Gly	Leu	Arg
		35					40					45			
Leu	Pro	Arg	Leu	Leu	Ser	Pro	Pro	Leu	Arg	Pro	Arg	Leu	Leu	Leu	Leu
	50					55				60					
Leu	Leu	Leu	Leu	Pro	Pro	Pro	Leu	Leu	Leu	Leu	Leu	Pro	Cys	Glu	
	65			70					75					80	
Ala	Glu	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Val	Ser	Gly	Ser	Ala	Ala	Ala
			85					90					95		
Glu	Ala	Lys	Glu	Cys	Asp	Arg	Pro	Cys	Val	Asn	Gly	Gly	Arg	Cys	Asn
			100					105					110		
Pro	Gly	Thr	Gly	Gln	Cys	Val	Cys	Pro	Ala	Gly	Trp	Val	Gly	Glu	Gln
		115					120					125			
Cys	Gln	His	Cys	Gly	Gly	Arg	Phe	Arg	Leu	Thr	Gly	Ser	Ser	Gly	Phe
	130					135					140				
Val	Thr	Asp	Gly	Pro	Gly	Asn	Tyr	Lys	Tyr	Lys	Thr	Lys	Cys	Thr	Trp
	145				150					155					160
Leu	Ile	Glu	Gly	Gln	Pro	Asn	Arg	Ile	Met	Arg	Leu	Arg	Phe	Asn	His
			165					170						175	
Phe	Ala	Thr	Glu	Cys	Ser	Trp	Asp	His	Leu	Tyr	Val	Tyr	Asp	Gly	Asp
		180						185					190		
Ser	Ile	Tyr	Ala	Pro	Leu	Val	Ala	Ala	Phe	Ser	Gly	Leu	Ile	Val	Pro
		195					200					205			
Glu	Arg	Asp	Gly	Asn	Glu	Thr	Val	Pro	Glu	Val	Val	Ala	Thr	Ser	Gly
	210					215					220				
Tyr	Ala	Leu	Leu	His	Phe	Phe	Ser	Asp	Ala	Ala	Tyr	Asn	Leu	Thr	Gly
	225				230					235					240
Phe	Asn	Ile	Thr	Tyr	Ser	Phe	Asp	Met	Cys	Pro	Asn	Asn	Cys	Ser	Gly
			245					250					255		
Arg	Gly	Glu	Cys	Lys	Ile	Ser	Asn	Ser	Ser	Glu	Thr	Val	Glu	Cys	Glu
		260						265					270		
Cys	Ser	Glu	Asn	Trp	Lys	Gly	Glu	Ala	Cys	Asp	Ile	Pro	His	Cys	Thr
		275					280					285			
Asp	Asn	Cys	Gly	Phe	Pro	His	Arg	Gly	Ile	Cys	Asn	Ser	Ser	Asp	Val
	290					295					300				
Arg	Gly	Cys	Ser	Cys	Phe	Ser	Asp	Trp	Gln	Gly	Pro	Gly	Cys	Ser	Val
	305				310					315					320
Pro	Val	Pro	Ala	Asn	Gln	Ser	Phe	Trp	Thr	Arg	Glu	Glu	Tyr	Ser	Asn
			325						330					335	
Leu	Lys	Leu	Pro	Arg	Ala	Ser	His	Lys	Ala	Val	Val	Asn	Gly	Asn	Ile
		340						345					350		
Met	Trp	Val	Val	Gly	Gly	Tyr	Met	Phe	Asn	His	Ser	Asp	Tyr	Asn	Met
		355					360					365			
Val	Leu	Ala	Tyr	Asp	Leu	Ala	Ser	Arg	Glu	Trp	Leu	Pro	Leu	Asn	Arg
	370					375					380				
Ser	Val	Asn	Asn	Val	Val	Val	Arg	Tyr	Gly	His	Ser	Leu	Ala	Leu	Tyr
					390					395					400

Lys Asp Lys Ile Tyr Met Tyr Gly Gly Lys Ile Asp Pro Thr Gly Asn
 405 410 415
 Val Thr Asn Glu Leu Arg Val Phe His Ile His Asn Glu Ser Trp Val
 420 425 430
 Leu Leu Thr Pro Lys Ala Lys Glu Gln Tyr Ala Val Val Gly His Ser
 435 440 445
 Ala His Ile Val Thr Leu Lys Asn Gly Arg Val Val Met Leu Val Ile
 450 455 460
 Phe Gly His Cys Pro Leu Tyr Gly Tyr Ile Ser Asn Val Gln Glu Tyr
 465 470 475 480
 Asp Leu Asp Lys Asn Thr Trp Ser Ile Leu His Thr Gln Gly Ala Leu
 485 490 495
 Val Gln Gly Gly Tyr Gly His Ser Ser Val Tyr Asp His Arg Thr Arg
 500 505 510
 Ala Leu Tyr Val His Gly Gly Tyr Lys Ala Phe Ser Ala Asn Lys Tyr
 515 520 525
 Arg Leu Ala Asp Asp Leu Tyr Arg Tyr Asp Val Asp Thr Gln Met Trp
 530 535 540
 Thr Ile Leu Lys Asp Ser Arg Phe Phe Arg Tyr Leu His Thr Ala Val
 545 550 555 560
 Ile Val Ser Gly Thr Met Leu Val Phe Gly Gly Asn Thr His Asn Asp
 565 570 575
 Thr Ser Met Ser His Gly Ala Lys Cys Phe Ser Ser Asp Phe Met Ala
 580 585 590
 Tyr Asp Ile Ala Cys Asp Arg Trp Ser Val Leu Pro Arg Pro Asp Leu
 595 600 605
 His His Asp Val Asn Arg Phe Gly His Ser Ala Val Leu His Asn Ser
 610 615 620
 Thr Met Tyr Val Phe Gly Phe Asn Ser Leu Leu Leu Ser Asp Ile
 625 630 635 640
 Leu Val Phe Thr Ser Glu Gln Cys Asp Ala His Arg Ser Glu Ala Ala
 645 650 655
 Cys Leu Ala Ala Gly Pro Gly Ile Arg Cys Val Trp Asn Thr Gly Ser
 660 665 670
 Ser Gln Cys Ile Ser Trp Ala Leu Ala Thr Asp Glu Gln Glu Lys
 675 680 685
 Leu Lys Ser Glu Cys Phe Ser Lys Arg Thr Leu Asp His Asp Arg Cys
 690 695 700
 Asp Gln His Thr Asp Cys Tyr Ser Cys Thr Ala Asn Thr Asn Asp Cys
 705 710 715 720
 His Trp Cys Asn Asp His Cys Val Pro Arg Asn His Ser Cys Ser Glu
 725 730 735
 Gly Gln Ile Ser Ile Phe Arg Tyr Glu Asn Cys Pro Lys Asp Asn Pro
 740 745 750
 Met Tyr Tyr Cys Asn Lys Lys Thr Ser Cys Arg Ser Cys Ala Leu Asp
 755 760 765
 Gln Asn Cys Gln Trp Glu Pro Arg Asn Gln Glu Cys Ile Ala Leu Pro
 770 775 780
 Glu Asn Ile Cys Gly Ile Gly Trp His Leu Val Gly Asn Ser Cys Leu
 785 790 795 800
 Lys Ile Thr Thr Ala Lys Glu Asn Tyr Asp Asn Ala Lys Leu Phe Cys
 805 810 815
 Arg Asn His Asn Ala Leu Leu Ala Ser Leu Thr Thr Gln Lys Lys Val
 820 825 830
 Glu Phe Val Leu Lys Gln Leu Arg Ile Met Gln Ser Ser Gln Ser Met
 835 840 845
 Ser Lys Leu Thr Leu Thr Pro Trp Val Gly Leu Arg Lys Ile Asn Val
 850 855 860
 Ser Tyr Trp Cys Trp Glu Asp Met Ser Pro Phe Thr Asn Ser Leu Leu
 865 870 875 880
 Gln Trp Met Pro Ser Glu Pro Ser Asp Ala Gly Phe Cys Gly Ile Leu
 885 890 895
 Ser Glu Pro Ser Thr Arg Gly Leu Lys Ala Ala Thr Cys Ile Asn Pro
 900 905 910
 Leu Asn Gly Ser Val Cys Glu Arg Pro Ala Asn His Ser Ala Lys Gln
 915 920 925

Cys Arg Thr Pro Cys Ala Leu Arg Thr Ala Cys Gly Asp Cys Thr Ser
 930 935 940
 Gly Ser Ser Glu Cys Met Trp Cys Ser Asn Met Lys Gln Cys Val Asp
 945 950 955 960
 Ser Asn Ala Tyr Val Ala Ser Phe Pro Phe Gly Gln Cys Met Glu Trp
 965 970 975
 Tyr Thr Met Ser Thr Cys Pro Pro Glu Asn Cys Ser Gly Tyr Cys Thr
 980 985 990
 Cys Ser His Cys Leu Glu Gln Pro Gly Cys Gly Trp Cys Thr Asp Pro
 995 1000 1005
 Ser Asn Thr Gly Lys Gly Lys Cys Ile Glu Gly Ser Tyr Lys Gly Pro
 1010 1015 1020
 Val Lys Met Pro Ser Gln Ala Pro Thr Gly Asn Phe Tyr Pro Gln Pro
 1025 1030 1035 1040
 Leu Leu Asn Ser Ser Met Cys Leu Glu Asp Ser Arg Tyr Asn Trp Ser
 1045 1050 1055
 Phe Ile His Cys Pro Ala Cys Gln Cys Asn Gly His Ser Lys Cys Ile
 1060 1065 1070
 Asn Gln Ser Ile Cys Glu Lys Cys Glu Asn Leu Thr Thr Gly Lys His
 1075 1080 1085
 Cys Glu Thr Cys Ile Ser Gly Phe Tyr Gly Asp Pro Thr Asn Gly Gly
 1090 1095 1100
 Lys Cys Gln Pro Cys Lys Cys Asn Gly His Ala Ser Leu Cys Asn Thr
 1105 1110 1115 1120
 Asn Thr Gly Lys Cys Phe Cys Thr Thr Lys Gly Val Lys Gly Asp Glu
 1125 1130 1135
 Cys Gln Leu Cys Glu Val Glu Asn Arg Tyr Gln Gly Asn Pro Leu Arg
 1140 1145 1150
 Gly Thr Cys Tyr Tyr Thr Leu Leu Ile Asp Tyr Gln Phe Thr Phe Ser
 1155 1160 1165
 Leu Ser Gln Glu Asp Asp Arg Tyr Tyr Thr Ala Ile Asn Phe Val Ala
 1170 1175 1180
 Thr Pro Asp Glu Gln Asn Arg Asp Leu Asp Met Phe Ile Asn Ala Ser
 1185 1190 1195 1200
 Lys Asn Phe Asn Leu Asn Ile Thr Trp Ala Ala Ser Phe Ser Ala Gly
 1205 1210 1215
 Thr Gln Ala Gly Glu Glu Met Pro Val Val Ser Lys Thr Asn Ile Lys
 1220 1225 1230
 Glu Tyr Lys Asp Ser Phe Ser Asn Glu Lys Phe Asp Phe Arg Asn His
 1235 1240 1245
 Pro Asn Ile Thr Phe Phe Val Tyr Val Ser Asn Phe Thr Trp Pro Ile
 1250 1255 1260
 Lys Ile Gln Ile Ala Phe Ser Gln His Ser Asn Phe Met Asp Leu Val
 1265 1270 1275 1280
 Gln Phe Phe Val Thr Phe Phe Ser Cys Phe Leu Ser Leu Leu Val
 1285 1290 1295
 Ala Ala Val Val Trp Lys Ile Lys Gln Ser Cys Trp Ala Ser Arg Arg
 1300 1305 1310
 Arg Glu Gln Leu Leu Arg Glu Met Gln Gln Met Ala Ser Arg Pro Phe
 1315 1320 1325
 Ala Ser Val Asn Val Ala Leu Glu Thr Asp Glu Glu Pro Pro Asp Leu
 1330 1335 1340
 Ile Gly Gly Ser Ile Lys Thr Val Pro Lys Pro Ile Ala Leu Glu Pro
 1345 1350 1355 1360
 Cys Phe Gly Asn Lys Ala Ala Val Leu Ser Val Phe Val Arg Leu Pro
 1365 1370 1375
 Arg Gly Leu Gly Gly Ile Pro Pro Pro Gly Gln Ser Gly Leu Ala Val
 1380 1385 1390
 Ala Ser Ala Leu Val Asp Ile Ser Gln Gln Met Pro Ile Val Tyr Lys
 1395 1400 1405
 Glu Lys Ser Gly Ala Val Arg Asn Arg Lys Gln Gln Pro Pro Ala Gln
 1410 1415 1420
 Pro Gly Thr Cys Ile
 1425

<210> 13

<211> 4290

<212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(4287)

<400> 13
 atg gtg gcc gca gcg gcg gca act gag gca agg ctg agg agg agg acg 48
 Met Val Ala Ala Ala Ala Ala Thr Glu Ala Arg Leu Arg Arg Arg Thr
 1 5 10 15
 gcg gcg acg gca gcg ctc gcg ggc agg agc ggc ggg ccg cac tgg gac 96
 Ala Ala Thr Ala Ala Leu Ala Gly Arg Ser Gly Gly Pro His Trp Asp
 20 25 30
 tgg gac gtg acc agg gct ggg agg ccg ggg ctg ggg gcc ggg ctg cgc 144
 Trp Asp Val Thr Arg Ala Gly Arg Pro Gly Leu Gly Ala Gly Leu Arg
 35 40 45
 ctc ccg cgg ctg ctg tct cca ccg ctg cgg cca ccg ctg ctg ctg ctg 192
 Leu Pro Arg Leu Leu Ser Pro Pro Leu Arg Pro Arg Leu Leu Leu Leu
 50 55 60
 ctg ttg ttg ctc ccg ccg ccg ctg ttg ctg ctg ctg ctg ccc tgt gag 240
 Leu Leu Leu Leu Pro Pro Pro Leu Leu Leu Leu Leu Leu Pro Cys Glu
 65 70 75 80
 gcc gag gcc gcg gcg gcg gcg gcg gcg gtg tgc ggc tca gcc gca gcc 288
 Ala Glu Ala Ala Ala Ala Ala Ala Val Ser Gly Ser Ala Ala Ala
 85 90 95
 gag gcc aag gaa tgt gac cgg ccc tgt gtc aac ggc ggt cgc tgc aac 336
 Glu Ala Lys Glu Cys Asp Arg Pro Cys Val Asn Gly Gly Arg Cys Asn
 100 105 110
 cct ggc acc ggc cag tgc gtc tgc ccc gcc ggc tgg gtg ggc gag caa 384
 Pro Gly Thr Gly Gln Cys Val Cys Pro Ala Gly Trp Val Gly Glu Gln
 115 120 125
 tgc cag cac tgc ggg ggc cgc ttc aga cta act gga tct tct ggg ttt 432
 Cys Gln His Cys Gly Gly Arg Phe Arg Leu Thr Gly Ser Ser Gly Phe
 130 135 140
 gtg aca gat gga cct gga aat tat aaa tac aaa acg aag tgc acg tgg 480
 Val Thr Asp Gly Pro Gly Asn Tyr Lys Tyr Lys Thr Lys Cys Thr Trp
 145 150 155 160
 ctc att gaa gga cag cca aat aga ata atg aga ctt cgt ttc aat cat 528
 Leu Ile Glu Gly Gln Pro Asn Arg Ile Met Arg Leu Arg Phe Asn His
 165 170 175
 ttt gct aca gag tgt agt tgg gac cat tta tat gtt tat gat ggg gac 576
 Phe Ala Thr Glu Cys Ser Trp Asp His Leu Tyr Val Tyr Asp Gly Asp
 180 185 190
 tca att tat gca ccg cta gtt gct gca ttt agt ggc ctc att gtt cct 624
 Ser Ile Tyr Ala Pro Leu Val Ala Ala Phe Ser Gly Leu Ile Val Pro
 195 200 205
 gag aga gat ggc aat gag act gtc cct gag gtt gtt gcc aca tca ggt 672
 Glu Arg Asp Gly Asn Glu Thr Val Pro Glu Val Val Ala Thr Ser Gly
 210 215 220
 tat gcc ttg ctg cat ttt ttt agt gat gct gct tat aat ttg act gga 720
 Tyr Ala Leu Leu His Phe Phe Ser Asp Ala Ala Tyr Asn Leu Thr Gly
 225 230 235 240

ttt aat att act tac agt ttt gat atg tgt cca aat aac tgc tca ggc	768
Phe Asn Ile Thr Tyr Ser Phe Asp Met Cys Pro Asn Asn Cys Ser Gly	
245 250 255	
cga gga gag tgt aag atc agt aat agc agc gaa act gtt gaa tgt gaa	816
Arg Gly Glu Cys Lys Ile Ser Asn Ser Ser Glu Thr Val Glu Cys Glu	
260 265 270	
tgt tct gaa aac tgg aaa ggt gaa gca tgt gac att cct cac tgt aca	864
Cys Ser Glu Asn Trp Lys Gly Glu Ala Cys Asp Ile Pro His Cys Thr	
275 280 285	
gac aac tgt ggt ttt cct cat cga ggc atc tgc aat tca agt gat gtc	912
Asp Asn Cys Gly Phe Pro His Arg Gly Ile Cys Asn Ser Ser Asp Val	
290 295 300	
aga gga tgc tcc tgc ttc tca gac tgg cag ggt cct gga tgt tca gtt	960
Arg Gly Cys Ser Cys Phe Ser Asp Trp Gln Gly Pro Gly Cys Ser Val	
305 310 315 320	
cct gta cca gct aac cag tca ttt tgg act cga gag gaa tat tct aac	1008
Pro Val Pro Ala Asn Gln Ser Phe Trp Thr Arg Glu Glu Tyr Ser Asn	
325 330 335	
tta aag ctc ccc aga gca tct cat aaa gct gtg gtc aat gga aac att	1056
Leu Lys Leu Pro Arg Ala Ser His Lys Ala Val Val Asn Gly Asn Ile	
340 345 350	
atg tgg gtt gtt gga gga tat atg ttc aac cac tca gat tat aac atg	1104
Met Trp Val Val Gly Gly Tyr Met Phe Asn His Ser Asp Tyr Asn Met	
355 360 365	
gtt cta gcg tat gac ctt gct tct agg gag tgg ctt cca cta aac cgt	1152
Val Leu Ala Tyr Asp Leu Ser Arg Glu Trp Leu Pro Leu Asn Arg	
370 375 380	
tct gtg aac aat gtg gtt gtt aga tat ggt cat tct ttg gca tta tac	1200
Ser Val Asn Asn Val Val Val Arg Tyr Gly His Ser Leu Ala Leu Tyr	
385 390 395 400	
aag gat aaa att tac atg tat gga gga aaa att gat cca act ggg aat	1248
Lys Asp Lys Ile Tyr Met Tyr Gly Gly Lys Ile Asp Pro Thr Gly Asn	
405 410 415	
gtg acc aat gag ttg aga gtt ttt cac att cat aat gag tca tgg gtg	1296
Val Thr Asn Glu Leu Arg Val Phe His Ile His Asn Glu Ser Trp Val	
420 425 430	
ttg ttg acc cct aag gca aag gag cag tat gca gtg gtt ggg cac tct	1344
Leu Leu Thr Pro Lys Ala Lys Glu Gln Tyr Ala Val Val Gly His Ser	
435 440 445	
gca cac att gtt aca ctg aag aat ggc cga gtg gtc atg ctg gtc atc	1392
Ala His Ile Val Thr Leu Lys Asn Gly Arg Val Val Met Leu Val Ile	
450 455 460	
ttt ggt cac tgc cct ctc tat gga tat ata agc aat gtg cag gaa tat	1440
Phe Gly His Cys Pro Leu Tyr Gly Tyr Ile Ser Asn Val Gln Glu Tyr	
465 470 475 480	
gat ttg gat aag aac aca tgg agt ata tta cac acc cag ggt gcc ctt	1488
Asp Leu Asp Lys Asn Thr Trp Ser Ile Leu His Thr Gln Gly Ala Leu	
485 490 495	

gtg caa ggg ggt tac ggc cat agc agt gtt tac gac cat agg acc agg Val Gln Gly Gly Tyr Gly His Ser Ser Val Tyr Asp His Arg Thr Arg 500 505 510	1536
gcc cta tac gtt cat ggt ggc tac aag gct ttc agt gcc aat aag tac Ala Leu Tyr Val His Gly Gly Tyr Lys Ala Phe Ser Ala Asn Lys Tyr 515 520 525	1584
cgg ctt gca gat gat ctc tac cga tat gat gtg gat acc cag atg tgg Arg Leu Ala Asp Asp Leu Tyr Arg Tyr Asp Val Asp Thr Gln Met Trp 530 535 540	1632
acc att ctt aag gac agc cga ttt ttc cgt tac ttg cac aca gct gtg Thr Ile Leu Lys Asp Ser Arg Phe Phe Arg Tyr Leu His Thr Ala Val 545 550 555 560	1680
ata gtg agt gga acc atg ctg gtg ttt ggg gga aac aca cac aat gac Ile Val Ser Gly Thr Met Leu Val Phe Gly Gly Asn Thr His Asn Asp 565 570 575	1728
aca tct atg agc cat ggc gcc aaa tgc ttc tct tca gat ttc atg gcc Thr Ser Met Ser His Gly Ala Lys Cys Phe Ser Ser Asp Phe Met Ala 580 585 590	1776
tat gac att gcc tgt gac cgc tgg tca gtg ctt ccc aga cct gat ctc Tyr Asp Ile Ala Cys Asp Arg Trp Ser Val Leu Pro Arg Pro Asp Leu 595 600 605	1824
cac cat gat gtc aac aga ttt ggc cat tca gca gtc tta cac aac agc His His Asp Val Asn Arg Phe Gly His Ser Ala Val Leu His Asn Ser 610 615 620	1872
acc atg tat gtg ttc ggt ggt ttc aat agt ctc ctc ctc agc gac atc Thr Met Tyr Val Phe Gly Gly Phe Asn Ser Leu Leu Leu Ser Asp Ile 625 630 635 640	1920
ctg gta ttc acc tcg gaa cag tgt gat gcg cat cgg agt gaa gcc gct Leu Val Phe Thr Ser Glu Gln Cys Asp Ala His Arg Ser Glu Ala Ala 645 650 655	1968
tgt tta gca gca gga cct ggt att cgg tgt gtg tgg aac aca ggg tcg Cys Leu Ala Ala Gly Pro Gly Ile Arg Cys Val Trp Asn Thr Gly Ser 660 665 670	2016
tct cag tgt atc tcg tgg gcg ctg gca act gat gaa caa gaa gaa aag Ser Gln Cys Ile Ser Trp Ala Leu Ala Thr Asp Glu Gln Glu Glu Lys 675 680 685	2064
tta aaa tca gaa tgt ttt tcc aaa aga act ctt gac cat gac aga tgt Leu Lys Ser Glu Cys Phe Ser Lys Arg Thr Leu Asp His Asp Arg Cys 690 695 700	2112
gac cag cac aca gat tgt tac agc tgt aca gcc aac acc aat gac tgc Asp Gln His Thr Asp Cys Tyr Ser Cys Thr Ala Asn Thr Asn Asp Cys 705 710 715 720	2160
cac tgg tgc aat gac cat tgt gtc ccc agg aac cac agc tgc tca gaa His Trp Cys Asn Asp His Cys Val Pro Arg Asn His Ser Cys Ser Glu 725 730 735	2208
ggc cag atc tcc att ttt agg tat gag aat tgc ccc aag gat aac ccc Gly Gln Ile Ser Ile Phe Arg Tyr Glu Asn Cys Pro Lys Asp Asn Pro 740 745 750	2256
atg tac tac tgt aac aag aag acc agc tgc agg agc tgt gcc ctg gac Met Tyr Tyr Cys Asn Lys Lys Thr Ser Cys Arg Ser Cys Ala Leu Asp 755 760 765	2304

cag aac tgc cag tgg gag ccc cgg aat cag gag tgc att gcc ctg ccc Gln Asn Cys Gln Trp Glu Pro Arg Asn Gln Glu Cys Ile Ala Leu Pro 770 775 780	2352
gaa aat atc tgt ggc att ggc tgg cat ttg gtt gga aac tca tgt ttg Glu Asn Ile Cys Gly Ile Gly Trp His Leu Val Gly Asn Ser Cys Leu 785 790 795 800	2400
aaa att act act gcc aag gag aat tat gac aat gct aaa ttg ttc tgt Lys Ile Thr Thr Ala Lys Glu Asn Tyr Asp Asn Ala Lys Leu Phe Cys 805 810 815	2448
agg aac cac aat gcc ctt ttg gct tct ctt aca acc cag aag aag gta Arg Asn His Asn Ala Leu Leu Ala Ser Leu Thr Thr Gln Lys Lys Val 820 825 830	2496
gaa ttt gtc ctt aag cag ctg cga ata atg cag tca tct cag agc atg Glu Phe Val Leu Lys Gln Leu Arg Ile Met Gln Ser Ser Gln Ser Met 835 840 845	2544
tcc aag ctc acc tta acc cca tgg gtc ggc ctt cgg aag atc aat gtg Ser Lys Leu Thr Leu Thr Pro Trp Val Gly Leu Arg Lys Ile Asn Val 850 855 860	2592
tcc tac tgg tgc tgg gaa gat atg tcc cca ttt aca aat agt tta cta Ser Tyr Trp Cys Trp Glu Asp Met Ser Pro Phe Thr Asn Ser Leu Leu 865 870 875 880	2640
cag tgg atg ccg tct gag ccc agt gat gct gga ttc tgt gga att tta Gln Trp Met Pro Ser Glu Pro Ser Asp Ala Gly Phe Cys Gly Ile Leu 885 890 895	2688
tca gaa ccc agt act cgg gga ctg aag gct gca acc tgc atc aac cca Ser Glu Pro Ser Thr Arg Gly Leu Lys Ala Ala Thr Cys Ile Asn Pro 900 905 910	2736
ctc aat ggt agt gtc tgt gaa agg cct gca aac cac agt gct aag cag Leu Asn Gly Ser Val Cys Glu Arg Pro Ala Asn His Ser Ala Lys Gln 915 920 925	2784
tgc cgg aca cca tgt gcc ttg agg aca gca tgt gga gat tgc acc agc Cys Arg Thr Pro Cys Ala Leu Arg Thr Ala Cys Gly Asp Cys Thr Ser 930 935 940	2832
ggc agc tct gag tgc atg tgg tgc agc aac atg aag cag tgt gtg gac Gly Ser Ser Glu Cys Met Trp Cys Ser Asn Met Lys Gln Cys Val Asp 945 950 955 960	2880
tcc aat gcc tat gtg gcc tcc ttc cct ttt ggc cag tgt atg gaa tgg Ser Asn Ala Tyr Val Ala Ser Phe Pro Phe Gly Gln Cys Met Glu Trp 965 970 975	2928
tat acg atg agc acc tgc ccc cct gaa aat tgt tca ggc tac tgt acc Tyr Thr Met Ser Thr Cys Pro Pro Glu Asn Cys Ser Gly Tyr Cys Thr 980 985 990	2976
tgt agt cat tgc ttg gag caa cca ggc tgt ggc tgg tgt act gat ccc Cys Ser His Cys Leu Glu Gln Pro Gly Cys Gly Trp Cys Thr Asp Pro 995 1000 1005	3024
agc aat act ggc aaa ggg aaa tgc ata gag ggt tcc tat aaa gga cca Ser Asn Thr Gly Lys Gly Lys Cys Ile Glu Gly Ser Tyr Lys Gly Pro 1010 1015 1020	3072

gtg aag atg cct tgc caa gcc cct aca gga aat ttc tat cca cag ccc	3120
Val Lys Met Pro Ser Gln Ala Pro Thr Gly Asn Phe Tyr Pro Gln Pro	
1025 1030 1035 1040	
ctg ctc aat tcc agc atg tgt cta gag gac agc aga tac aac tgg tct	3168
Leu Leu Asn Ser Ser Met Cys Leu Glu Asp Ser Arg Tyr Asn Trp Ser	
1045 1050 1055	
ttc att cac tgt cca gct tgc caa tgc aac ggc cac agt aaa tgc atc	3216
Phe Ile His Cys Pro Ala Cys Gln Cys Asn Gly His Ser Lys Cys Ile	
1060 1065 1070	
aat cag agc atc tgt gag aag tgt gag aac ctg acc aca ggc aag cac	3264
Asn Gln Ser Ile Cys Glu Lys Cys Glu Asn Leu Thr Thr Gly Lys His	
1075 1080 1085	
tgc gag acc tgc ata tct ggc ttc tac ggt gat ccc acc aat gga ggg	3312
Cys Glu Thr Cys Ile Ser Gly Phe Tyr Gly Asp Pro Thr Asn Gly Gly	
1090 1095 1100	
aaa tgt cag cca tgc aag tgc aat ggg cac gcg tct ctg tgc aac acc	3360
Lys Cys Gln Pro Cys Lys Cys Asn Gly His Ala Ser Leu Cys Asn Thr	
1105 1110 1115 1120	
aac acg ggc aag tgc ttc tgc acc acc aag ggc gtc aag ggg gac gag	3408
Asn Thr Gly Lys Cys Phe Cys Thr Thr Lys Gly Val Lys Gly Asp Glu	
1125 1130 1135	
tgc cag cta tgt gag gta gaa aat cga tac caa gga aac cct ctc aga	3456
Cys Gln Leu Cys Glu Val Glu Asn Arg Tyr Gln Gly Asn Pro Leu Arg	
1140 1145 1150	
gga aca tgt tat tat act ctt ctt att gac tat cag ttc acc ttt agt	3504
Gly Thr Cys Tyr Tyr Thr Leu Leu Ile Asp Tyr Gln Phe Thr Phe Ser	
1155 1160 1165	
cta tcc cag gaa gat gat cgc tat tac aca gct atc aat ttt gtg gct	3552
Leu Ser Gln Glu Asp Asp Arg Tyr Tyr Thr Ala Ile Asn Phe Val Ala	
1170 1175 1180	
act cct gac gaa caa aac agg gat ttg gac atg ttc atc aat gcc tcc	3600
Thr Pro Asp Glu Gln Asn Arg Asp Leu Asp Met Phe Ile Asn Ala Ser	
1185 1190 1195 1200	
aag aat ttc aac ctc aac atc acc tgg gct gcc agt ttc tca gct gga	3648
Lys Asn Phe Asn Leu Asn Ile Thr Trp Ala Ala Ser Phe Ser Ala Gly	
1205 1210 1215	
acc cag gct gga gaa gag atg cct gtt gtt tca aaa acc aac att aag	3696
Thr Gln Ala Gly Glu Glu Met Pro Val Val Ser Lys Thr Asn Ile Lys	
1220 1225 1230	
gag tac aaa gat agt ttc tct aat gag aag ttt gat ttt cgc aac cac	3744
Glu Tyr Lys Asp Ser Phe Ser Asn Glu Lys Phe Asp Phe Arg Asn His	
1235 1240 1245	
cca aat atc act ttc ttt gtt tat gtc agt aat ttc acc tgg ccc atc	3792
Pro Asn Ile Thr Phe Phe Val Tyr Val Ser Asn Phe Thr Trp Pro Ile	
1250 1255 1260	
aaa att cag att gcc ttc tct cag cac agc aat ttt atg gac ctg gta	3840
Lys Ile Gln Ile Ala Phe Ser Gln His Ser Asn Phe Met Asp Leu Val	
1265 1270 1275 1280	
cag ttc ttc gtg act ttc ttc agt tgt ttc ctc tct ttg ctc ctg gtg	3888
Gln Phe Phe Val Thr Phe Phe Ser Cys Phe Leu Ser Leu Leu Leu Val	
1285 1290 1295	

25

gct gct gtg gtt tgg aag atc aaa caa agt tgt tgg gcc tcc aga cgt 3936
 Ala Ala Val Val Trp Lys Ile Lys Gln Ser Cys Trp Ala Ser Arg Arg
 1300 1305 1310

aga gag caa ctt ctt cga gag atg caa cag atg gcc agc cgt ccc ttt 3984
 Arg Glu Gln Leu Leu Arg Glu Met Gln Gln Met Ala Ser Arg Pro Phe
 1315 1320 1325

gcc tct gta aat gtc gcc ttg gaa aca gat gag gag cct cct gat ctt 4032
 Ala Ser Val Asn Val Ala Leu Glu Thr Asp Glu Glu Pro Pro Asp Leu
 1330 1335 1340

att ggg ggg agt ata aag act gtt ccc aaa ccc att gca ctg gag ccg 4080
 Ile Gly Gly Ser Ile Lys Thr Val Pro Lys Pro Ile Ala Leu Glu Pro
 1345 1350 1355 1360

tgt ttt ggc aac aaa gcc gct gtc ctc tct gtg ttt gtg agg ctc cct 4128
 Cys Phe Gly Asn Lys Ala Ala Val Leu Ser Val Phe Val Arg Leu Pro
 1365 1370 1375

cga ggc ctg ggt ggc atc cct cct cct ggg cag tca ggt ctt gct gtg 4176
 Arg Gly Leu Gly Gly Ile Pro Pro Pro Gly Gln Ser Gly Leu Ala Val
 1380 1385 1390

gcc agc gcc ctg gtg gac att tct cag cag atg ccg ata gtg tac aag 4224
 Ala Ser Ala Leu Val Asp Ile Ser Gln Gln Met Pro Ile Val Tyr Lys
 1395 1400 1405

gag aag tca gga gcc gtg aga aac cgg aag cag cag ccc cct gca cag 4272
 Glu Lys Ser Gly Ala Val Arg Asn Arg Lys Gln Gln Pro Pro Ala Gln
 1410 1415 1420

cct ggg acc tgc atc tga 4290
 Pro Gly Thr Cys Ile
 1425

<210> 14
 <211> 25
 <212> PRT
 <213> Homo sapiens

<400> 14
 Met Ala Ile Ser Gly Val Pro Val Leu Gly Phe Phe Ile Ile Ala Val
 1 5 10 15
 Leu Met Ser Ala Gln Glu Ser Trp Ala
 20 25

<210> 15
 <211> 5
 <212> PRT
 <213> Bovidae

<400> 15
 Lys Phe Glu Arg Gln
 1 5

<210> 16
 <211> 15
 <212> PRT
 <213> Homo sapiens

<400> 16
 Met Asp Asp Gln Arg Asp Leu Ile Ser Asn Asn Glu Gln Leu Pro
 1 5 10 15

<210> 17
 <211> 4
 <212> PRT
 <213> Rattus rattus

<400> 17
 Lys Asp Glu Leu
 1

<210> 18
 <211> 1272
 <212> PRT
 <213> Homo sapiens

<400> 18
 Met Val Ala Ala Ala Ala Ala Thr Glu Ala Arg Leu Arg Arg Arg Thr
 1 5 10 15
 Ala Ala Thr Ala Ala Leu Ala Gly Arg Ser Gly Gly Pro His Trp Asp
 20 25 30
 Trp Asp Val Thr Arg Ala Gly Arg Pro Gly Leu Gly Ala Gly Leu Arg
 35 40 45
 Leu Pro Arg Leu Leu Ser Pro Pro Leu Arg Pro Arg Leu Leu Leu
 50 55 60
 Leu Leu Leu Leu Pro Pro Pro Leu Leu Leu Leu Leu Pro Cys Glu
 65 70 75 80
 Ala Glu Ala Ala Ala Ala Ala Ala Val Ser Gly Ser Ala Ala Ala
 85 90 95
 Glu Ala Lys Glu Cys Asp Arg Pro Cys Val Asn Gly Gly Arg Cys Asn
 100 105 110
 Pro Gly Thr Gly Gln Cys Val Cys Pro Ala Gly Trp Val Gly Glu Gln
 115 120 125
 Cys Gln His Cys Gly Gly Arg Phe Arg Leu Thr Gly Ser Ser Gly Phe
 130 135 140
 Val Thr Asp Gly Pro Gly Asn Tyr Lys Tyr Lys Thr Lys Cys Thr Trp
 145 150 155 160
 Leu Ile Glu Gly Gln Pro Asn Arg Ile Met Arg Leu Arg Phe Asn His
 165 170 175
 Phe Ala Thr Glu Cys Ser Trp Asp His Leu Tyr Val Tyr Asp Gly Asp
 180 185 190
 Ser Ile Tyr Ala Pro Leu Val Ala Ala Phe Ser Gly Leu Ile Val Pro
 195 200 205
 Glu Arg Asp Gly Asn Glu Thr Val Pro Glu Val Val Ala Thr Ser Gly
 210 215 220
 Tyr Ala Leu Leu His Phe Phe Ser Asp Ala Ala Tyr Asn Leu Thr Gly
 225 230 235 240
 Phe Asn Ile Thr Tyr Ser Phe Asp Met Cys Pro Asn Asn Cys Ser Gly
 245 250 255
 Arg Gly Glu Cys Lys Ile Ser Asn Ser Ser Glu Thr Val Glu Cys Glu
 260 265 270
 Cys Ser Glu Asn Trp Lys Gly Glu Ala Cys Asp Ile Pro His Cys Thr
 275 280 285
 Asp Asn Cys Gly Phe Pro His Arg Gly Ile Cys Asn Ser Ser Asp Val
 290 295 300
 Arg Gly Cys Ser Cys Phe Ser Asp Trp Gln Gly Pro Gly Cys Ser Val
 305 310 315 320
 Pro Val Pro Ala Asn Gln Ser Phe Trp Thr Arg Glu Glu Tyr Ser Asn
 325 330 335
 Leu Lys Leu Pro Arg Ala Ser His Lys Ala Val Val Asn Gly Asn Ile
 340 345 350
 Met Trp Val Val Gly Gly Tyr Met Phe Asn His Ser Asp Tyr Asn Met
 355 360 365
 Val Leu Ala Tyr Asp Leu Ala Ser Arg Glu Trp Leu Pro Leu Asn Arg
 370 375 380
 Ser Val Asn Asn Val Val Val Arg Tyr Gly His Ser Leu Ala Leu Tyr
 385 390 395 400
 Lys Asp Lys Ile Tyr Met Tyr Gly Gly Lys Ile Asp Pro Thr Gly Asn
 405 410 415

Val	Thr	Asn	Glu	Leu	Arg	Val	Phe	His	Ile	His	Asn	Glu	Ser	Trp	Val
			420					425					430		
Leu	Leu	Thr	Pro	Lys	Ala	Lys	Glu	Gln	Tyr	Ala	Val	Val	Gly	His	Ser
		435					440					445			
Ala	His	Ile	Val	Thr	Leu	Lys	Asn	Gly	Arg	Val	Val	Met	Leu	Val	Ile
	450					455					460				
Phe	Gly	His	Cys	Pro	Leu	Tyr	Gly	Tyr	Ile	Ser	Asn	Val	Gln	Glu	Tyr
465					470					475					480
Asp	Leu	Asp	Lys	Asn	Thr	Trp	Ser	Ile	Leu	His	Thr	Gln	Gly	Ala	Leu
			485						490					495	
Val	Gln	Gly	Gly	Tyr	Gly	His	Ser	Ser	Val	Tyr	Asp	His	Arg	Thr	Arg
			500					505					510		
Ala	Leu	Tyr	Val	His	Gly	Gly	Tyr	Lys	Ala	Phe	Ser	Ala	Asn	Lys	Tyr
		515					520					525			
Arg	Leu	Ala	Asp	Asp	Leu	Tyr	Arg	Tyr	Asp	Val	Asp	Thr	Gln	Met	Trp
	530					535					540				
Thr	Ile	Leu	Lys	Asp	Ser	Arg	Phe	Phe	Arg	Tyr	Leu	His	Thr	Ala	Val
545					550					555					560
Ile	Val	Ser	Gly	Thr	Met	Leu	Val	Phe	Gly	Gly	Asn	Thr	His	Asn	Asp
				565					570					575	
Thr	Ser	Met	Ser	His	Gly	Ala	Lys	Cys	Phe	Ser	Ser	Asp	Phe	Met	Ala
			580					585					590		
Tyr	Asp	Ile	Ala	Cys	Asp	Arg	Trp	Ser	Val	Leu	Pro	Arg	Pro	Asp	Leu
		595					600					605			
His	His	Asp	Val	Asn	Arg	Phe	Gly	His	Ser	Ala	Val	Leu	His	Asn	Ser
	610					615					620				
Thr	Met	Tyr	Val	Phe	Gly	Gly	Phe	Asn	Ser	Leu	Leu	Ser	Asp	Ile	
625					630					635				640	
Leu	Val	Phe	Thr	Ser	Glu	Gln	Cys	Asp	Ala	His	Arg	Ser	Glu	Ala	Ala
				645					650					655	
Cys	Leu	Ala	Ala	Gly	Pro	Gly	Ile	Arg	Cys	Val	Trp	Asn	Thr	Gly	Ser
			660					665					670		
Ser	Gln	Cys	Ile	Ser	Trp	Ala	Leu	Ala	Thr	Asp	Glu	Gln	Glu	Glu	Lys
		675					680					685			
Leu	Lys	Ser	Glu	Cys	Phe	Ser	Lys	Arg	Thr	Leu	Asp	His	Asp	Arg	Cys
	690					695					700				
Asp	Gln	His	Thr	Asp	Cys	Tyr	Ser	Cys	Thr	Ala	Asn	Thr	Asn	Asp	Cys
705					710					715					720
His	Trp	Cys	Asn	Asp	His	Cys	Val	Pro	Arg	Asn	His	Ser	Cys	Ser	Glu
			725						730					735	
Gly	Gln	Ile	Ser	Ile	Phe	Arg	Tyr	Glu	Asn	Cys	Pro	Lys	Asp	Asn	Pro
			740					745					750		
Met	Tyr	Tyr	Cys	Asn	Lys	Lys	Thr	Ser	Cys	Arg	Ser	Cys	Ala	Leu	Asp
		755					760					765			
Gln	Asn	Cys	Gln	Trp	Glu	Pro	Arg	Asn	Gln	Glu	Cys	Ile	Ala	Leu	Pro
	770					775						780			
Glu	Asn	Ile	Cys	Gly	Ile	Gly	Trp	His	Leu	Val	Gly	Asn	Ser	Cys	Leu
785					790					795					800
Lys	Ile	Thr	Thr	Ala	Lys	Glu	Asn	Tyr	Asp	Asn	Ala	Lys	Leu	Phe	Cys
				805					810					815	
Arg	Asn	His	Asn	Ala	Leu	Leu	Ala	Ser	Leu	Thr	Thr	Gln	Lys	Lys	Val
			820					825					830		
Glu	Phe	Val	Leu	Lys	Gln	Leu	Arg	Ile	Met	Gln	Ser	Ser	Gln	Ser	Met
		835					840					845			
Ser	Lys	Leu	Thr	Leu	Thr	Pro	Trp	Val	Gly	Leu	Arg	Lys	Ile	Asn	Val
	850					855					860				
Ser	Tyr	Trp	Cys	Trp	Glu	Asp	Met	Ser	Pro	Phe	Thr	Asn	Ser	Leu	Leu
865					870					875					880
Gln	Trp	Met	Pro	Ser	Glu	Pro	Ser	Asp	Ala	Gly	Phe	Cys	Gly	Ile	Leu
				885					890					895	
Ser	Glu	Pro	Ser	Thr	Arg	Gly	Leu	Lys	Ala	Ala	Thr	Cys	Ile	Asn	Pro
			900					905					910		
Leu	Asn	Gly	Ser	Val	Cys	Glu	Arg	Pro	Ala	Asn	His	Ser	Ala	Lys	Gln
		915					920					925			
Cys	Arg	Thr	Pro	Cys	Ala	Leu	Arg	Thr	Ala	Cys	Gly	Asp	Cys	Thr	Ser
	930					935					940				

Gly Ser Ser Glu Cys Met Trp Cys Ser Asn Met Lys Gln Cys Val Asp
 945 950 955 960
 Ser Asn Ala Tyr Val Ala Ser Phe Pro Phe Gly Gln Cys Met Glu Trp
 965 970 975
 Tyr Thr Met Ser Thr Cys Pro Pro Glu Asn Cys Ser Gly Tyr Cys Thr
 980 985 990
 Cys Ser His Cys Leu Glu Gln Pro Gly Cys Gly Trp Cys Thr Asp Pro
 995 1000 1005
 Ser Asn Thr Gly Lys Gly Lys Cys Ile Glu Gly Ser Tyr Lys Gly Pro
 1010 1015 1020
 Val Lys Met Pro Ser Gln Ala Pro Thr Gly Asn Phe Tyr Pro Gln Pro
 1025 1030 1035 1040
 Leu Leu Asn Ser Ser Met Cys Leu Glu Asp Ser Arg Tyr Asn Trp Ser
 1045 1050 1055
 Phe Ile His Cys Pro Ala Cys Gln Cys Asn Gly His Ser Lys Cys Ile
 1060 1065 1070
 Asn Gln Ser Ile Cys Glu Lys Cys Glu Asn Leu Thr Thr Gly Lys His
 1075 1080 1085
 Cys Glu Thr Cys Ile Ser Gly Phe Tyr Gly Asp Pro Thr Asn Gly Gly
 1090 1095 1100
 Lys Cys Gln Pro Cys Lys Cys Asn Gly His Ala Ser Leu Cys Asn Thr
 1105 1110 1115 1120
 Asn Thr Gly Lys Cys Phe Cys Thr Thr Lys Gly Val Lys Gly Asp Glu
 1125 1130 1135
 Cys Gln Leu Cys Glu Val Glu Asn Arg Tyr Gln Gly Asn Pro Leu Arg
 1140 1145 1150
 Gly Thr Cys Tyr Tyr Thr Leu Leu Ile Asp Tyr Gln Phe Thr Phe Ser
 1155 1160 1165
 Leu Ser Gln Glu Asp Asp Arg Tyr Tyr Thr Ala Ile Asn Phe Val Ala
 1170 1175 1180
 Thr Pro Asp Glu Gln Asn Arg Asp Leu Asp Met Phe Ile Asn Ala Ser
 1185 1190 1195 1200
 Lys Asn Phe Asn Leu Asn Ile Thr Trp Ala Ala Ser Phe Ser Ala Gly
 1205 1210 1215
 Thr Gln Ala Gly Glu Glu Met Pro Val Ser Lys Thr Asn Ile Lys
 1220 1225 1230
 Glu Tyr Lys Asp Ser Phe Ser Asn Glu Lys Phe Asp Phe Arg Asn His
 1235 1240 1245
 Pro Asn Ile Thr Phe Phe Val Tyr Val Ser Asn Phe Thr Trp Pro Ile
 1250 1255 1260
 Lys Ile Gln Val Gln Thr Glu Gln
 1265 1270

<210> 19
 <211> 3819
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(3816)

<400> 19
 atg gtg gcc gca gcg gcg gca act gag gca agg ctg agg agg agg acg 48
 Met Val Ala Ala Ala Ala Ala Thr Glu Ala Arg Leu Arg Arg Arg Thr
 1 5 10 15
 gcg gcg acg gca gcg ctc gcg ggc agg agc ggc ggg ccg cac tgg gac 96
 Ala Ala Thr Ala Ala Leu Ala Gly Arg Ser Gly Gly Pro His Trp Asp
 20 25 30
 tgg gac gtg acc agg gct ggg agg ccg ggg ctg ggg gcc ggg ctg cgc 144
 Trp Asp Val Thr Arg Ala Gly Arg Pro Gly Leu Gly Ala Gly Leu Arg
 35 40 45

ctc	ccg	cgg	ctg	ctg	tct	cca	ccg	ctg	cgg	cca	cgg	ctg	ctg	ctg	ctg	192
Leu	Pro	Arg	Leu	Leu	Ser	Pro	Pro	Leu	Arg	Pro	Arg	Leu	Leu	Leu	Leu	
	50					55					60					
ctg	ttg	ttg	ctc	ccg	ccg	ccg	ctg	ttg	ctg	ctg	ctg	ctg	ccc	tgt	gag	240
Leu	Leu	Leu	Leu	Pro	Pro	Pro	Leu	Leu	Leu	Leu	Leu	Leu	Pro	Cys	Glu	
	65				70					75					80	
gcc	gag	gcc	gcg	gcg	gcg	gcg	gcg	gcg	gtg	tgc	ggc	tca	gcc	gca	gcc	288
Ala	Glu	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Val	Ser	Gly	Ser	Ala	Ala	Ala	
				85					90					95		
gag	gcc	aag	gaa	tgt	gac	cgg	ccc	tgt	gtc	aac	ggc	ggt	cgc	tgc	aac	336
Glu	Ala	Lys	Glu	Cys	Asp	Arg	Pro	Cys	Val	Asn	Gly	Gly	Arg	Cys	Asn	
			100					105					110			
cct	ggc	acc	ggc	cag	tgc	gtc	tgc	ccc	gcc	ggc	tgg	gtg	ggc	gag	caa	384
Pro	Gly	Thr	Gly	Gln	Cys	Val	Cys	Pro	Ala	Gly	Trp	Val	Gly	Glu	Gln	
		115					120					125				
tgc	cag	cac	tgc	ggg	ggc	cgc	ttc	aga	cta	act	gga	tct	tct	ggg	ttt	432
Cys	Gln	His	Cys	Gly	Gly	Arg	Phe	Arg	Leu	Thr	Gly	Ser	Ser	Gly	Phe	
	130					135					140					
gtg	aca	gat	gga	cct	gga	aat	tat	aaa	tac	aaa	acg	aag	tgc	acg	tgg	480
Val	Thr	Asp	Gly	Pro	Gly	Asn	Tyr	Lys	Tyr	Lys	Thr	Lys	Cys	Thr	Trp	
	145				150					155					160	
ctc	att	gaa	gga	cag	cca	aat	aga	ata	atg	aga	ctt	cgt	ttc	aat	cat	528
Leu	Ile	Glu	Gly	Gln	Pro	Asn	Arg	Ile	Met	Arg	Leu	Arg	Phe	Asn	His	
				165					170					175		
ttt	gct	aca	gag	tgt	agt	tgg	gac	cat	tta	tat	gtt	tat	gat	ggg	gac	576
Phe	Ala	Thr	Glu	Cys	Ser	Trp	Asp	His	Leu	Tyr	Val	Tyr	Asp	Gly	Asp	
			180					185					190			
tca	att	tat	gca	ccg	cta	gtt	gct	gca	ttt	agt	ggc	ctc	att	gtt	cct	624
Ser	Ile	Tyr	Ala	Pro	Leu	Val	Ala	Ala	Phe	Ser	Gly	Leu	Ile	Val	Pro	
		195					200					205				
gag	aga	gat	ggc	aat	gag	act	gtc	cct	gag	gtt	gtt	gcc	aca	tca	ggt	672
Glu	Arg	Asp	Gly	Asn	Glu	Thr	Val	Pro	Glu	Val	Val	Ala	Thr	Ser	Gly	
	210					215					220					
tat	gcc	ttg	ctg	cat	ttt	ttt	agt	gat	gct	gct	tat	aat	ttg	act	gga	720
Tyr	Ala	Leu	Leu	His	Phe	Phe	Ser	Asp	Ala	Ala	Tyr	Asn	Leu	Thr	Gly	
	225				230					235					240	
ttt	aat	att	act	tac	agt	ttt	gat	atg	tgt	cca	aat	aac	tgc	tca	ggc	768
Phe	Asn	Ile	Thr	Tyr	Ser	Phe	Asp	Met	Cys	Pro	Asn	Asn	Cys	Ser	Gly	
			245						250					255		
cga	gga	gag	tgt	aag	atc	agt	aat	agc	agc	gaa	act	gtt	gaa	tgt	gaa	816
Arg	Gly	Glu	Cys	Lys	Ile	Ser	Asn	Ser	Ser	Glu	Thr	Val	Glu	Cys	Glu	
			260					265					270			
tgt	tct	gaa	aac	tgg	aaa	ggg	gaa	gca	tgt	gac	att	cct	cac	tgt	aca	864
Cys	Ser	Glu	Asn	Trp	Lys	Gly	Glu	Ala	Cys	Asp	Ile	Pro	His	Cys	Thr	
		275					280					285				
gac	aac	tgt	ggg	ttt	cct	cat	cga	ggc	atc	tgc	aat	tca	agt	gat	gtc	912
Asp	Asn	Cys	Gly	Phe	Pro	His	Arg	Gly	Ile	Cys	Asn	Ser	Ser	Asp	Val	
	290					295					300					
aga	gga	tgc	tcc	tgc	ttc	tca	gac	tgg	cag	ggg	cct	gga	tgt	tca	gtt	960
Arg	Gly	Cys	Ser	Cys	Phe	Ser	Asp	Trp	Gln	Gly	Pro	Gly	Cys	Ser	Val	
	305				310					315					320	

cct	gta	cca	gct	aac	cag	tca	ttt	tgg	act	cga	gag	gaa	tat	tct	aac	1008
Pro	Val	Pro	Ala	Asn	Gln	Ser	Phe	Trp	Thr	Arg	Glu	Glu	Tyr	Ser	Asn	
				325					330					335		
tta	aag	ctc	ccc	aga	gca	tct	cat	aaa	gct	gtg	gtc	aat	gga	aac	att	1056
Leu	Lys	Leu	Pro	Arg	Ala	Ser	His	Lys	Ala	Val	Val	Asn	Gly	Asn	Ile	
			340					345					350			
atg	tgg	gtt	gtt	gga	gga	tat	atg	ttc	aac	cac	tca	gat	tat	aac	atg	1104
Met	Trp	Val	Val	Gly	Gly	Tyr	Met	Phe	Asn	His	Ser	Asp	Tyr	Asn	Met	
		355					360					365				
gtt	cta	gcg	tat	gac	ctt	gct	tct	agg	gag	tgg	ctt	cca	cta	aac	cgt	1152
Val	Leu	Ala	Tyr	Asp	Leu	Ala	Ser	Arg	Glu	Trp	Leu	Pro	Leu	Asn	Arg	
	370					375					380					
tct	gtg	aac	aat	gtg	gtt	gtt	aga	tat	ggt	cat	tct	ttg	gca	tta	tac	1200
Ser	Val	Asn	Asn	Val	Val	Val	Arg	Tyr	Gly	His	Ser	Leu	Ala	Leu	Tyr	
385				390					395						400	
aag	gat	aaa	att	tac	atg	tat	gga	gga	aaa	att	gat	cca	act	ggg	aat	1248
Lys	Asp	Lys	Ile	Tyr	Met	Tyr	Gly	Gly	Lys	Ile	Asp	Pro	Thr	Gly	Asn	
				405					410					415		
gtg	acc	aat	gag	ttg	aga	gtt	ttt	cac	att	cat	aat	gag	tca	tgg	gtg	1296
Val	Thr	Asn	Glu	Leu	Arg	Val	Phe	His	Ile	His	Asn	Glu	Ser	Trp	Val	
			420					425					430			
ttg	ttg	acc	cct	aag	gca	aag	gag	cag	tat	gca	gtg	gtt	ggg	cac	tct	1344
Leu	Leu	Thr	Pro	Lys	Ala	Lys	Glu	Gln	Tyr	Ala	Val	Val	Gly	His	Ser	
		435					440					445				
gca	cac	att	gtt	aca	ctg	aag	aat	ggc	cga	gtg	gtc	atg	ctg	gtc	atc	1392
Ala	His	Ile	Val	Thr	Leu	Lys	Asn	Gly	Arg	Val	Val	Met	Leu	Val	Ile	
	450					455					460					
ttt	ggt	cac	tgc	cct	ctc	tat	gga	tat	ata	agc	aat	gtg	cag	gaa	tat	1440
Phe	Gly	His	Cys	Pro	Leu	Tyr	Gly	Tyr	Ile	Ser	Asn	Val	Gln	Glu	Tyr	
465				470					475						480	
gat	ttg	gat	aag	aac	aca	tgg	agt	ata	tta	cac	acc	cag	ggt	gcc	ctt	1488
Asp	Leu	Asp	Lys	Asn	Thr	Trp	Ser	Ile	Leu	His	Thr	Gln	Gly	Ala	Leu	
				485				490						495		
gtg	caa	ggg	ggt	tac	ggc	cat	agc	agt	gtt	tac	gac	cat	agg	acc	agg	1536
Val	Gln	Gly	Gly	Tyr	Gly	His	Ser	Ser	Val	Tyr	Asp	His	Arg	Thr	Arg	
			500					505					510			
gcc	cta	tac	gtt	cat	ggt	ggc	tac	aag	gct	ttc	agt	gcc	aat	aag	tac	1584
Ala	Leu	Tyr	Val	His	Gly	Gly	Tyr	Lys	Ala	Phe	Ser	Ala	Asn	Lys	Tyr	
		515					520					525				
cgg	ctt	gca	gat	gat	ctc	tac	cga	tat	gat	gtg	gat	acc	cag	atg	tgg	1632
Arg	Leu	Ala	Asp	Asp	Leu	Tyr	Arg	Tyr	Asp	Val	Asp	Thr	Gln	Met	Trp	
	530					535					540					
acc	att	ctt	aag	gac	agc	cga	ttt	ttc	cgt	tac	ttg	cac	aca	gct	gtg	1680
Thr	Ile	Leu	Lys	Asp	Ser	Arg	Phe	Phe	Arg	Tyr	Leu	His	Thr	Ala	Val	
545				550					555						560	
ata	gtg	agt	gga	acc	atg	ctg	gtg	ttt	ggg	gga	aac	aca	cac	aat	gac	1728
Ile	Val	Ser	Gly	Thr	Met	Leu	Val	Phe	Gly	Gly	Asn	Thr	His	Asn	Asp	
				565					570					575		

aca	tct	atg	agc	cat	ggc	gcc	aaa	tgc	ttc	tct	tca	gat	ttc	atg	gcc	1776
Thr	Ser	Met	Ser	His	Gly	Ala	Lys	Cys	Phe	Ser	Ser	Asp	Phe	Met	Ala	
			580					585					590			
tat	gac	att	gcc	tgt	gac	cgc	tgg	tca	gtg	ctt	ccc	aga	cct	gat	ctc	1824
Tyr	Asp	Ile	Ala	Cys	Asp	Arg	Trp	Ser	Val	Leu	Pro	Arg	Pro	Asp	Leu	
		595					600					605				
cac	cat	gat	gtc	aac	aga	ttt	ggc	cat	tca	gca	gtc	tta	cac	aac	agc	1872
His	His	Asp	Val	Asn	Arg	Phe	Gly	His	Ser	Ala	Val	Leu	His	Asn	Ser	
	610					615					620					
acc	atg	tat	gtg	ttc	ggg	ggg	ttc	aat	agt	ctc	ctc	ctc	agc	gac	atc	1920
Thr	Met	Tyr	Val	Phe	Gly	Gly	Phe	Asn	Ser	Leu	Leu	Leu	Ser	Asp	Ile	
625					630					635					640	
ctg	gta	ttc	acc	tcg	gaa	cag	tgt	gat	gcg	cat	cgg	agt	gaa	gcc	gct	1968
Leu	Val	Phe	Thr	Ser	Glu	Gln	Cys	Asp	Ala	His	Arg	Ser	Glu	Ala	Ala	
				645					650					655		
tgt	tta	gca	gca	gga	cct	ggg	att	cgg	tgt	gtg	tgg	aac	aca	ggg	tcg	2016
Cys	Leu	Ala	Ala	Gly	Pro	Gly	Ile	Arg	Cys	Val	Trp	Asn	Thr	Gly	Ser	
			660					665					670			
tct	cag	tgt	atc	tcg	tgg	gcg	ctg	gca	act	gat	gaa	caa	gaa	gaa	aag	2064
Ser	Gln	Cys	Ile	Ser	Trp	Ala	Leu	Ala	Thr	Asp	Glu	Gln	Glu	Glu	Lys	
		675					680					685				
tta	aaa	tca	gaa	tgt	ttt	tcc	aaa	aga	act	ctt	gac	cat	gac	aga	tgt	2112
Leu	Lys	Ser	Glu	Cys	Phe	Ser	Lys	Arg	Thr	Leu	Asp	His	Asp	Arg	Cys	
	690					695					700					
gac	cag	cac	aca	gat	tgt	tac	agc	tgt	aca	gcc	aac	acc	aat	gac	tgc	2160
Asp	Gln	His	Thr	Asp	Cys	Tyr	Ser	Cys	Thr	Ala	Asn	Thr	Asn	Asp	Cys	
705					710					715					720	
cac	tgg	tgc	aat	gac	cat	tgt	gtc	ccc	agg	aac	cac	agc	tgc	tca	gaa	2208
His	Trp	Cys	Asn	Asp	His	Cys	Val	Pro	Arg	Asn	His	Ser	Cys	Ser	Glu	
				725					730					735		
ggc	cag	atc	tcc	att	ttt	agg	tat	gag	aat	tgc	ccc	aag	gat	aac	ccc	2256
Gly	Gln	Ile	Ser	Ile	Phe	Arg	Tyr	Glu	Asn	Cys	Pro	Lys	Asp	Asn	Pro	
			740					745					750			
atg	tac	tac	tgt	aac	aag	aag	acc	agc	tgc	agg	agc	tgt	gcc	ctg	gac	2304
Met	Tyr	Tyr	Cys	Asn	Lys	Lys	Thr	Ser	Cys	Arg	Ser	Cys	Ala	Leu	Asp	
		755					760					765				
cag	aac	tgc	cag	tgg	gag	ccc	cgg	aat	cag	gag	tgc	att	gcc	ctg	ccc	2352
Gln	Asn	Cys	Gln	Trp	Glu	Pro	Arg	Asn	Gln	Glu	Cys	Ile	Ala	Leu	Pro	
	770					775					780					
gaa	aat	atc	tgt	ggc	att	ggc	tgg	cat	ttg	gtt	gga	aac	tca	tgt	ttg	2400
Glu	Asn	Ile	Cys	Gly	Ile	Gly	Trp	His	Leu	Val	Gly	Asn	Ser	Cys	Leu	
785					790					795					800	
aaa	att	act	act	gcc	aag	gag	aat	tat	gac	aat	gct	aaa	ttg	ttc	tgt	2448
Lys	Ile	Thr	Thr	Ala	Lys	Glu	Asn	Tyr	Asp	Asn	Ala	Lys	Leu	Phe	Cys	
				805					810					815		
agg	aac	cac	aat	gcc	ctt	ttg	gct	tct	ctt	aca	acc	cag	aag	aag	gta	2496
Arg	Asn	His	Asn	Ala	Leu	Leu	Ala	Ser	Leu	Thr	Thr	Gln	Lys	Lys	Val	
			820					825					830			
gaa	ttt	gtc	ctt	aag	cag	ctg	cga	ata	atg	cag	tca	tct	cag	agc	atg	2544
Glu	Phe	Val	Leu	Lys	Gln	Leu	Arg	Ile	Met	Gln	Ser	Ser	Gln	Ser	Met	
		835					840					845				

tcc aag ctc acc tta acc cca tgg gtc ggc ctt cgg aag atc aat gtg Ser Lys Leu Thr Leu Thr Pro Trp Val Gly Leu Arg Lys Ile Asn Val 850 855 860	2592
tcc tac tgg tgc tgg gaa gat atg tcc cca ttt aca aat agt tta cta Ser Tyr Trp Cys Trp Glu Asp Met Ser Pro Phe Thr Asn Ser Leu Leu 865 870 875 880	2640
cag tgg atg ccg tct gag ccc agt gat gct gga ttc tgt gga att tta Gln Trp Met Pro Ser Glu Pro Ser Asp Ala Gly Phe Cys Gly Ile Leu 885 890 895	2688
tca gaa ccc agt act cgg gga ctg aag gct gca acc tgc atc aac cca Ser Glu Pro Ser Thr Arg Gly Leu Lys Ala Ala Thr Cys Ile Asn Pro 900 905 910	2736
ctc aat ggt agt gtc tgt gaa agg cct gca aac cac agt gct aag cag Leu Asn Gly Ser Val Cys Glu Arg Pro Ala Asn His Ser Ala Lys Gln 915 920 925	2784
tgc cgg aca cca tgt gcc ttg agg aca gca tgt gga gat tgc acc agc Cys Arg Thr Pro Cys Ala Leu Arg Thr Ala Cys Gly Asp Cys Thr Ser 930 935 940	2832
ggc agc tct gag tgc atg tgg tgc agc aac atg aag cag tgt gtg gac Gly Ser Ser Glu Cys Met Trp Cys Ser Asn Met Lys Gln Cys Val Asp 945 950 955 960	2880
tcc aat gcc tat gtg gcc tcc ttc cct ttt ggc cag tgt atg gaa tgg Ser Asn Ala Tyr Val Ala Ser Phe Pro Phe Gly Gln Cys Met Gln Trp 965 970 975	2928
tat acg atg agc acc tgc ccc cct gaa aat tgt tca ggc tac tgt acc Tyr Thr Met Ser Thr Cys Pro Pro Glu Asn Cys Ser Gly Tyr Cys Thr 980 985 990	2976
tgt agt cat tgc ttg gag caa cca ggc tgt ggc tgg tgt act gat ccc Cys Ser His Cys Leu Glu Gln Pro Gly Cys Gly Trp Cys Thr Asp Pro 995 1000 1005	3024
agc aat act ggc aaa ggg aaa tgc ata gag ggt tcc tat aaa gga cca Ser Asn Thr Gly Lys Gly Lys Cys Ile Glu Gly Ser Tyr Lys Gly Pro 1010 1015 1020	3072
gtg aag atg cct tcg caa gcc cct aca gga aat ttc tat cca cag ccc Val Lys Met Pro Ser Gln Ala Pro Thr Gly Asn Phe Tyr Pro Gln Pro 1025 1030 1035 1040	3120
ctg ctc aat tcc agc atg tgt cta gag gac agc aga tac aac tgg tct Leu Leu Asn Ser Ser Met Cys Leu Glu Asp Ser Arg Tyr Asn Trp Ser 1045 1050 1055	3168
ttc att cac tgt cca gct tgc caa tgc aac ggc cac agt aaa tgc atc Phe Ile His Cys Pro Ala Cys Gln Cys Asn Gly His Ser Lys Cys Ile 1060 1065 1070	3216
aat cag agc atc tgt gag aag tgt gag aac ctg acc aca ggc aag cac Asn Gln Ser Ile Cys Glu Lys Cys Glu Asn Leu Thr Thr Gly Lys His 1075 1080 1085	3264
tgc gag acc tgc ata tct ggc ttc tac ggt gat ccc acc aat gga ggg Cys Glu Thr Cys Ile Ser Gly Phe Tyr Gly Asp Pro Thr Asn Gly Gly 1090 1095 1100	3312

aaa tgt cag cca tgc aag tgc aat ggg cac gcg tct ctg tgc aac acc 3360
 Lys Cys Gln Pro Cys Lys Cys Asn Gly His Ala Ser Leu Cys Asn Thr
 1105 1110 1115 1120
 aac acg ggc aag tgc ttc tgc acc acc aag ggc gtc aag ggg gac gag 3408
 Asn Thr Gly Lys Cys Phe Cys Thr Thr Lys Gly Val Lys Gly Asp Glu
 1125 1130 1135
 tgc cag cta tgt gag gta gaa aat cga tac caa gga aac cct ctc aga 3456
 Cys Gln Leu Cys Glu Val Glu Asn Arg Tyr Gln Gly Asn Pro Leu Arg
 1140 1145 1150
 gga aca tgt tat tat act ctt ctt att gac tat cag ttc acc ttt agt 3504
 Gly Thr Cys Tyr Tyr Thr Leu Leu Ile Asp Tyr Gln Phe Thr Phe Ser
 1155 1160 1165
 cta tcc cag gaa gat gat cgc tat tac aca gct atc aat ttt gtg gct 3552
 Leu Ser Gln Glu Asp Asp Arg Tyr Tyr Thr Ala Ile Asn Phe Val Ala
 1170 1175 1180
 act cct gac gaa caa aac agg gat ttg gac atg ttc atc aat gcc tcc 3600
 Thr Pro Asp Glu Gln Asn Arg Asp Leu Asp Met Phe Ile Asn Ala Ser
 1185 1190 1195 1200
 aag aat ttc aac ctc aac atc acc tgg gct gcc agt ttc tca gct gga 3648
 Lys Asn Phe Asn Leu Asn Ile Thr Trp Ala Ala Ser Phe Ser Ala Gly
 1205 1210 1215
 acc cag gct gga gaa gag atg cct gtt gtt tca aaa acc aac att aag 3696
 Thr Gln Ala Gly Glu Glu Met Pro Val Val Ser Lys Thr Asn Ile Lys
 1220 1225 1230
 gag tac aaa gat agt ttc tct aat gag aag ttt gat ttt cgc aac cac 3744
 Glu Tyr Lys Asp Ser Phe Ser Asn Glu Lys Phe Asp Phe Arg Asn His
 1235 1240 1245
 cca aat atc act ttc ttt gtt tat gtc agt aat ttc acc tgg ccc atc 3792
 Pro Asn Ile Thr Phe Phe Val Tyr Val Ser Asn Phe Thr Trp Pro Ile
 1250 1255 1260
 aaa att cag gtg caa act gaa caa tga 3819
 Lys Ile Gln Val Gln Thr Glu Gln
 1265 1270

<210> 20
 <211> 17
 <212> PRT
 <213> Homo sapiens

<400> 20
 Cys Glu Val Glu Asn Arg Tyr Gln Gly Asn Pro Leu Arg Gly Thr Cys
 1 5 10 15
 Tyr

<210> 21
 <211> 12
 <212> PRT
 <213> Homo sapiens

<400> 21
 Ala Ala Leu Ala Gly Arg Ser Gly Gly Pro His Cys
 1 5 10

<210> 22
 <211> 5
 <212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> (1)...(4)

<223> Xaa = Any Amino Acid

<221> VARIANT

<222> (5)...(5)

<223> Xaa = Gly, Ser, or Ala

<400> 22

Gly Xaa Ser Xaa Xaa
1 5

<210> 23

<211> 30

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> (2)...(8)

<223> Xaa = Any Amino Acid

<221> VARIANT

<222> (9)...(9)

<223> Xaa = Leu, Ile, Val, Met, Phe, Tyr, or Trp

<221> VARIANT

<222> (10)...(29)

<223> Xaa = Any Amino Acid

<221> VARIANT

<222> (30)...(30)

<223> Xaa = Leu, Ile, Val, Met, Phe, Tyr, or Trp

<400> 23

Asp Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Ser Xaa Gly Gly Xaa
20 25 30

<210> 24

<211> 11

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> (3)...(4)

<223> Xaa = Any Amino Acid

<221> VARIANT

<222> (6)...(6)

<223> Xaa = Asp or Glu

<221> VARIANT

<222> (9)...(9)

<223> Xaa = Gly or Ser

<400> 24

Ala Ala Xaa Xaa Gly Xaa Ser Gly Xaa Pro His
1 5 10

<210> 25

<211> 10

<212> DNA
<213> Homo sapiens

<400> 25
gggaagatgg

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/20948

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04; C12N 15/63, 1/21, 15/00

US CL : 536/23.5, 23.4; 435/320.1, 252.1, 69.7

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.5, 23.4; 435/320.1, 252.1, 69.7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, medline, embase, BIOSIS, caplus,
KEYWORDS: attractin, DPPT-L

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DUKE-COHAN et al. A Novel Form of Dipeptidylpeptidase IV Found in Human Serum. J. Biol. Chem. June 1995, Vol. 270, No. 23, pages 14107-14114, see entire document.	1-3, 6, 20-27
Y	DUKE-COHAN et al. Serum High Molecular Weight Dipeptidyl Peptidase IV (CD26) Is Similar To A Novel Antigen DPPT-L Released From Activated T Cells. J. Immunol. 1996, Vol. 156, pages 1714-1721, see entire document.	1-3, 6, 20-27



Further documents are listed in the continuation of Box C.



See patent family annex.

*

Special categories of cited documents:

A

document defining the general state of the art which is not considered to be of particular relevance

E

earlier document published on or after the international filing date

L

document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O

document referring to an oral disclosure, use, exhibition or other means

P

document published prior to the international filing date but later than the priority date claimed

T

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

A

document member of the same patent family

Date of the actual completion of the international search

06 JANUARY 2000

Date of mailing of the international search report

07 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

GERALD R. EWOLDT

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/20948

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-3, 6, 20-27

Remark on Protest☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-3, 6, and 20-27, drawn to a DNA encoding a polypeptide.

Group II, claims 4-5 and 33-36, drawn to a polypeptide.

Group III, claim 7, drawn to a method of enhancing spreading of a macrophage or monocyte in vitro.

Group IV, claims 8-14, 32, and 37, drawn to a method of treating a mammal in need of an enhanced immune response.

Group V, claims 15-19, drawn to a method of inhibiting spreading of a macrophage or a monocyte in a mammal.

Group VI, claim 28, drawn to a method of identifying a compound that inhibits an immune response.

Group VII, claim 29, drawn to a method of identifying a compound that enhances an immune response.

Group VIII, claims 30-31, drawn to an antibody.

The inventions listed as Groups I, II, III, IV, V, VI, VII and VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The technical feature linking Groups I-VIII appears to be that they all relate to attractin nucleic acids and polypeptides and methods of using the polypeptide.

However Duke-Cohan et al. (J. Biol. Chem. 270(23): 14107-14114, 1995) and Duke-Cohan et al. (J. Immunol. 156: 1714-1721, 1996) teach the isolation and characterization of the DPPT-L (i.e. attractin) (see entire documents). Given the art known, and well known practice of isolating nucleic acids encoding proteins of interest to determine the structure-function characterization of such nucleic acids and their respective proteins, at the time the invention was made as well as the motivation and expectation of success in isolating cDNA encoding DPPT-L, as set forth in Duke-Cohan et al. (1995; see Discussion), it would have been obvious to isolate a nucleic acid that encodes and/or hybridizes to the claimed attractin sequences of claim 1. Therefore, the special technical feature linking the inventions of Groups I-VIII does not constitute a special technical feature as it does not define a contribution over the prior art.

The special technical feature of Group I is a DNA encoding a nucleic acid, vectors, and cells expressing fusion proteins.

The special technical feature of Group II is a polypeptide encoding an attractin.

The special technical feature of Group III is a method of using the polypeptide of Group II to enhance spreading of macrophages in vitro.

The special technical feature of Group IV is a method of using the polypeptide of Group II to treat a mammal in need of an enhanced immune response.

The special technical feature of Group V is a method of using the polypeptide of Group II to inhibit spreading of a macrophage or monocyte in a mammal.

The special technical feature of Group VI is a method of using the polypeptide of Group II to identify a compound that inhibits an immune response.

The special technical feature of Group VII is a method of using the polypeptide of Group II to identify a compound that enhances an immune response.

The special technical feature of Group VIII is an antibody to the polypeptide of Group II.

Accordingly, Groups I-VIII are not so linked by the same special technical feature as to form a single inventive concept.

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The nucleic acids of Group I, the polypeptides of Group II, and the antibody of Group VIII are different products with different biochemical structures and different functions.

The methods of Groups III-V require different starting materials, employ different steps, and have different endpoints.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as

follows:

Group IV is drawn to a method of treating different diseases, i.e., immunodeficiency diseases or cancer.

Group V is drawn to a method of inhibiting the spread of a macrophage or a monocyte in a mammal suffering from different medical conditions, i.e., an autoimmune disease or a transplant.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: patients with immunodeficiency diseases, cancer, autoimmune diseases, and transplant patients suffer from conditions with different etiologies, pathologies, and endpoints.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/20948

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04; C12N 15/63, 1/21, 15/00

US CL : 536/23.5, 23.4; 435/320.1, 252.1, 69.7

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.5, 23.4; 435/320.1, 252.1, 69.7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, medline, embase, BIOSIS, caplus,

KEYWORDS: attractin, DPPT-L

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DUKE-COHAN et al. A Novel Form of Dipeptidylpeptidase IV Found in Human Serum. J. Biol. Chem. June 1995, Vol. 270, No. 23, pages 14107-14114, see entire document.	1-3, 6, 20-27
Y	DUKE-COHAN et al. Serum High Molecular Weight Dipeptidyl Peptidase IV (CD26) Is Similar To A Novel Antigen DPPT-L Released From Activated T Cells. J. Immunol. 1996, Vol. 156, pages 1714-1721, see entire document.	1-3, 6, 20-27

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* *A* *B* *L* *O* *P*	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	*T* *X* *Y* *Z*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
--------------------------------------	---	--------------------------	--

Date of the actual completion of the international search

06 JANUARY 2000

Date of mailing of the international search report

07 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Gerald R. Ewoldt
GERALD R. EWOLDT

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/20948**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-3, 6, 20-27

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-3, 6, and 20-27, drawn to a DNA encoding a polypeptide.

Group II, claims 4-5 and 33-36, drawn to a polypeptide.

Group III, claim 7, drawn to a method of enhancing spreading of a macrophage or monocyte in vitro.

Group IV, claims 8-14, 32, and 37, drawn to a method of treating a mammal in need of an enhanced immune response.

Group V, claims 15-19, drawn to a method of inhibiting spreading of a macrophage or a monocyte in a mammal.

Group VI, claim 28, drawn to a method of identifying a compound that inhibits an immune response.

Group VII, claim 29, drawn to a method of identifying a compound that enhances an immune response.

Group VIII, claims 30-31, drawn to an antibody.

The inventions listed as Groups I, II, III, IV, V, VI, VII and VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The technical feature linking Groups I-VIII appears to be that they all relate to attractin nucleic acids and polypeptides and methods of using the polypeptide.

However Duke-Cohan et al. (J. Biol. Chem. 270(23): 14107-14114, 1995) and Duke-Cohan et al. (J. Immunol. 156: 1714-1721, 1996) teach the isolation and characterization of the DPPT-L (i.e. attractin) (see entire documents). Given the art known, and well known practice of isolating nucleic acids encoding proteins of interest to determine the structure-function characterization of such nucleic acids and their respective proteins, at the time the invention was made as well as the motivation and expectation of success in isolating cDNA encoding DPPT-L, as set forth in Duke-Cohan et al. (1995; see Discussion), it would have been obvious to isolate a nucleic acid that encodes and/or hybridizes to the claimed attractin sequences of claim 1. Therefore, the special technical feature linking the inventions of Groups I-VIII does not constitute a special technical feature as it does not define a contribution over the prior art.

The special technical feature of Group I is a DNA encoding a nucleic acid, vectors, and cells expressing fusion proteins.

The special technical feature of Group II is a polypeptide encoding an attractin.

The special technical feature of Group III is a method of using the polypeptide of Group II to enhance spreading of macrophages in vitro.

The special technical feature of Group IV is a method of using the polypeptide of Group II to treat a mammal in need of an enhanced immune response.

The special technical feature of Group V is a method of using the polypeptide of Group II to inhibit spreading of a macrophage or monocyte in a mammal.

The special technical feature of Group VI is a method of using the polypeptide of Group II to identify a compound that inhibits an immune response.

The special technical feature of Group VII is a method of using the polypeptide of Group II to identify a compound that enhances an immune response.

The special technical feature of Group VIII is an antibody to the polypeptide of Group II.

Accordingly, Groups I-VIII are not so linked by the same special technical feature as to form a single inventive concept.

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The nucleic acids of Group I, the polypeptides of Group II, and the antibody of Group VIII are different products with different biochemical structures and different functions.

The methods of Groups III-V require different starting materials, employ different steps, and have different endpoints.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/20948

follows:

Group IV is drawn to a method of treating different diseases, i.e., immunodeficiency diseases or cancer.

Group V is drawn to a method of inhibiting the spread of a macrophage or a monocyte in a mammal suffering from different medical conditions, i.e., an autoimmune disease or a transplant.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: patients with immunodeficiency diseases, cancer, autoimmune diseases, and transplant patients suffer from conditions with different etiologies, pathologies, and endpoints.